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Abstract 
 
Over the last three decades, cyclotron-produced radioisotopes have attracted 
considerable interest for biomedical applications. For example, the positron 
emission tomography (PET) isotopes 18F, 11C, 13N and 15O have established roles 
in diagnosis and management of human diseases, or in research into their 
mechanisms, particularly in oncology, cardiology and neurology. However, in 
recent years many advanced cyclotron sites have also added solid targetry 
systems to produce PET radiometals and radiohalides with half-lives ranging 
from several minutes (e.g. 60Cu) to several days (e.g. 89Zr & 124I). The 
predominant reactions are (p,x), with equipment-limited primary proton energies 
of less than 19 MeV. These transmutations facilitate chemical extraction and 
purification of products with high no-carrier-added (NCA) specific activities 
because the product atomic number (Z) is usually different from that of the 
target. The relatively long physical half-lives of some of the products are in 
accord with the characteristic lifetimes of biodistributions of numerous 
therapeutic and diagnostic (theranostic) agents that utilise monoclonal 
antibodies, their bioengineered constructs or nanoparticles as target-seeking 
delivery platforms. A typical target would be a tumour-cell surface receptor.  
Though the radioisotope may be chosen for its half-life and radioactive emission, 
its independent chemical properties may pose challenges for bonding or 
complexing to a targeting ligand. Copper isotopes are an exemplar. 
 
Recent advances in the complexation of copper isotopes using bifunctional 
macrocyclic chelators such as DOTA, NOTA and sarcophagine (sar) derivatives 
have facilitated biomedical applications of the PET-reporter isotopes 61Cu and 
64Cu, as well as the promising radiotherapy isotope 67Cu.  With its ‘intermediate’ 
half-life of 3.33 h, 61Cu seems particularly well-positioned to; (i) map the 
biodistributions of engineered-antibody immunoPET constructs such as 
diabodies and minibodies; (ii) label nanospheres (NS) delivering theranostic 
agents to tumours using the enhanced permeation-retention (EPR) effect and; 
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(iii) construct metal-chelator imaging compounds such as Cu-ATSM that target 
hypoxic tissue, for example in the cores of some solid tumours. However, in 
order to apply these tools to phase-I studies of human diseases, numerous 
preliminary validation studies (including dosimetry) are required to be performed 
on cell cultures and animal models. 
 
This thesis describes novel contributions to the production and purification of 
61Cu, its complexation to bifunctional macrocyclic and sarcophagine chelators 
and its application as a PET imaging agent in a murine model for quantitatively 
mapping the in vivo biodistribution of functionalised silica nanospheres (Si NS). 
The thesis has been divided into three parts, according to the linked categories of 
investigations. 
 
The first category focussed on optimization of the cyclotron-based production of 
61Cu by refining the solid targetry technique and measuring the excitation 
functions for products arising from the chosen production nuclear reaction.  
Specifically;  
 
(i) using natCu(p,xn) monitor reactions, the stacked-foils technique was used 
to devise a novel simple and precise method for measuring the primary proton 
beam energy of an isochronous auto-extraction cyclotron. This was performed 
before and following a major upgrade of the ion sources and non-magnetic beam 
controls, converting a (nominal) 18/9 MeV (proton/deuteron) configuration to 
18/18 MeV (proton/proton). This acquired knowledge assisted in optimizing 
solid-targetry yields and facilitated subsequent precise measurements of reaction 
cross sections, particularly that yielding 61Cu. Measured proton beam energy was 
18.03 MeV ± 0.02 (SD) and 18.11 MeV ± 0.05 (NS) before and following the 
upgrade, respectively.  
 
(ii) This study also evaluated the excitation functions of natZn (p,x) reactions  
using a high purity natural-zinc target, proton energies up to 17.6 MeV and 
employing the stacked-foils technique; yielding the products 61Cu, 66,67,68Ga and 
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65Zn. Thick-target integral yields were also deduced from the measured 
excitation functions, in particular for the natZn(p,α)61Cu reaction.  All results 
agreed well with the recent published literature and can contribute to the 
statistical weighting of published data for assembly of the ‘best’ composite 
excitation function from published results, for most of the reactions of the 
natZn(p,x) set. 
 
The second category of investigations devised an improved method for the 
production and chemical separation of 61Cu from natZn or enriched 64Zn targets. 
Subsequently, the complexation of 61Cu by three different chelators was 
compared, using the macrocyclic bifunctional chelators NOTA-NCS and DOTA-
NCS plus the macrobicyclic sarcophagine diamsar.  Specifically;  
 
(i) an improved chemical separation method using one or three  types of 
resins (for 64Zn target and natZn target respectively) was developed to rapidly 
isolate 61Cu as the chloride with high (> 99%) radionuclide purity from the co-
produced gallium radionuclides and the target material into separate collections, 
allowing recycling of target 64Zn, if relevant.  
 
(ii) In replicated experiments the effective specific activity of 61Cu was 
determined by titration with each of the three chelating agents. Results ranged 
from 4.7 ± 0.2 (SD) to 412.5 ± 15.3 MBq/µg (corrected to EOB), with diamsar 
yielding the highest value. For comparison, NCA specific activity determined 
following radioactive decay using ICP-MS ranged from 143.3 ± 14.3 to 506.2 ± 
50.6 MBq/µg.  There was reasonable agreement between the two estimates of 
specific activity for diamsar only. ICP-MS also revealed that the good results for 
diamsar were achieved despite relatively high background concentrations of Zn+2 
and Pb2+, demonstrating the high specificity of the sarcophagine for Cu2+. These 
metals compete with Cu2+ when using DOTA or NOTA and explain the lack of 
agreement between titration and ICP-MS for these chelators. This study revealed 
the importance of choice of chelator when determining the specific activity using 
the titration method. 
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In the final category of investigations functionalised polystyrene nanospheres 
(PS NS) of different sizes and functionalised silica nanospheres (Si NS) were 
radiolabelled with 64Cu (plus 57Co as comparator) and 61Cu, respectively, using 
the bifunctional chelators SarAr-NH2 (PS NS only), NOTA-NCS, DOTA-NCS 
and ‘MeSar-Ph-NCS’ (the last, Si NS only). This last molecule is a novel Cu2+-
chelating sarcophagine, [Mg(CH3)(p-NCS-Ph)Sar](CF3SO3)2, developed recently 
by collaborators of our laboratory. (The metal protector magnesium ion is 
extruded from the molecule following conjugation to the nanosphere and prior to 
radiolabelling). Copper-61 labelled Si NS were then injected into normal 
immunodeficient mice and their in vivo biodistributions were measured by 
µPET/CT imaging. Biodistributions were also measured directly by post-imaging 
dissection and γ-counting of major organs and tissues. Specifically;  
 
(i) carboxylate-functionalised PS NS of three sizes ranging from 365 to 840 
nm were conjugated with SarAr-NH2 and labelled with 57Co2+ and 64Cu2+ (the 
latter 680 nm only). Increasing the labelling temperature (23oC to 37oC) and 
reaction time (1.25 h to 24 h) improved the labelling efficiency for 57Co but not 
for 64Cu. The number of SarAr molecules conjugated to the NS depended on 
available functional groups present on the surfaces of the NS. This study 
provided valuable pilot data for subsequent radiolabelling of Si NS. 
 
(ii) In separate and replicated experiments, amino-functionalised Si NS of 
nominal diameter 100 nm were conjugated with the novel bifunctional chelator 
MeSar-Ph-NCS and compared with NOTA-NCS and DOTA-NCS for stability of 
radiocopper labelling and chelator occupancy on the nanosphere surface. The in 
vitro stabilities of all 61Cu-chelator-Si NS complexes were approximately equal; 
however the occupancy areal density of radiolabelled MeSar-Ph-NCS molecules 
on the Si NS surface was approximately double the areal densities of 
radiolabelled NOTA-NCS or DOTA-NCS. 
 
(iii)  In replicated experiments the in vivo biodistributions at one and four 
hours post-injection of the radiolabels 61Cu (delivered as the aqueous chloride), 
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61Cu-MeSar-Ph-NCS-Si NS, 61Cu-NOTA-NCS-Si NS and 61Cu-DOTA-NCS-Si 
NS were evaluated using µPET/CT. A normal immunodeficient-mouse model 
was chosen in anticipation of later parallel experiments employing xenograft 
tumours (beyond the scope of this thesis). Immediately following the four-hour 
imaging time-point, the biodistribution for each radiolabel was also determined 
directly by dissection and γ-counting.  
 
For the control group injected with 61Cu-chloride, the dissection-derived 
biodistribution (4 h) revealed mainly uptake in liver (including gallbladder) and 
kidneys as expected, with lower uptakes in lung, stomach, spleen and bladder.  
The quantitative µPET images at 1 and 4 h confirmed the liver uptake. 
Dissection-derived biodistributions for the three 61Cu-chelator-Si NS radiolabels 
at 4 h were broadly similar, showing marked uptake in the spleen (43-70% of 
injected dose/g tissue [%ID/g]) with substantial but less uptake in the liver-plus-
gall bladder (39-48%ID/g), and approximately the same levels as controls in the 
kidneys (6-10%ID/g). However the activity level of 61Cu-MeSar-Ph-NCS-Si NS 
in the lungs and bladder exceeded (37.4 ± 5.7%ID/g and 14.9 ± 1.9%ID/g that 
for the 61Cu-NOTA-NCS and 61Cu-DOTA-NCS (macrocyclic) radiolabelled NS.  
These results were broadly confirmed by analysis of µPET images at both 1 and 
4 h, though the apparent lungs uptake of 61Cu-MeSar-Ph-NCS-Si NS was not as 
markedly different from the other chelators as for the dissection-derived data. 
 
These are the first reported in vivo biodistribution studies for the novel 
bifunctional sarcophagine chelator MeSar-Ph-NCS conjugated to NS. The reason 
for the enhanced uptake of MeSar-Ph-NCS-conjugated NS in the lungs 
compared to two commonly used (macrocyclic) bifunctional copper chelators is 
unknown. It may have been caused by deconjugation of 61Cu-MeSar-Ph-NCS 
from the NS in vivo, or it may be an intrinsic pharmacokinetic property of the 
entire radiolabelled complex. A possible explanation is a relatively high net 
positive charge on the 61Cu-MeSar moiety, leading to binding of the 
sarcophagine-mediated complex to the net negatively charged lung interstitial 
tissues. A relatively high uptake of 61Cu-MeSar-Si NS was not seen in the 
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kidneys compared with NOTA and DOTA, where net negatively charged basal 
cells of the glomerulus might have been expected to elicit the same qualitative 
effect as in the lungs. However, the Si NS size of about 100 nm may preclude 
any of the 61Cu-labelled Si NS complexes from accumulating in the kidneys, 
which are refractory to NS sizes above about 5 nm. 
 
In any event, these results strongly suggest that despite the relative advantages of 
MeSar-Ph-NCS as a bifunctional chelator (room-temperature conjugation 
chemistry, relatively rapid conjugation, relatively high occupancy areal-density 
on NS, high elemental specificity for copper-chelation), its accumulation and 
(when radiolabelled) related dose burden in the lungs require further study.  
 
These linked studies of the PET radioisotope 61Cu, from cyclotron-based 
production to its radiotracer application in a murine model, have contributed to 
its more efficient production and purification plus its comparative evaluation in 
radiolabelling of Si NS using different Cu2+ bifunctional chelators, including a 
novel sarcophagine chelator developed by a collaborating laboratory. This 
‘proof-of-principle’ application of 61Cu as a PET imaging agent for mapping the 
temporal biodistributions of Si NS in an immunodeficient murine model will 
contribute to future laboratory-based studies of the growth mechanisms and 
treatments of human tumours such as (metastatic ovarian cancer), plus other 
applications using Si NS with less than 100 nm size.  Some of the outcomes may 
in time be translated to the patient bedside. 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1  Molecular Imaging  
 
Molecular imaging allows the non-invasive visualization of molecular processes 
in vivo. The term “molecular imaging” implies the convergence of various 
disciplines from cell and molecular biology, chemistry, medicine, pharmacology, 
physics, bioinformatics, through to engineering (Ottobrini, Ciana, Biserni, 
Lucignani, & Maggi, 2006). Several modalities including positron emission 
tomography (PET), single photon emission computed tomography (SPECT), 
magnetic resonance imaging (MRI) and optical imaging (OI) have been 
developed for molecular imaging. A major advantage of PET and SPECT in 
molecular imaging is their high sensitivity and use of highly specific imaging 
agents (Saji et al., 2004; Massoud & Gambhir, 2003; Hong, Zhang, Sun, & Cai, 
2009). 
 
Molecular imaging has its roots in nuclear medicine and in many ways is a direct 
extension of that existing discipline. Nuclear medicine is a medical field that 
employs molecular imaging through the use of radioactive agents (e.g. 
radiopharmaceuticals), for the purpose of diagnosis and therapy of diseases. 
Radiopharmaceuticals range from tracers to measure blood flow and 
inflammation, to chemical species for measuring basic physiological function 
(e.g. energy metabolism) as well as the size and location of diseased tissues. 
These radiopharmaceuticals are used at low concentration levels and incorporate 
gamma (γ) ray- emitting radionuclides. The γ rays used in imaging are energetic 
enough to pass through the human tissues and can be externally detected. Thus, 
this process is markedly different from anatomical methods of imaging, such as 
x-ray imaging and magnetic resonance imaging (MRI). These latter methods are 
primarily used to characterise differences in density either by transmission (x-ray 
imaging) or by interactions of radiofrequency radiation with hydrogen nuclei 
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(MRI). Another difference is that in order to acquire a signal with sufficient 
spatial resolution by MRI about a millimole of material is required in each voxel 
(e.g. tissue mass, proton abundance) compared with only picomoles (radioactive 
nuclei) for radioisotopic imaging. 
 
Molecular imaging is used as a tool for phenotype screening in drug 
development programs (Hoit, 2001). Transgenic or immune compromised 
animals are used in early drug discovery to “validate” target proteins and to 
evaluate the efficacy and toxicological effects of new test compounds for their 
potential use in humans (Livingston, 1999). The use of molecular imaging tools 
such as PET and SPECT in the drug discovery process offers an opportunity to 
study the pharmacokinetics of drugs and to identify dose-limiting toxicity in 
vivo.  More importantly, trialing those drugs in animal models helps identify 
molecules most likely to succeed in humans. As an example, Figure 1.1 shows 
the types of receptors in breast cancers that have been selectively targeted using 
molecular imaging techniques. The contrast in the uptake of the molecular 
imaging agents allows one to identify where the breast cancers cells are in the 
body.  
 
 
 
Figure 1.1    The potential targets for breast cancer molecular imaging (adapted 
from Oude Munnink et al., 2009). 
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1.2  Basic Principles of Positron Emission Tomography  
 
Positron emission tomography (PET) is one of the most sensitive and specific 
techniques for imaging molecular pathways in vivo.  It is based on the detection 
of small (nano-to picomolar) quantities of active molecules labelled with a 
positron emitter. Common PET radioisotopes currently used in the clinic include 
fluorine-18 (half-life=109.8 min), carbon-11 (half-life=20.33 min), nitrogen-13 
(half-life=9.97 min) and oxygen-15 (half-life=2.03 min) (Ziegler, 2005), as well 
as other radioisotopes such as 60,61,64Cu, 68Ga, 89Zr, 86Y and 124I (McCarthy et al., 
1999; Avila-Rodriguez, Nye, & Nickles, 2007; Suzuki et al., 2011; Deri, Zeglis, 
Francesconi, & Lewis, 2013; Sadeghi, Kakavand, Mokhtari, & Giholamzadel, 
2009B; Nye, Avila-Rodriguez, & Nickles, 2007) which are being investigated 
for various novel diagnostic and/or radiotherapeutic applications. These 
radionuclides are generally incorporated into biologically active compounds that 
play a specific role in living organisms (see Table 1.1) (Welch & Redvanly, 
2005). 
 
PET images are obtained from the administration of a radiopharmaceutical 
incorporating a positron (β+) emitting radioisotope. The radioactive decay of 
positron emitting radioisotope occurs in the following manner  
               
                                 p → n + β+ + ѵe                                                (1) 
 
The positron is a positively charged particle that is the antimatter counterpart to 
the electron. The emitted positron collides with matter as it travels a few 
millimetres into the tissue, losing its kinetic energy.  Once most of the energy 
has been lost, the positron associates with an electron, forms a positronium 
intermediate which is unstable, and completely annihilates to give off two 
annihilation gamma photons (each energy = 511 keV) emitted at 180° from each 
other (Figure 1.2).  When detected, within a short time window (~ nsec) 
(effectively in coincidence) their directions and the small difference in their 
arrival times at the detector are used in a statistical analysis of many such events 
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to resolve where the radioisotope is positioned in the body (Martinez, Ziegler, & 
Beyer, 2008). 
 
A PET scanner consists of an array of detectors surrounding the subject, and 
linked by coincidence circuitry. A decay event is recorded when a pair of 
photons are received at connected detectors positioned 180o from each other 
(Figure 1.3). 
 
A large number of coincidence events are recorded across the detectors of the 
scanner. This information is used in complex computer algorithms to reconstruct 
the numerous events that have been registered into an image. This gives 
information on the spatial distribution of radioactivity as a function of time. 
Eventually, the recorded radioactivities can be calculated (in Bq/mL) as values 
representing the different voxel intensities of the reconstructed 3D images. 
 
Several factors affect image resolution; these include photon attenuation, 
positron range and random coincidences from scattered and truly random 
photons. In some cases, it may not be possible to localize an area of increased 
activity on a PET scan alone due to poor anatomic resolution. In general, whole 
body PET has a spatial resolution of ~ 4 mm. Brain PET imaging can achieve a 
spatial resolution of ~2.5 mm. The strength of PET imaging lies in its ability to 
image a range of positron emitting radioisotopes attached to a wide range of 
carrier agents, as well as its exquisitely high sensitivity compared to other 
modalities. It is particularly powerful when used in understanding metabolic 
processes (Kapoor, McCook, & Torok, 2004).  
 
In comparison to the higher spatial resolution (~1 mm) of CT images, PET 
resolution is lower but it gives important metabolic or biochemical functional 
information whereas CT (particularly when used in conjunction with PET) 
largely provides anatomical information. The modern combination of PET/CT 
scanners provide a powerful tool that capitalises on the complementary strengths 
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of the two imaging technologies for accurate localisation of functional 
abnormalities (Beyer et al., 2000).   
 
The success of these combined modalities has also led to the development of a 
wide range of small animal (preclinical) PET/CT, SPECT/CT and PET/MRI 
cameras that are in routine use in drug discovery programs around the world 
(Nanni et al., 2007; Cherry & Gambhir, 2001). Spatial resolution (1.9-3.2 mm) 
and sensitivity (2.1-3.4%) are routinely achieved with small animal cameras (Tai 
et al., 2005), which allow the study of neoplastic masses at an early stage. 
 
Table 1.1   PET isotopes employed in common clinical and preclinical 
applications. 
 
Radionuclide 
Production 
Route (direct 
[D]/generator 
[G]) 
Half- 
life 
 
βmax 
(keV), 
max. range 
in 
H2O (mm) 
Radiolabelling 
Chemistry 
Applications 
15O (D) 1.03 
min 
1732 keV, 
8.0 mm 
Fast on-line 
None – Gas 
phase Chemistry 
• [15O]H2O; cerebral 
blood flow 
• 15O16O; oxygen 
metabolism 
• Blood volume 
• Local use only 
13N (D) 9.97 
min 
 
1198 keV, 
5.1 mm 
Covalently 
attached to 
target agent 
• 13N ammonia;  
heart blood flow 
• 13N amino acids; 
protein synthesis 
• Local use only 
11C (D) 20.33 
min 
 
960keV, 
3.9 mm 
Covalently 
attached to 
target agent 
• 11C-acetate; heart 
metabolism 
• 11C-MET; amino 
acid metabolism 
• 11C-PIB;  β-
amyloid deposit in 
Alzheimer’s 
disease 
• 11C-Choline; 
prostate cancer 
imaging. Local use 
only 
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68Ga (G) 68 
min 
 
1899keV, 
8.9 mm 
Chelated • 68Ga-DOTA-TATE 
68Ga-DOTA-NOC; 
neuroendocrine 
tumours 
• 68Ga-PSMA; 
prostate cancer 
imaging 
• Local use only 
18F (D) 109.8 
min 
 
634keV, 
2.3 mm 
Covalently 
attached to 
target agent 
 
• 18F-FDG; glucose 
metabolism 
• 18F-FLT;  DNA 
synthesis,  cell 
proliferation 
• 18F-FET;  amino 
acid transport 
• 18F-FMISO;  
hypoxia 
• Non-local transport 
possible 
 
64Cu (D) 12.7 
h 
 
653 keV, 
2.4 mm 
Chelated • Radiolabelling of 
small molecules 
(64Cu-ATSM, 64Cu-
peptides) and larger 
molecules (64Cu-
antibodies, 64Cu 
nanoparticles) 
• •Non-local 
transport possible 
89Zr (D) 78.4 
h 
 
897 keV, 
3.6 mm 
Chelated • Radiolabelling of 
small molecules 
(e.g. 89Zr- peptides)  
and larger 
molecules (89Zr-
transferrin, 89Zr-
antibodies) 
• Non-local transport 
possible 
124I (D) 4.17 
d 
 
1535 keV , 
6.9 mm 
2138 keV , 
10.2 mm 
Covalently 
attached to 
target agent 
• 124I-MIBG, 124I- 
β CIT  
• 124I-antibodies; 
thyroid cancer 
• Non-local transport 
possible 
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Figure 1.2  A positron is emitted from an unstable proton-rich nucleus. After 
travelling a short distance, it annihilates upon binding with an 
electron to form a positronium. The positronium has a short half-
life (10-10 seconds) and decays almost instantly to give off two 
detectable 511 keV gamma photons approximately 180° apart 
(adapted from Royal Adelaide Hospital, 2015). 
 
 
 
Figure 1.3  A clinical PET scanner. A circular array of detectors surrounds the 
patient and records the coincident photon pairs (adapted from 
University of Michigan Medical School, 2015). 
 
1.3  Cyclotron  
 
A cyclotron is a charged particle accelerator used to accelerate nuclear particles 
such as H-, D- ions to very high energies (5-90 MeV and 8-35 MeV, 
respectively) by an applied electrical field (Papash & Alenitsky, 2008). It also 
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has a magnetic field to guide these particles into a spiral flight path inside a 
vacuum chamber. The electric fields are generated by a pair of hollow 
semicircular metal electrodes called “dees” because of their D-shape (see Figure 
1.4). The accelerating particles are produced in an ion source, constrained in a 
spiralling path by a magnetic static field, and are accelerated in their orbit by an 
alternating (RF) electric field. The alternating electric field is applied to 2 hollow 
“dees”. The radius of the particle orbit is determined by the magnetic field 
strength, the particle charge/mass ratio and the particle kinetic energy. The 
magnitude of the magnetic field does not change during the acceleration of the 
beam, except to compensate for relativistic effects on particle mass. 
 
A charge Q moving with a velocity ν in a static magnetic field is subject to the 
magnetic component of the Lorentz force  
 
                                   F= Q (ν x B)                                                                 (1) 
 
In the simplest case of the particle moving perpendicularly to a constant 
magnetic field, the equation of motion describes a circular orbit constrained by 
an inward radially directed centripetal force Ff 
              
                              Ff = m. ν 2/ r = Q.v.B                                                        (2) 
 
where m is the particle mass and r the orbit radius. The centripetal force is 
balanced exactly by an outward radially directed centrifugal force. 
Using equation (2) the angular velocity ω = ν/r is;  
                   
                                   ω = Q.B/m                                                                   (3) 
and is independent of the orbital radius. 
From the equation (3) the kinetic energy T is given by: 
 
             Tmax = m.ν 2/2 = Q2.B2.r2/ 2m = m.ω 2.r2 /2                                     (4) 
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The maximum kinetic energy, Tmax, is reached when the radius of the beam orbit 
is at its maximum value, rmax, at the outer perimeter of the high-vacuum 
accelerating chamber, immediately prior to deflecting the beam onto the target. 
Since according to eqaution (3) the angular velocity of the beam does not depend 
on particle energy and therefore its orbital radius; the acceleration is 
isochronous. The alternating electric field placed across the dees has amplitude 
of tens of kilovolts and an angular frequency equal to the Larmor angular 
frequency ω of the circulating particle beam, enabling a resonant ramping of 
particle energy on every pass of the beam through a dee. Modern cyclotrons used 
in biomedical applications usually accelerate negative ions. In the case of the 
acceleration of H- or D-, once they reach Tmax, the negative ions hit a stripping 
foil (usually 5 µm thick graphite), which removes their electrons revealing a 
proton (from H-) or a deuteron (from D-). These new particles are positively 
charged, they instantaneously reverse the sense of their orbit and are thus 
directed onto a target (Strijckmans, 2001). Modern medium-energy cyclotrons, 
including the IBA 18/9 (IBA, Louvain la Neuve, Belgium) are specially designed 
for the production of radioisotopes by (p,x) and (if deuterons are provided) (d,x) 
reactions in gaseous, liquid and (with some additional equipment) solid targets. 
These isotopes find widespread applications in nuclear medicine for both 
diagnostic and therapeutic purposes. The IBA 18/9 proton/deuteron isochronous 
cyclotron utilised in this study was upgraded into a 18/18 MeV proton/proton 
configuration during the course of this thesis, with the maximum beam current 
upgraded from 75 µA to 150 µA. 
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Figure 1.4  Schematic of the operation of a simplified cyclotron (adapted 
  from Strijchmans, 2001). 
 
Cyclotron-produced radioisotopes are often of:  
 
• High Specific Activity - Chemically different from the target material; 
for example, 18F is produced from an 18O target and 61Cu from a Zn or Ni 
target depending on the nuclear reaction. 
. 
• Neutron Poor - Have more protons than neutrons in their nucleus, 
decaying by electron capture (EC) or positron (ß+) emission, and giving 
off gamma rays that are imageable by SPECT or PET. 
 
1.3.1  Solid Targetry  
 
Figure 1.5 shows a targetry system demonstrating these elements, for irradiation 
of solids in the form of foil discs (Scharli et al., 2012), partly based on a design 
by Ĉomor, Stevanoviü, Rajþeviü, & Košutiü (2004).  This is optimised for a 
biomedical cyclotron of 18 MeV or less.  A ten-mm graphite beam collimator 
up-beam of a Havar® vacuum foil ‘window’ (see Worked Example 4 for its 
elemental compostion) incorporates a removable beam-degrading insert of the 
same material, both cooled by chilled water. Cooled helium gas is passed over 
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the front of the target, between the vacuum foil and the front face of the target, to 
assist in heat removal.  Pressurised chilled water (250 mL/s; 18oC) is applied to 
the target backing plate.  For a cyclotron with a proton beam energy of nominally 
18 MeV this system is capable of beam currents exceeding 40 µA at energies up 
to 17.6 MeV (after losses in the vacuum and vacuum foil window), requiring 
removal of about (potential x current) = (17.6 MeV x 40 µA) = 700 W of heat 
energy. Only a tiny proportion of beam kinetic energy contributes to nuclear 
reactions. 
  
The target consists of 25-mm diameter foil discs, which depending on 
requirements, may be packed in a stack of sufficent thickness to achieve the 
‘thick-target’ condition. Typical solid-target materials are natCu, 89Y, 45Sc, natZn, 
124Te and 64Ni to produce the radiometal isotopes 63,65Zn, 89Zr, 45Ti, 61Cu, 124I and 
64Cu, respectively. Isotopically enriched targets such as 124Te and 64Ni are 
usually electroplated onto substrates that are inert to the chemical processes 
applied following irradiation, to remove the target material for subsequent 
separation and purification of product.  For example, 64Ni for the 64Ni (p,n)64Cu 
reaction can be electro-deposited onto a gold foil using a 10 mL aqueous 
electroplating solution of 64NiSO4 (150 mg per target) and (NH4)2SO4 (60-500 
mg) (Jeffery, Smith,  Asad, Chan, & Price, 2012). The thicknesses of such target 
preparations (typically < 100 µm) will not satisfy the ‘thick-target’ condition, 
unlike what is achievable with stacks of foils of naturally monoisotopic elements 
such as 89Y and 45Sc, or natural isotopic mixtures such as natCu and natZn.  
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Figure 1.5  Schematic of external beam line and solid targetry apparatus for 
  18/18 MeV IBA cyclotron. (1) Proton beam entry; (2) connection 
flange; (3) graphite collimator; (4) collimator water cooling; (5) 
connecting body; (6) Havar® foil window; (7) target guiding plate; 
(8) window-target helium cooling cavity; (9) target disc(s) & 
backing plate; (10) cooling water jet for backing plate (adapted 
from Scharli et al., 2012). 
 
The following criteria are essential in the design of a solid target station:   
 
1. Target holder: should be heat resistant and have high thermal 
conductivity.  
  
2. Cooling system: can be gas, liquid or both. Figure 1.5 shows a target 
cooled on its front face by helium gas flow and on the back by firm 
connection to a backing plate over which flows chilled water. The ability 
to remove heat is important for maintaining high current on the target and 
to prevent loss of product. 
 
3. Automated release and target expulsion mechanism to deliver the 
irradiated target into a shielded container to reduce radiation exposure.  
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4. Robust vacuum window that prevents target material being sucked into 
cyclotron vacuum in the event of mechanical failure. 
 
5. Ability to insert materials of varying thickness to degrade the beam 
energy on the target. Degraders are made of materials that minimally 
scatter the beam (e.g. graphite, stainless steel, aluminium or copper) and 
are a good thermal conductor.  
 
6. Ability to degrade the beam to produce a particle of suitable energy to 
ensure optimal production of the desired isotope and minimal production 
of contaminating isotopes.  For example, in the production of 64Cu from 
enriched 64Ni target (> 95%), the 64Ni(p,n)64Cu reaction can be optimised. 
An energy < 12 MeV captures a productive section of the excitation curve 
for this reaction but minimises the undesired nuclear reactions, such as 
58Ni(p,α)55Co, 60Ni(p,n)60Cu, 64Ni(p,α)61Co, 61Ni(p,n)61Cu and 
62Ni(p,n)62Cu. 
 
1.3.2  Target Cooling  
 
The thermal power delivered to a target, WT   is given by:  
 
                               WT = I. E                                                                           (4) 
 
where I is the target current expressed in µA and E the beam energy expressed in 
MeV. WT is typically a few hundred W (watts).  For a typical cyclotron system, 
this energy is delivered over a target area of approximately 1 cm2.  Therefore, it 
is essential that there is good contact between the target material and backing 
plate to ensure adequate cooling of the target assembly.  The front of the target 
face is cooled with He gas and the foil target cover must be adequately sealed 
with an “O” ring to ensure no loss of He gas, to promote adequate cooling. 
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1.4  PET Isotopes: Targeted Radiopharmaceuticals 
 
Only a small number of the radionuclides have the appropriate physical and 
chemical properties to become suitable candidates for the preparation of 
diagnostic or therapeutic radiotracers.  In general, radiopharmaceuticals may be 
divided into two types; substrate specific and non-substrate specific agents. The 
more common substrate specific radiopharmaceuticals are designed to target a 
specific biological process, receptor or other type of protein expressed in distinct 
regions of the body, and usually in a specific cell types (metabolic substrates, 
drugs or analogs and antibodies). Non-substrate specific agents include 
radiolabelled liposomes, microspheres, perfusion agents and inert gases. 
 
Many positron emitting nuclides of biomedical importance can be produced in a 
cyclotron by a specific target irradiated with protons of energy up to 18 MeV. 
The number of isotopes produced on a target depends on both the energy of the 
proton beam and the elemental composition of the target (target impurities). 
Selection of the prepared radionuclide in radiopharmaceutical design is very 
important and depends on several factors. The half-life of the radionuclide 
should allow sufficient uptake and distribution to yield quality images with good 
contrast. Also, the mode of decay and energies of the radionuclide emission 
should be suitable for the chosen imaging modality (Asabella, Cascini, Altini, & 
Paparella, 2014). 
 
Fluorine-18 is probably the most widely used isotope for the synthesis of PET 
radiopharmaceuticals. It has a small positron range (2.3 mm) and a reasonable 
half-life (109.8 min) allowing the preparation of the widely used radiotracer 
[18F]-2-fluoro-D-deoxyglucose (FDG) relatively quickly (< 30 min synthesis 
time) with acceptable radiochemical yields. FDG is used for the diagnosis of a 
large variety of cancers (e.g. lung, colorectal carcinomas, breast, and 
lymphomas) (Abouzied, Crawford, Nabi, 2005). 
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The relatively short physical half-life of 18F inhibits its application in labelling 
antibodies. The ‘slow’ pharmacokinetics of antibodies require that they be 
radiolabelled with isotopes that have longer half-lives, such as 64Cu, 89Zr and 
124I, to match the biological half-life of the biodistribution of the antibody. The 
radiometals (64Cu, 89Zr) can be readily attached to targeting agent (e.g. 
antibodies, peptides and nanoparticles) using bifunctional chelators (BFCs).  The 
BFC is either attached to the targeting agent and then radiolabelled with the 
desired radiometal, or the radiometal is complexed to the BFC and then attached 
to the targeting agent.  
 
In all cases the BFC complexation/radiolabelling chemistry should be well-
established and should have no significant effect on the targeting agents’ ability 
to bind to the target receptors in vivo. As noted above, a range of radiometals 
with different half-lives are available, allowing the investigator to match the 
radiological half-life of the resultant radiolabelled agent to the biological half-life 
of the agent (Reichert, Lewis, & Anderson, 1999).  
 
1.5  Production of Copper Radiosotopes  
 
There are five copper radioisotopes (60Cu, 61Cu, 62Cu, 64Cu, and 67Cu) that are 
used in nuclear medicine and molecular imaging; their physical properties are 
summarised in Table 1.2 (Wadas, Wong, Weisman, & Anderson, 2007). Though 
64Cu and 67Cu can in theory be produced in nuclear reactors, they are mostly 
produced using accelerators via the (p,x) nuclear reactions. Copper isotopes 
(60,61,62&64Cu) are produced efficiently at energies < 18 MeV and can be produced 
on medium-energy cyclotrons commonly used in nuclear medicine PET centres, 
while 67Cu requires higher energies. Production of 61Cu and 64Cu are of greatest 
interest to the current study as they have the physical characteristics most suited 
for radiolabelling nanomaterials, which could be the next generation of carrier 
agents in molecular imaging.  
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Table 1.2  Decay Characteristics of Copper Radionuclides (adapted from 
Wadas et al., 2007). 
 
Isotope T1/2 β+ MeV(%) β- MeV (%) EC (%) γ MeV (%) 
60Cu 23.4 min 2.00(69%) 
3.00(18%) 
3.92(6%) 
- 7.4% 0.511(186%) 
0.85(15%) 
1.33(80%) 
1.76(52%) 
2.13(6%) 
61Cu 3.33 h 1.22(61.5%) - 38.5% 0.284(12%) 
0.656(10.6%) 
0.511(120%) 
62Cu 9.76 min 2.91(97%) - 2% 0.511(194%) 
64Cu 12.7 h 0.655(17.4%) 0.573(39.6%) 41% 0.511(34.8%) 
1.35(0.6%) 
67Cu 62.0 h  0.395(45%) 
0.484(35%) 
0.577(50%) 
- 
 
0.184(40%) 
 
 
1.5.1  Current Production Methods for 61Cu 
 
Copper-61 (61Cu) is a positron emitter (β+=61.5%, EC= 38.5%). It has a 3.33 h 
physical half-life and a Eβ+ max of 2.237 MeV (Table of Nuclides; 
http://atom.kaeri.re.kr/). Its half-life is most suited to radiolabelling small 
molecules with short biological half-lives. It has been used for radiolabelling 
TETA-octreotide (where TETA is the chelating group 1,4,8,11-
tetraazacyclotetradecane-N,N′,N′′,N′′′-tetraacetic acid), ATSM (diacetyl-bis(N4-
methylthiosemicarbazone) and PTSM (pyruvaldehyde-bis(N4-
methylthiosemicarbazone)) for imaging of tumours (McCarthy et al., 1997).  
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Nickel and zinc are generally used as target materials for the production of 61Cu. 
Reactions reported in the literature include:  
 
(1) 61Ni(p,n)61Cu (Singh, Sharma, Mustafa, Bharwaj, & Prasad, 2006; 
Szelecsènyi, Blessing, & Qaim, 1993; Antropov et al., 1992; 
Tingwell,  Hansper, Tims, Scott, & Sargood, 1988; Johnson, Trail, & 
Galonsky, 1964; Tanaka, Furukawa, & Chiba, 1972), 62Ni(p,2n)61Cu 
( Piel, Qaim, & Stoecklin,1992 ; Levkovskij, 1991).  
 
(2) 64Zn(p,α)61Cu (Barradon, Deburn, Kohn & Spear, 1975; Cohen, 
Newman, Charpie, & Handly,1954).  
 
(3) 64Zn(d,αn)61Cu (Daraban, Abbas, Simonelli, Rebeles, & Gibson, 
 2008; Williams & Irvine, 1963).  
 
In deciding the optimum nuclear reaction route for production of 61Cu, one must 
consider: 
 
1) Target material purity and cost. 
 
2) Nuclear yield.  
 
3) Beam characteristics; that is particle type (i.e proton, deuteron or alpha 
particle) energy and current.  
 
Target isotopic abundances are one of the main factors involved in target 
material selection. For example, we note that natural nickel contains the 
following five stable isotopes 58Ni (68.77%), 60Ni (26.223%), 61Ni (1.140%), 
62Ni (3.634%) and 64Ni (0.926%). Considering the relatively low natural 
abundance of 61Ni, in the quest to produce 61Cu irradiation of a natural nickel 
will give arise to cobalt and other copper radioisotopic contaminants with half-
lives ranging from 23.2 min to 271 days, using energies up to 27.5 MeV (Al 
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Saleh, Al Mugren, & Azzam, 2009). Therefore, enriched target material is 
required to reduce these sources of contamination and also to increase 61Cu 
production yield. Thus, production of the desired radioisotope in sufficiently 
high yield often requires the use of expensive, highly enriched target materials. 
In the case of 61Cu, only a low fraction (< 0.004%) of the target is converted to 
the desired radioisotopes, so the (expensive) target material needs to be recycled 
after each irradiation to keep the cost of production to a minimum. 
 
1.5.1.1  61Cu Production Using Nickel Targets  
 
As discussed above, copper-61 can be produced from enriched 61,62Ni targets 
(Figure 1.6 and 1.7) but not from natural Ni targets, because of the low natural 
abundance of 61Ni (1.16%) and 62Ni (3.634%). Figure 1.6 shows the cross 
section for protons on 61Ni target over a proton energy range of 2.5-18.6 MeV 
(Szelecsènyi et al., 1993; Antropov et al., 1992; Tingwell et al., 1988; Johnson  
et al., 1964; Tanaka et al., 1972; Tanaka & Furukawa, 1959). There are less 
reported data for the 62Ni(p,2n)61Cu reactions, and while there is some variation, 
there is good agreement between Piel et al. (1992) and Levkovskij (1991) in the 
energy range of 13.8-18.3 MeV (see Figure 1.7).  McCarthy et al. (1997) 
reported that the most cost-effective way of making 61Cu (starting with Ni as a 
target) was from a 61Ni target using protons from a biomedical cyclotron (14.7 
MeV). 
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Figure 1.6  Experimentally determined excitation function of 61Ni(p,n)61Cu 
reaction (adapted from EXFOR). 
 
 
 
Figure 1.7  Experimentally determined excitation function of 62Ni(p,2n)61Cu 
reaction (adapted from EXFOR). 
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1.5.1.2  61Cu Production Using Zinc Targets  
 
Alternatively, 61Cu can be produced from irradiation of natural Zn (natural 
abundance of 64Zn (48.8%)) or enriched 64Zn targets. They have the following 
advantages over Ni targets: 
 
(i) Zn target materials are much cheaper. 
  
(ii) The predominant nuclear reaction is natZn(p,α)61Cu and the main 
radiocontaminants  arise from the reaction natZn(p,x)66,67,68Ga. That is, only 
one contaminating element is produced. Furthermore, a natural Zn target 
does not need to undergo a recovery process for cost-related reasons. 
  
(iii) Zn targets are commercially available in either foil or powder form.  
 
Figure 1.8 shows the cross sections for natZn target over a proton energy range of 
6.0-18.3 MeV (Uddin, Khandaker, Kim, Lee, & Kim, 2007;   Szelecsènyi et al., 
2005 ; Barrandon et al., 1975).  As Figure 1.9 shows, there are less data available 
for the 64Zn (p,α) reaction, with some variation up to 16 MeV (Levkovskij, 1991; 
Cohen et al., 1954). The 64Zn(d,n+α)61Cu  reaction is another route used for the 
production of 61Cu, with a similar range of particle energies, as shown in Figure 
1.10.  Deuteron energies range from 7.5 to 25.8 MeV.  However, this range is 
unsuitable for production in low- and medium-energy cyclotrons commonly 
found in biomedical institutions, where the ‘rule of thumb’ is that the deuteron 
beam energy is 50% of the proton beam energy from the same machine.  
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Figure 1.8   Experimentally determined excitation function of natZn(p,α)61Cu 
reaction (adapted from EXFOR). 
 
 
 
Figure 1.9  Experimentally determined excitation function of 64Zn(p,α)61Cu 
reaction (adapted from EXFOR). 
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Figure 1.10   Experimentally determined excitation functions of 
64Zn(d,n+α)61Cu reaction (adapted from EXFOR). 
 
1.5.2  Current Methods of Radiochemical Separation of 61Cu 
 
Table 1.3 below summarises the production methods for 61Cu reported in the 
literature (McCarthy et al., 1997; Rowshanfarzad, Sabet, Jalilian & 
Kamalidehghan, 2006; Thieme et al., 2013). McCarthy et al. (1997) used ion 
exchange chromatography to separate the 61Cu from the Ni target material and 
the Co isotopes by-products. Other methods have also been reported for 
separating Cu and Ga from the Zn target materials by cation and anion exchange 
chromatography (Rowshanfarzad et al., 2006; Dasgupta, Mausner, & Srivastava, 
1991; Schwarzbach, Zimmermann, Blaeuenstein, Smith, & Schubiger, 1995; 
Asad et al., 2012). Briefly, the irradiated zinc target was dissolved in 
concentrated hydrochloric acid.  The solution was evaporated to dryness, 
redissolved in concentrated hydrochloric acid and transferred to a cation 
exchange column (AG50W-X8) to separate the 61Cu and Zn target material from 
the Ga isotopes. In the next step, 61Cu was eluted through an anion exchange 
column (AG 1-X8) with 2 M HCl while the Zn remained on the column. 
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Table 1.3   Published cyclotron-derived production methods for 61Cu. 
 
    Reaction Target 
Enrichment 
(%) 
Energy 
(MeV) 
Yield  
(MBq/µAh/mg) 
References 
61Ni(p,n) 99.44 14.7 7.65-14.1   McCarthy et al. 
(1997) 
60Ni(d,n) 99.59 14.7  1.35-2.93 McCarthy et al. 
(1997) 
62Ni(p,2n) 3.63 ≥17.8 - Piel et al. 
(1992) 
natZn(p,α) 99.99 12-22  0.67  Rowshanfarzad 
et al. (2006) 
64Zn(p,α) 99.30 16  0.25-0.47 Thieme et al. 
(2013) 
 
1.5.3  Current Production Methods for 64Cu 
 
64Cu is produced by (p,n) or (d,x) nuclear reactions by cyclotron or (n,γ) and 
(n,p) reactions using a reactor. The decay properties of 64Cu (β+ = 17.4%, β- = 
39.6% and EC = 41%) make it potentially useful in nuclear medicine for PET 
imaging and possibly for molecular radiotherapy (Wadas et al., 2007). Several 
production methods for 64Cu have been published in the literature (Elomaa, 
Jurttila, Rajander, & Solin, 2014; Obata et al., 2003; Szelecsényi et al., 1993; 
Abbas et al., 2006; Tarkànyi et al., 2005; Hilgers, Stoll, Skakun, Coenen, & 
Qaim, 2003; Rebeles, Winkel, Hermanne, & Tàrkànyi, 2009; Zweit, Smith, 
Downey, & Sharma, 1991; Szelecsényi et al., 2005B; Matarrese et al., 2010). 
The most widely used method is the 64Ni(p,n)64Cu reaction leading to high yield 
and high specific activity of the product (McCarthy et al., 1997; Szelecsényi et 
al., 1993).  Table 1.4 summarises potential nuclear reactions and their respective 
yields reported in the literature.   
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64Ni target disks are produced by direct electroplating onto silver or gold target 
foils. The expensive enriched 64Ni can be recovered after irradiation of the target 
during the purification process (Hou, Jacobsen, & Jørgenesen, 2002).  The 
advantages of using the 64Ni(p,n)64Cu reaction are its very high cross section, 
[836.7 mb at 10.6 MeV (Rebeles et al., 2009)] and its very high product specific 
activity (> 370,000 GBq/mmol) which can easily be produced at low proton 
currents. It was also reported that 64Cu may be produced using a zinc target. 
 
Table 1.4  Published cyclotron-derived production methods for 64Cu. 
 
Reaction Target 
Enrichmen
t (%) 
Energy 
Range 
(MeV) 
Yield  
(MBq/µAh/mg) 
Reference 
64Ni(p,n) 94.80 12 → 9  4.5-6.2 Obata et al. 
(2003) 
64Ni(d,2n) 96.48 19 → 15  19.04  Zweit et al. 
(1991) 
64Zn(d,2p) 99.40 19.5 0.40 Abbas et al. 
(2006) 
66Zn(d,α) 99.00 13 → 7 -* Hilgers et al. 
(2003) 
68Zn(p,αn) ≥99.00 35 → 20 -* Hilgers et al. 
(2003) 
* The yield was reported as thick target yield (6.6 MBq/µAh, 65 MBq/µAh for 66Zn(d,α) and 
68Zn(p,αn), respectively. The masses of each target are not reported. 
 
All the reactions presented in Table 1.4 require high target isotopic enrichment to 
suppress contaminating co-produced radionuclides and to optimise yields. They 
can all be perfomed using a standard biomedcial cyclotron with solid targetry 
enhancement. The  major production pathways for 64Cu are considered in more 
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detail below. Figure 1.11 shows the excitation functions for the nuclear reactions 
summarised in Table 1.4. 
 
 
 
Figure 1.11 Experimentally determined excitation functions for different 
nuclear reactions to produce 64Cu (adapted from EXFOR). 
 
1.5.3.1  64Cu Production Using Nickel Targets  
 
1.5.3.1.1   natNi(p,n)64Cu Reaction  
 
Copper-64 has also been produced from the irradiation of natural Ni, using the 
same chemical separation process as the one used for the enriched target 
(Antropov et al., 1992). However, very low yields of 64Cu were obtained, due to 
the low abundance (0.926%) of 64Ni in natural Ni (Table of Nuclides; 
http://atom.kaeri.re.kr/). Furthermore, other isotopes such as 57Co, 58Co and 61Cu 
are also produced from the other naturally abundant Ni isotopes (58Ni 68.077%, 
60Ni 26.223%, 61Ni 1.140%, 62Ni 3.634%, 64Ni 0.926%). An enriched 64Ni target 
is therefore the target of choice for the production of 64Cu with high yield and 
high radionuclidic purity.  
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1.5.3.1.2  64Ni(p,n)64Cu Reaction 
 
Figure 1.12 compares published data on the cross sections of the 64Ni(p,n)64Cu 
reaction.  This is the most efficient and the most widely used reaction for the 
production of 64Cu because it has a wide energy range for production. 64Cu is 
also easily separated from the Ni target (Wadas et al., 2007). Enriched 64Ni (> 
95%) is required as a target material, and is commercially available as a powder 
(metal or metal oxide) from Isoflex and Trace Sciences International. As 
reported previously by Avila-Rodriguez et al. (2007), the optimum proton energy 
for high-yielding production of 64Cu from a 64Ni thin target was 11-12 MeV.  
 
 
 
Figure 1.12  Experimentally determined excitation function of 64Ni(p,n)64Cu 
reaction (adapted from EXFOR). 
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1.5.3.1.3  64Ni(d,2n)64Cu Reaction  
 
The 64Ni(d,2n)64Cu reaction is another route used for the production of 64Cu with 
relatively high yields. As shown in Figure 1.13, deuteron energies ranging from 
5.0 to 9.5 MeV are most suitable and today this is achievable with low to 
medium energy cyclotrons [i.e. 18/9 MeV (protons/deuterons)]. Unfortunately 
65Ni (T1/2= 2.5 h) is co-produced (via a d,p reaction) along with copper and 
cobalt radioisotopes, making this pathway less attractive (Daraban, Rebeles, & 
Hermanne, 2009). 
 
 
 
Figure 1.13 Experimentally determined excitation function of 64Ni(d,2n)64Cu 
reaction (adapted from EXFOR). 
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1.5.3.2  64Cu Production Using Zinc Targets  
 
1.5.3.2.1  natZn(p,x)64Cu Reaction 
 
The proton irradiation of natural Zn target can be used to produce 64Cu at higher 
proton energies (> 25 MeV, Figure 1.14). The natural Zn target possesses the 
advantage of being available in both powder and foil forms and of being much 
cheaper than the enriched targets. However, this reaction produces other 
radionuclides such as 61Cu, 66,67Ga, 57,58Co and 65,69mZn, as well as requiring a 
medium-energy cyclotron.  
 
 
 
Figure 1.14  Experimentally determined excitation function of natZn(p,x)64Cu 
reaction (adapted from EXFOR). 
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1.5.3.2.2  68Zn(p,n+α)64Cu Reaction  
 
There are only two published data of this reaction. However, they are in marked 
disagreement (see Figure 1.15) . The most useful energies for this reaction lie 
between 10 and 35 MeV. The production of 64Cu from this reaction is not 
recommended due to the low measured cross sections.  
 
 
 
Figure 1.15 Experimentally determined excitation function of 68Zn(p,n+α)64Cu 
reaction (adapted from EXFOR). 
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1.5.3.2.3  64Zn(d,2p)64Cu Reaction  
 
The excitation function of the 64Zn(d,2p)64Cu reaction is higher than the 
excitation functions of other isotopic Zn targets with a maximum cross section of 
65.5 mb at 15.5 MeV (see Figure 1.16) (Williams & Irvine, 1963). However, this 
reaction produces lower yields of 64Cu than that produced via the 64Ni(d,2n)64Cu 
and the 64Ni(p,n)64Cu reactions, and requires a relatively high energy deuteron 
(i.e. up to 16 MeV). 
 
 
 
Figure 1.16  Experimentally determined excitation function of 64Zn(d,2p)64Cu  
reaction (adapted from EXFOR). 
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1.5.3.2.4  66Zn(d,α)64Cu Reaction  
 
The 66Zn(d,α)64Cu reaction has a maximum cross section of 28 mb at 11 MeV 
deuteron energy (see Figure 1.17). The best energy deuterons for this reaction are 
between 7-13 MeV. Although enriched 66Zn is much cheaper than enriched 64Ni. 
However, 64Ni is still preferred in most sites due to its relatively high reaction 
cross section with a proton beam (Hilgers, Qaim, & Coenen, 2004). 
 
 
 
Figure 1.17  Experimentally determined excitation function of 64Zn(d,α)64Cu 
reaction  (adapted from EXFOR). 
 
1.5.4  64Cu Target Preparation  
 
Natural foils such as 89Y and 45Sc used for the production of 89Zr and 45Ti, 
respectively are commercially available. Foils of enriched 64Zn for the 
production of  61Cu are also commercially available (Asad et al., 2014; Holland, 
Sheh, & Lewis, 2009; Sadeghi, Enferadi, & Nadi, 2011). However, in the case of 
64Cu, enriched nickel foils are not readily available, and electroplating with 
enriched 64Ni is required for target preparation. Several methods are reported for 
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electroplating nickel or zinc for the production of 64Cu, depending on the energy 
and the beam used (Matarrese et al., 2010; Kim, Park, & Chun, 2001; Manrique-
Arias & Avila-Rodriguez, 2014). Electroplating of enriched 64Ni on a gold foil 
was reported by McCarthy et al. (1997). Nickel oxide was first dissolved in 6 M 
nitric acid and evaporated to dryness prior to the addition of concentrated 
sulphuric acid, dilution with water and further evaporation to dryness. The 
residue was diluted with water, adjusted to pH 9 with ammonium hydroxide and 
then used for electroplating of the Ni onto a gold foil using a graphite or 
platinum electrode. 
 
 
 
Figure 1.18  One-cm diameter layer of 64Ni plated onto gold foil. 
 
1.5.5  Current Methods for Radiochemical Separation of 64Cu 
 
Several methods such as ion exchange chromatography, solvent extraction, 
electroplating and precipitation have been described for the separation of 64Cu 
from 64Ni and other isotopic impurities (i.e. 61Co, 55Co, 57Co, 60Cu and 61Cu) 
produced during irradiation of the target (Hou et al., 2002). Ion exchange 
chromatography is considered to be the best method used for no-carrier-added 
64Cu (Manrique-Arias & Avila-Rodriguez, 2014; McCarthy et al., 1997. Briefly, 
the irradiated enriched 64Ni target is dissolved in concentrated hydrochloric acid.  
The solution is evaporated to dryness, redissolved in concentrated hydrochloric 
acid and transferred to an anion exchange column (AG1-X8). The 64Ni target 
material and Co isotopes are eluted with 6 M HCl while most of the 64Cu 
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remains on the column. The desired 64Cu is then eluted from the ion exchange 
column with 0.1-0.5 M HCl with efficiencies ranging 90-95% depending on the 
volumes used (Avila-Rodriguez et al., 2007; McCarthy et al., 1997). Hou et al., 
2002, reported 64Cu separation by ion exchange chromatography using low (0.3 
M) concentration of HCl in ethanol solution (72%) to separate Ni and Co from 
Cu ion. In the last step, the Cu is finally eluted with water (Figure 1.19). 
Watanabe et al. (2009) developed a new method of 64Cu separation using a 
chelating resin bearing iminodiacetic acid groups. Briefly, Ni and Co ion were 
eluted off the column with 0.1 M HCl and 64Cu was eluted with 2 M HCl with 
radiochemical purity over 99%.  
 
Figure 1.19  Separation of Cu, Co and Ni by ion exchange column (1.0 cm × 
12 cm), elution of Ni and Co with 28 mL of 0.3 M HCl in ethanol 
solution (72%), followed by elution of Cu with 18 mL of water 
(adapted from  Hou et al., 2002).  
 
1.5.6  Specific Activity of Final Product 
 
The concentration of a radioactive isotope in a sample in comparison with the 
total ‘cold’ mass of element to which that isotope belongs is described by the 
“specific activity” and is expressed as radioactivity per total elemental mass (e.g. 
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Bq/mol, GBq/µmol). The specific activity of (say) 64Cu in a solution can be 
determined experimentally. For example, measurement of the 64Cu radioactivity 
compared with the total Cu content can be performed by titration with a chelator 
(i.e. TETA) as described by McCarthy et al. (1997), this yields the effective 
specific activity. ICP-MS is a more direct way to measure the specific activity 
precisely by determining the Cu ion concentration in the final 64Cu solution 
(Jeffery et al., 2012; Mastren et al., 2014).  If the radioisotope of atomic number 
Z is separated and purified from a bombarded target containing no isotopes with 
the same Z (as for the 64Ni(p,n)64Cu reaction)  this determination is known as the 
no-carrier-added specific activity. 
 
1.6  Bifunctional Chelators for Cu Isotopes 
 
Bifunctional chelators (BFCs) that form kinetically stable radiometal complexes 
are required for bioconjugation of the radiometal to targeting molecules (i.e. 
peptide, protein or nanoparticles) used in PET and targeted radiotherapy (De 
Silva et al., 2012; Cooper et al., 2012). Many types of chelators have been used 
for complexing Cu, as illustrated in Figure 1.20. 
 
Acyclic chelating agents such as ethylenediamine tetraacetic acid (EDTA) and 
diethylenetriamine pentaacetic acid (DTPA) were initially used as chelators for 
Cu2+ complexes. However, though possessing high thermodynamic stability, 
their low kinetic stability prevented them from being used in vivo (Moi, Keares, 
McCall, Cole & De Nardo, 1985). Due to the acyclic nature of these chelators, 
their complexes are kinetically labile and suffer transchelation in the presence of 
competing species in solution. A series of BFCs that are derivatives of the 
macrocyclics 1,4,7,10-tetra-azacylcododecane-N,N′,N″,N′″-tetraacetic acid 
(DOTA) and 1,4,8,11-tetraazacyclotetra decane-N,N′,N″,N′″-tetraacetic acid 
(TETA) have been developed for the  complexation of Cu isotopes. These 
macrocyclic chelating agents form complexes with Cu2+ that are kinetically more 
inert compared to Cu2+- EDTA and Cu2+- DTPA. However, they still have 
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limitations with regards to in vivo stability and slow formation rates of their 
complexes (Boswell et al., 2004), which can result in high uptake of activity by 
non-target organs such as the liver (Rogers et al., 2003; Rogers, Della Manna, & 
Safavy, 2004). Previous studies have demonstrated the high stability of the 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA) Cu2+ complex and described 
NOTA as a BFC of choice for labelling 64Cu (Craft  et al., 2012 ; Dearling  et al., 
2011). Other types of chelators include hexa-aza cages such as 3,6,10,13,16,19-
hexaazabicyclo[6.6.6]eicosane-1,8-diamine pentahydrate (diamsar, (e)) and 1-N-
(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]eicosane-1,8-diamine 
(SarAr-NH2, (f)), which form Cu2+ complexes that are both kinetically and 
thermodynamically stable.  They can complex Cu isotopes rapidly, at room 
temperature, over pH ranges 4 to 9 and at low concentrations (µM) (Smith, 
2004).  
 
 
 
Figure 1.20 Structures of some chelators used for complexing Cu2+. (a) 
EDTA, (b) DTPA, (c) NOTA-NCS, (d) DOTA-NCS, (e) diamsar 
and (f) SarAr-NH2. 
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Figure 1.21  Schematic diagram of the role of bifunctional chelators (BFCs), 
which bind the radiometal at one terminus and contain a 
functional group at the second terminus for the covalent linkage to 
a target. The choice of BFC is determined by the donor groups 
present, the metal preferred coordination geometry and the metal’s 
oxidation state.  
 
1.7  Overview of Nanoparticles in Medicine  
 
Cancer is a leading cause of death around the world. The World Health 
Organisation estimated that 84 million people died of cancer between 2005 and 
2015. For effective cancer therapy, it is necessary for researchers to improve 
their knowledge of cancer physiopathology, discover new anti-cancer drugs and 
develop novel biomedical technologies. Currently, cancer therapy and diagnosis 
has become a multidisciplinary challenge requiring close collaboration among 
clinicians, biological and materials scientists, and biomedical engineers. 
Nanomedicine (using targeted functional nanoparticles) is a promising avenue 
for cancer diagnosis and therapy. There is a wide variety of nanoparticles (NPs) 
with diameters ranging between 1-1000 nm. Drugs may be encapsulated, 
adsorbed or dispersed in these NPs. NPs can vary in size, shape and chemical 
structure (liposomes, polymeric NPs, micellar NPs, albumin-based particles, 
inorganic or other solid particles (gold, iron oxide, quantum dots and carbon 
nanotubes). They have been extensively studied as carriers for molecules 
(targeting tracers or drugs) aimed at diagnosis and targeted therapy of cancers 
(Xiao et al., 2011; Miteva et al., 2015; Eloya et al., 2014; Rao, Gruenberga, & 
Targeting Molecules  
(i.e., peptides,  
nanoparticles
Covalent Linkage 
Radioactive Metal Ion 
Bifunctional Chelator 
 Molecules  
 Peptides or  
N rticles) 
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Gecklera, 2015; Hanafi-Bojd et al., 2015; Krishnaraj, Muthukumaran, 
Ramachandran, Balakumaran, & Kalaichelvan, 2014).  
 
In this section, a brief overview of the different types of NPs used in medicine is 
given. The key characteristics of NPs (size, charge, and coating) will then be 
discussed. Finally, the EPR effect will be introduced and the principles of 
passive and active targeting will be discussed. 
 
1.7.1  Overview of the Different Types of Nanoparticles 
 
Several nanomaterials have already been identified and have made strong 
contributions in biomedicine for preclinical and clinical use.  Some examples are 
shown schematically in Figure 1.22.  The work described later in this thesis will 
focus exclusively on inorganic silica nanospheres (Si NS) and polystyrene 
nanospheres (PS NS).  
 
 
 
 
Figure 1.22 schematic representations of inorganic and organic types of 
nanoparticles for the construction of radiolabelling materials 
(Xing, Zhao, Conti, & Chen, 2014). 
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1.7.1.1  Polymeric Nanoparticles  
 
The polymeric nanoparticles (10-1000 nm) are prepared from biocompatible and 
biodegradable polymers where the drug is dissolved, entrapped, encapsulated or 
attached to a nanoparticle matrix. Depending on the process used for their 
preparation, two different types of nanoparticles can be obtained: nanospheres 
and nanocapsules. Nanospheres have a matrix-type structure in which a drug is 
dispersed, whereas nanocapsules exhibit a membrane-wall structure with a core 
containing the drug (Kumari, Yadav, & Yadav, 2010; Soppimath, Aminabhavi, 
Kulkarni, & Rudzunski, 2001; Mohanraj & Chen, 2006). Because these systems 
have very high surface areas, drugs may also be adsorbed on their surfaces. 
Polymeric nanoparticles (P NPs) are widely used in areas such as environmental 
technology, sensors, conducting materials and medicine (Brahim, Narinesingh, 
& Elie, 2001; Zhang & Chuang, 2001). For example, polystyrene nanoparticles 
(PS NPs) are used as hydrophobic encapsulation materials in biomedical 
applications (Singer, 1987). These inexpensive, hydrophobic polymers allow 
physical adsorption of antibodies or proteins. These types of nanoparticles can 
also be functionalised on their surface with carboxylic groups that enable 
covalent binding of antibodies or proteins. 
 
Polymers and biopolymers are favoured to increase the biocompatibility of a 
nanomaterial as well as to increase their lifetime in blood. In that respect, coating 
with polyethylene glycol (PEG) is the principal strategy to obviate or at least 
delay the action of the body’s natural defenders. This is because macrophages 
and complement proteins need more time to detect the neutral polymer.  
 
1.7.1.2  Inorganic Nanoparticles  
 
Many types of inorganic NPs have been developed as nanoprobes for imaging 
and therapy applications (e.g. semiconductor, metal, metal-oxide and lanthanide-
doped NPs). This section briefly describes silica nanoparticles (Si NPs), which 
were studied in this work.  
38 
 
1.7.1.2.1  Silica Nanoparticles  
  
Silica nanoparticles (Si NPs) have received much attention because of their 
practical importance in a variety of plastic, construction composite, drug 
delivery, and theranostic applications (Santra, Zhang, Wang, Tapec, & Tan, 
2001; Jain, Roy, De, & Maitra, 1998; Tolnai et al., 2001; Shibata, Tanighuchi, 
Yano, & Yamane, 1997, Van Helden, Jansen, & Vrji, 1980; Butterwort, Illum, & 
Davis, 2001; Liu & Chen, 1999; Chen, 1998). Si NPs are produced by the sol-gel 
process (Stöber method) (Stöber, Fink, & Bohn, 1968; Patra et al., 1999; Achatz, 
Heiligtag, Li, Link, & Wolfbeis, 2010) or by reverse microemulsion (water-in-
oil, W/O) (Wang et al., 2009; Ke, Yang, Xia, Xu, & Li, 2010; Ye, Tan, Wang, & 
Yuan, 2005). A sol-gel process requires precursors in solution that react with 
water and yield an oxide network through inorganic polymerisation (Figure 
1.23). Typical precursors are metallo-organic compounds such as metallic 
alkoxides M(OR)n, where M is a metal or metalloid (titanium, zirconium, 
aluminium, silicon, etc.) and R is an alkyl group (methyl CH3, ethyl C2H5, etc.). 
Silica is one of the most studied metals of the sol-gel process, because of the 
lower costs of its precursors and the greater flexibility of silica chemistry. 
Tetramethoxysilane (TMOS) Si–(OCH3)4 and tetraethoxysilane (TEOS) Si–
(OC2H5)4 are the most common silicon precursors (Schubert, Husing, & Lorenz, 
1995). Figure 1.23 shows the synthesis silica nanoparticles by sol-gel process.   
 
In the reverse microemulsion method, monodispersed core/shell silica 
nanoparticles (C/S-Si NPs) can be easily constructed with a controllable size. 
Tang, Li, & Chen (2012) investigated how the amount of ammonium hydroxide, 
surfactant, tetraethyl orthosilicate (TEOS), H2O and reaction time affects the size 
of Si NPs. They found that the size of the dye-doped Si NPs was reverse-
proportional to the concentration of ammonium hydroxide and water to 
surfactant molar ratio, but directly-proportional to the amount of TEOS and 
reaction time. Zhao, Trewyn, Slowing, & Lin (2009) found that they could affect 
the surface area occupied by surfactant molecules by varying the organic 
solvents, while the diameter of  the water droplet could be increased with the 
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length of the organic molecule (Bagwe, Yang, Hilliard, & Tan, 2004; Jin et al., 
2008). Silica nanoparticles are being considered for several biomedical 
applications due to their biocompatibility, low toxicity, and scalable synthetic 
availability (Liberman, Mendez, Trogler, & Kumme, 2014). In recent years, Si 
NPs have been used for in vitro and in vivo diagnosis, analysis, and 
measurements inside intact biological systems (e.g. tissues, blood, and single 
cells). Along with the use of nanoparticle devices, they have attracted 
considerable attention (Jain et al., 1998; Tolnai et al., 1998; Butterworth et al., 
2001; Gruttner & Teller, 1999). 
 
 
 
Figure 1.23  Flow chart of a typical sol-gel process (adapted from Rahman & 
Padavettan,   2012). 
 
1.7.2  Key Characteristics of Nanoparticles 
 
1.7.2.1  Particle Size  
 
The size of the particles is an important factor in determining the performance of 
nanoparticles systems in vitro as well as in vivo. It has an advantage for 
delivering NPs drugs, allowing direct injection into the systemic circulation 
without the risk of blocking blood vessels (Letchford & Burt, 2007; Gref et al., 
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1995; Douglas, Davis, & Illum, 1987). The circulation time of NPs can be 
increased by the inclusion of surface bound hydrophilic molecules such as 
polyethylene glycol (PEG) (Gref et al., 1994; Klibanov, Maruyama, Torchilin, & 
Huang, 1990). These NPs can cross tumour mass barriers and become 
preferentially retained within target cells via the enhanced permeability and 
retention (EPR) effect (Maeda, 2012; Maeda, Bharate, & Daruwalla, 2009; 
Torchilin, 2004; Ernsting, Murakami, Roy, & Li, 2013). The conditions used for 
the preparation of the particles highly affect their size (Lu, Wu, Hung, & Mou, 
2009; Pan et al., 2012; Rossi, Shi, Quina, & Rosenzweig, 2005). NPs size may 
affect the active or passive uptake efficiency, kinetics and subcellular 
distribution. A size-dependent uptake in different cell lines has been observed for 
gold NPs (Wang, Lee, Chiou, Wei, 2010), mesoporous Si NPs (Lin & Haynes, 
2010), and PS NPs (Varela, Bexiga, Åberg, Simpson, & Dawson, 2012) with 
maximum cellular uptake for core sizes in the range of 30-50 nm. For active 
uptake, Rejman, Oberle, Zuhorn, & Hoekstrta (2004) used a range of latex beads 
sizes (50-1000 nm) to investigate the size effects on the entry pathway in non-
phagocytic B16 cells. They found beads with diameters less than 200 nm were 
optimum for targeting this pathway. Mironava, Hadjiargyrou, Simon, 
Jurukovski, & Rafalovich (2010) reported that 45 nm gold NPs penetrated cells 
via clathrin-mediated endocytosis, while the smaller 13 nm NPs entered mostly 
via phagocytosis.  
 
In addition to active transport, NPs may also enter cells by passive penetration of 
the cell membrane. In fact, for cells lacking the endocytosis machinery such as 
red blood cells (RBCs), passive transport is the only option (Shang, Nienhaus, & 
Nienhaus, 2014). Geiser et al. (2005) analysed the uptake of PS NPs by red 
blood cells (RBCs) and found that particles less than 200 nm entered the RBC 
most effectively. Table 1.5 lists particle sizes, their interactions with biological 
systems, and some examples of applications. 
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Table 1.5  Impact of particle size on interaction with biological systems 
(adapted from Bae & Park, 2011) 
 
Particle size Biological Impact 
4.5 nm Abundant small pores present in normal tissue endothelium 
25 nm Relatively few large pores present in normal tissue endothelium 
20-50 nm Average size of polymeric micelles without loaded drugs 
100 nm Frequently tested size of drug-loaded polymer micelles 
150 nm Proposed cut-off size for particle extravasation in liver. Liver has 
blood vessels with fenestrations of 100-175 nm 
200 nm Nanoparticles less than 200 nm have significantly longer circulation 
time due to low uptake by the reticuloendothelial system (RES) 
380 nm A tumour-dependent functional pore cut off size ranges from 200 nm 
to 1.2 µm, but the pore cut off size of porous blood vessels in the 
majority tumours is known to be 380-780 nm.  Therefore, the range 
for using the EPR effect should be similar.  
400 nm Sterically stabilized liposomes of 400 nm in diameter were able to 
penetrate into tumour interstitium. Accumulation of hyaluronic acid-
coated nanoparticles (400 nm) in tumour tissue 
500 nm The maximum size of nanoparticles allowing penetration through 
cell membranes is known to be 500 nm 
1 µm Particles below 1 µm were taken up by Peyer’s patches and then 
migrated to mesenteric lymph nodes 
5 µm The upper limit for rigid particles circulating within the smallest 
capillaries  
40 µm Particles larger than 40 µm haven been used for embolization therapy 
 
1.7.2.2  Surface Charge  
 
The surface of NPs can be net negatively, positively or neutrally charged with or 
without further modification, depending on the type of NPs. It has been reported 
that surface charge is a very important factor for determining the efficiency and 
mechanism of cellular uptake, and the in vivo fate of NPs (Osaka, Nakanishi, 
Shanmugam, Takahama, & Zhang, 2009; Juliano & Stamp, 1975; He, Hu, Yin, 
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Tang, & Yin 2010; Chung et al., 2007). For example, Si based NS are usually 
negatively charged because of the presence of the hydroxyl group after 
hydrolysis of TEOS. It is possible to modify the charge of these particles by 
functionalising them with amine, carboxyl or PEG by hydrolysis of the 
corresponding silanes (Wu, Wu, & Zhao, 2014). When nanoparticles with 
hydrophobic surfaces are administered they are recognised easily by lymphatic 
cells in the body as foreign substances. To circumvent this problem, the surface 
of the nanoparticles is often modified with a hydrophilic polymer, which acts as 
a shield between NPs and lymphatic cells (Nishioka & Yoshino, 2001).  Surface 
properties of NPs can be measured by various methods (e.g. zeta potential, x-ray 
photoelectron spectroscopy and column chromatography). These methods are 
used to estimate the surface charge, density or surface hydrophilicity of the 
functional groups. For example, the zeta potential provides information 
regarding the ionic nature of carrier particles: a zeta potential of -30 mV 
indicates a strongly anionic nature. Zeta potentials between +10 and -10 mV 
indicate neutral behaviour, and zeta potentials over 30 mV indicate a cationic 
nature (Clogston & Patri, 2011). To avoid the aggregation of the particles, those 
with a zeta potential in the range ± 30 mV have been shown to be more stable in 
suspension (Selvaraj, Karthikeyan, & Saravanakumar, 2012). 
 
1.8  Polyethylene glycol (PEG) 
 
Polyethylene glycol (PEG)-coated nanoparticles have attracted interest since they 
have shown increased circulation time and reduced reticuloendothelial system 
uptake compared to non-PEGylated nanoparticles after intravenous 
administration (Gref et al., 1994; Bazile et al., 1995; Gref, Couvreur, Barratt, & 
Mysiakine, 2003; Moghimi & Szebeni, 2003; Vonarbourg, Passirani, Saulnier, & 
Benoit, 2006). Nanoparticles modified with PEG possess favourable intrinsic 
physicochemical properties (e.g. high flexibility, hydrophilicity, low toxicity and 
immunogenicity), and have been found to reduce nanoparticle accumulation in 
organs such as liver and spleen (Knop, Hoogenboom, Fischer, & Schubert, 
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2010). The shape, density and length of PEG chains attached to nanoparticles 
have an effect on surface hydrophilicity and phagocytosis (Gref et al., 2000). For 
example, long PEG chains increase the size of nanoparticles and would create 
more effective blocking than small PEG chains (Vonarbourg et al., 2006). PEG 
surface coating can counteract the hydrophobic and electrostatic interactions 
between NPs and plasma proteins or macrophages, resulting in a reduction in 
reticuloendothelial system (RES) uptake and prolonged blood circulation time 
(Zahr, Davis, & Pishko, 2006). 
 
1.9  EPR Effect and Principle of Passive and Active 
Targeting 
 
1.9.1  Enhanced Permeability and Retention (EPR) Effect  
 
The main tumour-targeting principle of many drug delivery systems is based on 
the EPR effect of NPs first proposed by Maeda, Ueda, Morinaga, & Matsumoto 
(1985) and Matsumura & Maeda, (1986) who observed that macromolecules 
such as polymers and proteins with molecular weight larger than 40-50 kDa 
showed selective accumulation in tumour tissues (far more than that observed in 
normal tissues) and that they were retained in tumour tissues for long periods, 
i.e. > 24 h. This was attributed to the Enhance Permeability and Retention (EPR) 
effect. EPR effect is a phenomenon resulting from the unique anatomical and 
pathophysiological characteristics of solid tumours. Most solid tumours show a 
higher vascular density (hypervascularity) compared to normal tissues and 
organs.  
 
Irregular or inconsistent blood flow is also commonly observed in tumours, and 
most solid tumours have blood vessels with defective architecture, such as large 
gaps between endothelial cells (e.g. ~ 1 µm) plus a lack of smooth muscle layers. 
As a result, macromolecules will have the opportunity to escape from tumour 
blood vessels and accumulate selectively in tumour tissues, in a manner which 
would otherwise not be possible in normal blood vessels. Although the main 
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factor influencing the EPR effect is the particle size (> 40 kDa), biocompatibility 
and surface charge are also key factors in the EPR effect (Maeda, Nakamura, & 
Fang, 2013). Ideally, the chosen nanomedicinal or macromolecular drug should 
present no interaction with blood components or blood vessels, no antigenicity, 
no RES clearance and no cell lysis. Positively charged polymeric drugs will tend 
to bind non-specifically to the luminal surface of the vascular walls, which are 
negatively charged, and then are rapidly cleared from the blood circulation.  
Negatively charged particles, however, will result in blood coagulation. Weakly 
negative to near neutral particles are ideal for the use of the EPR effect in 
nanomedicine 
 
Table 1.6 Ideal Characteristics of the EPR effect of nanomedicines and 
macromolecular drugs (adapted from Maeda et al., 2013).  
  
Drug Characteristic Ideal Properties 
Biocompatibility No interaction with blood components or 
blood vessels, no antigenicity, no 
clearance by the reticuloendothelial 
system, no cell lysis. 
Molecular size Larger than 40 kDa (larger than the renal 
clearance threshold) 
Surface charge Weakly negative to near neutral  
Time required to achieve Longer than several hours in systemic 
circulation in mice, with distinct 
accumulation seen at 30 min 
Drug retention time Usually days to weeks, in great contrast 
to passive targeting, in which low-
molecular-weight molecules are rapidly 
cleared and enter the systemic circulation 
in a few minutes (compare with low-
molecular-weight contrast agents). 
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1.9.2  Passive Targeting of Tumours  
 
The most common type of passive tumour targeting is targeting by the EPR 
effect. It can be observed in almost all human cancers with the exception of 
hypovascular tumours such as prostate cancer or pancreatic cancer (Maeda et al., 
2009), and is applicable in almost all rapidly growing solid tumours 
(Dobrovolskaia & McNeil, 2007). The desired particle size of NPs is designed to 
be around 10-100 nm to allow NPs to extravasate from defects in tumour 
vasculature (Phillips, Gran, & Peppas, 2010). The nanocarrier’s size should be 
more than 10 nm to avoid glomerular filtration by the kidneys, and less than 100 
nm to avoid specific capture by the liver and RES clearance (Xing et al., 2014). 
Generally, when NPs are administered intravascularly, most are removed by the 
cells of the RES while only a small fraction of NPs will reach the tumour 
(Maeda, Sawa, & Komo, 2001). This is why, for optimal EPR effect, NPs should 
be less than 100 nm, and their surfaces should be biocompatible (i.e. hydrophilic 
and almost neutral in electric charge) to minimise RES clearance.  
 
 
 
 
 
 
 
 
 
 
Figure 1.24  Passive targeting by EPR effect: NPs can be passively 
extravasated through leaky vascularisation, leading to their 
accumulation at the tumour region.  
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1.9.3  Active Targeting of Tumours 
 
Active targeting consists of coupling a ligand to the surface of NPs that can 
interact with its specific receptor at the target cell site (Danhier et al., 2009), 
which occurs only after blood circulation and extravasation. The ligand is chosen 
to bind to a receptor overexpressed by tumour cells or tumour vasculature and 
not to various receptors expressed by normal cells. Representative ligands 
include antibodies, proteins, peptides, nucleic acids, sugars, and small molecules 
such as vitamins (Saha et al., 2010). The interaction of the ligand-functionalised 
NP systems with its target is enhanced by the multivalent nature of the NP’s 
architecture. Multiple copies of the ligand on the NP surface will increase the 
avidity of the NP for its target (Wang et al., 2010). When evaluating the 
efficiency of an active-targeting system, there are two important factors to 
consider; the targeting specificity and the delivery capacity. The targeting 
specificity is determined by the biodistribution of the ligand-functionalised NPs 
and by how the conjugated ligand and the NPs system interact with off-target 
molecules and cells. It is defined by both the ligand and the NP’s properties. The 
delivery capacity is related to the NP’s material and structure (Kamaly, Xiao, 
Valencia, Radovic-Moreno, & Farokhzad, 2012). 
 
 
 
 
 
 
 
 
Figure 1.25  The delivery of NPs to the tumour. Some of the NPs circulating in 
blood accumulate at the tumour region through the EPR effect. If 
for example, the NPs possess a chelator to a specific marker on 
tumour cells, specific chelator–receptor interactions can occur. 
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1.10  Aims 
  
The aims of this thesis, as linked to successive chapters are: 
 
Chapter 2 
 
• To measure precisely the primary proton beam energy of an isochronous 
auto-extraction cyclotron to ensure optimum production of radioisotopes 
using solid targetry. This section was focused on the development of a 
simple and practical method for cyclotron beam energy measurement, 
avoiding the use of complex analytical methods or an array of energy-
specific degraders. This method was also used subsequently to evaluate a 
custom degrader constructed to reduce the 18 MeV proton beam to the 
optimal energy for the thin-target production of the desired isotopes. 
 
Chapter 3 
 
• To determine the excitation functions of the accessible natZn (p,x) 
reactions  using a high purity natural-zinc target and proton energies up to 
17.6 MeV, delivered by an IBA 18/18 MeV cyclotron with an in-house 
designed solid targetry system.  
 
Chapter 4 
 
• To evaluate methods for the separation and purification of 61Cu produced 
from enriched 64Zn target or natZn target. To develop a chemically novel 
and cost effective separation process that may be applied in routine 
production, which yields the highest purity final product. This also 
involved the assessment of three different chelators NOTA-NCS, DOTA-
NCS and the macrobicyclic sarcophagine diamsar for determining the 
effective specific activities of replicated 61Cu productions, and the 
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comparison of these values with the NCA specific activities obtained 
from ICP-MS analysis. 
 
Chapter 5 
 
• To radiolabel functionalised polystyrene and silica nanospheres with 
64Cu, 57Co or 61Cu and determine the most effective bifunctional chelator 
from the group SarAr-NH2, NOTA-NCS, DOTA-NCS and MeSar-Ph-
NCS for this purpose. MeSar-Ph-NCS is a novel macrobicyclic 
sarcophagine developed recently by collaborators of our laboratory. 
 
Chapter 6 
 
• To evaluate the stabilities and some physical properties of 61Cu labelled 
silica nanosphere complexes, where radiolabelling is achieved using three 
separate bifunctional chelators; NOTA-NCS, DOTA-NCS and MeSar-
Ph-NCS. The in vivo biodistributions of these complexes would then be 
studied comparatively at two time-points in an immunodeficient mouse 
model using µPET/CT and post-imaging dissection plus γ-counting.  
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CHAPTER TWO  
PRECISE MEASUREMENT OF CYCLOTRON BEAM 
ENERGY 
 
A version of this chapter was published in: 
 
Asad, A.H., Chan, S., Cryer, D., Burrage, J.W., Siddiqui, S.A. & Price R.I. 
(2015). A New, Simple & Precise Method for Measuring Cyclotron Proton Beam 
Energies Using the Activity vs. Depth Profile of Zinc-65 in a Thick Target of 
Stacked Copper Foils. Applied Radiation and Isotopes, 105, 20-25. 
 
2.1  Introduction  
 
It is periodically important to precisely measure the primary beam energy of a 
cyclotron; for example, following alterations to components controlling the 
beam, for research applications including measurement of reaction cross 
sections, or to optimise the yield of a particular isotope while suppressing the 
production of co-produced ‘contaminating’ radionuclides (Gagnon et al., 2011; 
Asad et al., 2014; Kim, Park, Kim, Lee, & Chun, 2006).  
 
This is particularly relevant when producing the radiometal 64Cu from the 
64Ni(p,n)64Cu reaction, as a proton beam energy of 11.5-12 MeV is specifically 
and precisely selected  to avoid the production of 61Co, because at this energy, 
the yield of the side-reaction 64Ni(p,α)61Co is significantly reduced (Avil-
Rodriguez et al., 2007). To accurately degrade the proton energy to the desired 
value, a good knowledge of the primary beam energy is required in order to 
calculate the appropriate thickness of material (e.g. copper, graphite, or 
aluminium) used to degrade the beam.  These stopping power calculations are 
conducted using industry software such as Stopping and Range of Ions in Matter 
(SRIM) software (Ziegler, Ziegler, & Biersack, 2011).  
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In the current work an IBA isochronous 18/9 cyclotron is used.  The IBA 
isochronous 18/9 (or 18/18 in its proton-only beam mode) cyclotron (Ion Beam 
Applications, Belgium) accelerates negative hydrogen ions (H-) extracted from 
its ion source up to a nominal energy of 18 MeV, with a maximum extracted 
current of 150 µA. The circulating beam experiences a magnetic field that varies 
harmonically with orbit azimuth, resulting in a non-circular beam path, unlike in 
an idealised classical cyclotron (Strijckmans, 1994). Consequently, it is difficult 
to calculate the beam energy of an isochronous cyclotron from knowledge of the 
magnetic field strength and nominal beam orbit diameter alone (more details are 
given in Section 1.3 in the previous chapter). 
 
Conventional cyclotrons used for medical PET radionuclide productions usually 
do not include apparatus for direct beam energy measurements, such as those 
based on time-of-flight principles or by use of magnetic energy analysers 
(Kormány, 1994; Chêne, Garnir, Marchal, Mathis, & Stivay, 2008). Therefore, 
several indirect methods have been devised to sample the energy of the beam 
following its extraction from the cyclotron, using one or two nuclear reactions in 
a target containing high-purity metal foils of precise thicknesses. The cross 
sections of these ‘monitor’ reactions, which are usually chosen from the group 
natCu(p,x)62,63,65Zn to cover useful proton irradiation energies up to 19 MeV, are 
well documented and intended for comparison purposes (IAEA, 2009).  One of 
these methods requires measurement of the ratio of activities of 62Zn to 65Zn co-
produced in the same monitor foil. This ratio is then used to determine the ratio 
of the respective cross sections of these isotopes at the sampled energy in the 
foil.  In turn, this calculation is compared with the ratio of cross sections as a 
function of energy from published data, and therefore the beam energy can be 
determined provided that it falls within the monotonic section of this calibration 
curve. Though the method requires a gamma energy detector calibrated with 
standard sources (since it requires the measurement of the activities of two 
isotopes) it does not need a direct measurement of beam current on the target 
(Kopecky, 1985). 
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  Another method uses activity measurements from only one monitor reaction 
and requires neither calibrated gamma-spectroscopy nor knowledge of beam 
current.  In this process, two monitor foils are bracketed by aluminium energy-
degraders of precise thickness; one specific degrader for each contiguous energy 
segment comprising the measureable energy range.  The activity of 63Zn from the 
natCu(p,x)63Zn reaction is measured in each foil and its ratio between the foils 
(reflecting different mean beam energies in the foils) is used to calculate the 
equivalent ratio of cross sections (Gagnon et al., 2011).   
 
This study reports an extension of the method of Burrage et al. (2009) which 
utilises the 65Cu(p,n)65Zn monitor reaction to measure energies below and 
beyond the nominal energy of the proton beam of the cyclotron. The technique 
requires neither a direct beam-current measurement nor gamma-spectroscopy 
efficiency calibration with standard sources; though a characteristic reaction 
photopeak must be identified. Briefly, the method employs the well-known 
stacked foil technique (Qaim, 1982) in a ‘thick target’ configuration, to sample 
an interval of the well-characterised monitor reaction excitation function. This is 
combined with an iterative method (using ‘incident beam energy’ as the 
regression variable) for achieving congruence of the experimental and calculated 
65Zn activity vs. depth profiles in the target stack. The technique exploits the 
uniqueness of the shape of the activity profile vs. depth of the monitored isotope 
in the target stack for specified incident energy.  It represents the uniqueness of 
the sampled section of the reaction cross-section, but does not require the entire 
cross section to be sampled.   
 
In summary, the proposed method is based on a comparison of the normalised 
profile of activities measured in the monitor-foil stack with the calculated 
normalised profile derived using the published monitor-reaction excitation 
function.  Since the latter profile depends on the assumed starting energy of the 
beam, that energy is adjusted iteratively until the experimental and theoretical 
values agree.  
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In this work the method was used to measure the primary beam energy before 
and after a scheduled cyclotron upgrade. This upgrade comprised a change of 
configuration (from18/9 proton/deuteron to 18/18 proton/proton configuration) 
as well as upgrades to beam generation and (nonmagnetic) control components 
of the IBA cyclotron at the Department of Medical Technology and Physics, Sir 
Charles Gairdner Hospital (Perth, Australia).  The same method was also used to 
validate a custom-designed water-cooled graphite degrader to reduce the primary 
beam energy to 11.6 MeV at the target face, which was required for routine 
production of both 89Zr and 64Cu using an in-house designed solid-targetry 
system. 
 
2.2  Materials and Methods  
 
2.2.1  Targetry and Irradiation 
  
Natural-Cu foils (natCu; 99.99% chemical purity; 69.15% 63Cu, 30.85% 65Cu) of 
diameter 25 mm and nominal thicknesses 25, 50, 75 and 100 μm were used as 
the target materials (Goodfellow, Huntington, UK). The mean thickness of each 
foil was calculated from its density prior to irradiation by measuring its diameter 
and weight, and it was this measurement that was used for thickness calculations 
rather than the nominal value. For each independent experiment (indexed by foil 
thickness) a stack of total thickness of approximately 700 µm was constructed to 
stop the beam according to simulations in SRIM software (Ziegler et al., 2011). 
Each stack was placed in an in-house constructed solid-target holder and 
bombarded by a proton beam of approximately 9 mm in diameter following 
passage through a water-cooled graphite collimator and a ‘vacuum window’ of 
50 μm thick Havar® foil (Goodfellow), but without a beam degrader. The target 
was cooled on its front face by a flow of helium gas (between the Havar® and 
the leading target foil) and from behind by a chilled water jet (further details are 
given in Section 1.3.1 in the previous chapter). Nominal target currents were 
measured with a Fluke 289 multimeter using Fluke View software (Ver. 3, 
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Fluke, Everett, Washington, USA), though these measurements were not used in 
the beam energy determination. Irradiation was for 60 s (measured precisely) at 
approximately 10 μA. 
 
Target stacks of 50 μm-thick Cu foils were used to re-measure the cyclotron 
energy following a cyclotron beam system upgrade. This intervention had altered 
the beam configuration from 18/9 MeV (proton/deuteron) to 18/18 MeV 
(proton/proton) and raised the primary beam current (as measured on a beam-
stop at one of the cyclotron’s eight exit ports) from 100 µA to 150 µA.  All 
experiments were performed in triplicate. 
 
2.2.2  Measurement of Activity Profile of Foil Target Stack 
 
Irradiation of a stack of natCu foils by protons at the nominal energy of the 
cyclotron is known to produce three Zn isotopes (62,63,65Zn) by the (p,x) reactions 
shown in Figure 2.1  (IAEA, 2009). After an irradiation, the activity of 65Zn (T1/2 
= 243.66 d) was measured by gamma spectrometry, by integration of the 1115 
keV signature photopeak several days following end of bombardment (EOB) in 
each of the foils. A HPGe γ-spectrograph (Canberra Industries, Meriden, USA) 
was used, incorporating a S5000 multi-channel analyser (MCA), and a 
cryogenically-cooled GC1018 high-purity germanium (HPGe) detector. Though 
the γ-spectrograph was calibrated for sensitivity and photopeak energies, a 
sensitivity calibration was not an essential requirement since only the relative 
activities of the foils were required. For comparison, the activities of 62Zn (T1/2 = 
9.186 h) and 63Zn (T1/2 = 38.47 min) were also measured at 2 h following EOB 
by integration of the 596 and 669 keV signature photopeaks, respectively. Each 
foil was placed 25 cm from the detector end cap and dead times were less than 
5%. The net counts (Nc, in units of Bq.s-1) in a photopeak were calculated by 
subtracting continuum counts in the spectrum from total photopeak counts, 
performed automatically by the CAM tools program of the Genie 2000 (Gamma 
Acquisition & Analysis) software (Canberra).  Activities forming each profile 
were corrected to EOB, AEOB, using the relation: 
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where  
λ (=ln [2]/T1/2 ) is the decay constant for the produced isotope,  
T1/2 is the half-life of the isotope, 
Nc is the net peak area,  
Tc is the counting time for the photopeak,  
e is the detection efficiency of the γ-spectrograph at the photopeak 
energy, 
η is the branching fraction for the decay mode leading to the photopeak, 
and 
Te is the elapsed time between EOB and the start of counting.   
 
Since the measured activity profile in a stack was normalized (i.e. foil 
activity/maximum activity seen across all foils), e and η may be set to unity, 
obviating the need for sensitivity calibration of the spectrograph. However, its 
detection efficiency at the chosen photopeak energy must be stable over time and 
the relevant characteristic photopeak must be able to be identified. 
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Figure 2.1 Cross sections of the natCu(p,x)62,63,65Zn  reactions as a function of 
proton energy from IAEA recommended cross section data 
(adapted from IAEA, 2009). 
 
2.2.3  Calculation of Expected Activities of Foils  
 
Incident proton energy was described briefly in the following steps.  (i) The 
stopping power for a proton in solid natCu was expressed as a continuous 
function of proton energy (from 1×10-3 to > 20 MeV) using data from The 
National Institute of Standards & Technology (Berger, Coursey, Zucker, & 
Chang, 2005) and curve-fitting equations from CurveExpert 1.4 (copyright 2013, 
Daniel Hyams).  (ii) Similarly, a combination of fitted curves were used together 
with published cross section data to represent the excitation function for the 
65Cu(p,n)65Zn monitor reaction as a continuous function of proton energy (IAEA, 
2009). (iii) The target stack was modelled as being divided into 0.001 mm 
penetration increments, (indexed as i = 1,…,n) along the beam path. A plausible 
starting estimate of the primary beam energy, E0, was assumed. The proton 
energy at the entrance and exit of each penetration increment ‘i’ was then 
calculated using the fitted stopping power curve. The exit energy from one 
increment was used as the entrance energy for the next. The beam energy, Ei, 
assigned to the penetration increment ‘i’ was the mean of these entrance and exit 
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energies.  (iv) If beam straggling of the penetrating beam is ignored (Section 
2.2.5), then Ei uniquely represents the beam energy in the very thin penetration 
increment ‘i’ and σ(Ei) is its unique representative monitor-reaction cross 
section. The activity, Ai(Ei) (in Bq) of 65Zn arising from proton transport through 
penetration increment ‘i’ at EOB is then given by the simple equation: 
 
M
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=                                       (2) 
 
where Ai is expressed in Bq,  NA is Avogadro’s number; T is the bombardment 
time (s); ρ is the target material density (kg m-3); F is the atom fraction of the 
65Cu isotope in natCu; x is the thickness of a penetration increment ‘i’ (in this 
calculation, x = 1 × 10-6 m; total target stack thickness = nx); I is the incident 
proton beam current and assumed constant (A); σ(Ei) is the reaction microscopic 
cross section at energy Ei (m2) and M is the molar mass of natCu (g.mol-1).  
 
The constant arises from the choice of units for the variables on the RHS of the 
equation. By computing the activity of 65Zn produced in each penetration 
increment ‘i’ and then summing these activities over the increments comprising 
the complete irradiated foil, the expected total activity of 65Zn in that foil was 
calculated.  
 
The process was repeated for each irradiated foil in the stack, so that the 
calculated expected activity profile along the axis of the stack of foils was 
determined for the specified trial incident energy E0.  In this computation the 
beam current (strictly, the total received proton charge on target) need not to be 
known and was set at an arbitrarily value. The expected activity profile was 
subsequently normalized to unity at peak activity for comparison with the 
normalized experimentally determined profile described in the previous section. 
 
 
 
57 
 
2.2.4  Iterative Calculation of Primary Beam Energy 
 
For each foil in an irradiated stack the measured and expected normalized 65Zn 
activities were compared and the residual calculated. Residuals were then 
squared, summed and used in an iterative least-squares minimisation technique 
to adjust the trial incident beam energy E0 for the re-calculation of the expected 
activity for each foil using equation (2), until the residual sum of squares was 
minimised.  Figure 2.2 shows the analysis of a single experiment where the 
target stack consisted of fourteen 50 µm-thick foils (foil ‘1’ at the front face).  
The normalised measured 65Zn activities are shown as solid circles.  The optimal 
(best fit) profile resulting from minimisation of the sum of squared residuals is 
shown as solid triangles, yielding a beam energy of 18.15 MeV (solid connecting 
lines to aid visualisation; profile B). Sample ‘outlier’ profiles under-estimating 
(A) and over-estimating (C) energy by 0.5 MeV are also shown for comparison.  
Convergence of the regression as a function of trial beam energy, to reflect ‘best-
fit’ profile B, is shown in the insert. 
 
Though their data were not required obligatorily for determining the beam 
energy, the profiles of the monitor isotopes 62Zn and 63Zn were also measured 
and compared with calculations in order to predict beam energy using the same 
methods, and consequently to determine if the technique was adaptable to these 
isotopes. (Inclusion of 62Zn and 63Zn was only possible because the γ-
spectrograph used in this study was calibrated with standard sources whose 
combined energy range covered the characteristic photopeaks).  Though it was 
believed that 50 µm-thick foils were appropriate for building a target stack 
(being thin but robust) other foil thicknesses (i.e. 25, 75 and 100 µm) were also 
measured to determine if foil thickness influenced results.  
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Figure 2.2  Example of a beam energy determination. Normalised measured 
65Zn activities of 50 µm-thick natCu foils of a target stack (solid 
circles). Equivalent best-fit regression calculation of normalised 
activities, yielding a beam energy of 18.15 MeV (Profile B), compared 
with sample profiles underestimating (A) and overestimating (C) energy 
by 0.5 MeV.  Insert: convergence of the regression to B.  Foil ‘1’ is the 
target front face.  
 
2.2.5  Effect of Energy Straggling 
 
It can be shown for a monoenergetic proton beam of energy < 100 MeV 
penetrating a ‘thick’ target that its energy at any depth is not a unique value but 
assumes an approximately Gaussian distribution (Noshad & Bahador, 2012), 
which can be computed using the SRIM Monte Carlo code (Ziegler et al., 2011) 
This study used the method of Burrage et al. (2009) to assess the effect of beam 
straggling on computed beam energy. Briefly, the propagation of the energy-
straggling effect through the target, in depth-increments of 0.05 mm was 
considered.  Starting with a monoenergetic beam, the distribution of beam 
energies at depth z was derived from a SRIM-based simulation of the energy 
spread.  These data were then described by a fitted curve of the form:  
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                                                                      (3) 
 
where E is the proton energy, zE  is the mean energy of protons at penetration 
depth z, and where a and s are fitting parameters with s2 being an estimate of the 
variance of the (assumed Gaussian) energy distribution.  Those parameters (a, 
zE , s) describing the evolution of the shape of the energy straggling distribution 
vary smoothly with z, allowing continuous functions to be fitted that describe the 
variation of these parameters with penetration depth, particularly for the discreet 
values z = ix (i=1,…,n).  Each y(E,ix) was then approximated by a normalized 
histogram with p(i) elements, H(i,j) (j=1,…, p[i]), with energy increments ΔE = 
0.01 MeV.  The element H(i,j) represents the fraction of protons with energies 
between E(i,j) and E(i,j+1), where E(i,j+1) – E(i,j) = ΔE, and where E(i,j) is the 
energy of the jth histogram element at penetration depth z = ix.  Then, to account 
for energy straggling, σ(Ei) in equation (2) was replaced by the summation over 
(j=1,…,p[i]) of ΣH(i,j) Σ (E[i,j]) for the iterative calculation of beam energy.  
Since the effect of beam straggling on the best-fit derived beam energy was 
found to be < 0.1% (as was also found by Burrage et al., 2009) it was therefore 
ignored.   
 
2.2.6  Choice and Measurement of Beam Degrader 
 
In cyclotrons, without a tuneable beam energy, the primary beam energy can be 
degraded using materials placed in the beam path (Anferov, 2003). Candidate 
materials include copper, graphite and aluminium.  In this study the degrader 
may be positioned 48.5 mm up-beam from the solid target.   
 
Beam angular divergence occurs within the degrader because of scattering; 
however, divergence can be minimised by the choice of degrader material. This 
is illustrated in Figure 2.3 which shows the results of SRIM scattering 
calculations that assume a thin collimated proton beam encountering a degrader 
at normal incidence (Ziegler et al., 2011).  Beam scattering is expressed as 
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normalized counts/unit solid angle, as a function of the scattering angle. The 
computational thickness of each degrader material was set so that the on-target 
beam energy was 11.6 MeV, following correction for prior transport through the 
50 µm-thick Havar® foil immediately anterior to the target. It is seen that the 
angular spread of the beam at the point of exiting from the degrader is minimised 
if the choice is graphite.  Havar® would not normally be used to significantly 
degrade the beam because of its poor thermal conductivity, but it is included as a 
comparison. 
 
 
 
Figure 2.3 Calculated scattering profiles, per unit solid angle, for a thin 
collimated proton beam emerging from various degrader 
materials.  Each degrader is designed to reduce beam energy from 
18.1 MeV to an on-target value of 11.6 MeV, after accounting for 
a 50 µm-thick Havar® vacuum window immediately anterior to 
the target.  Area under each scattering profile is normalised to 
unity. 
 
Following the measurement of primary beam energy without a degrader, separate 
replicate measurements of the energy loss in the degrader were also made, during 
routine production of the PET radionuclides 89Zr, 64Cu and 61Cu. The degrader 
consisted of a machined graphite disc (ρ = 1.85g/cm3) with thickness 1020 µm, 
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inserted in the custom-constructed water-cooled graphite collimator which lies 
up-beam of the Havar® vacuum window. According to a SRIM calculation, this 
degrader converted a primary beam energy of 18.1 MeV (see Results & 
Discussion) to 11.6 MeV at the target after accounting for energy loss in the 
vacuum window, immediately up-beam of the target. 
 
Using 50 µm-thick copper foils, the 65Cu(p,n)65Zn monitor reaction and the 
above methods, the degraded proton beam energy was measured as 11.65 ± 0.06 
(SD) MeV (CV=0.5%; N=3; 95% CI=11.50-11.80) at the target. The difference 
between the measured and the calculated values was not significant. Thus the 
method proved valid for accurately assessing the decrease in beam energy arising 
from this degrader insert, when compared with the theoretical estimate. 
 
2.2.7  Measurement of Beam Cross Sectional Intensity Profile  
 
The transverse proton-beam intensity profile at the target face was checked 
before and following insertion of the degrader described above, as shown in 
Figure 2.4.  Gafchromic films EBT and EBT2 (International Specialty Products, 
Wayne, USA) were used as reported by Avila-Rodriguez, Wilson, & McQuarrie 
(2009). This identified the beam shape as well as any intensity ‘hot spots’ (see 
Figure 2.5). This technique also proved useful when checking off-axis or 
asymmetric behaviour of the beam following cyclotron maintenance and 
installation of new stripper foils.  
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Figure 2.4 Normalised transaxial intensity profile of the proton beam at the 
target position, measured from exposed Gafchromic film. 
 
                        
 
                   (a)                                                           (b)                          
 
Figure 2.5 The autoradiographic image on Radiochromic EBT film without 
degrader analysed with DoseLab (DoseLab software, 2009) shows 
(a) a beam “hot spot”, just off-centre. (b) This has implications for 
heat dissipation in the target material, in order to avoid burning or 
melting of target at high or sustained beam currents. 
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2.3  Results and Discussion 
 
This study describes a simple, indirect method for determining the primary 
proton beam energy using the stacked-foils technique and the monitor reaction 
65Cu(p,n)65Zn, without a direct measurement of beam current. It relies on the 
uniqueness of the shape of the activity profile of the monitor isotope in a foil 
stack, at a specified energy. Calibration of the sensitivity of the γ-spectrograph 
was not required, though the measurement system needed to be able to recognise 
a characteristic photopeak.  Measurement in the foils of the relative activities of 
only one monitor isotope is required.  The monitor isotope, 65Zn is recommended 
because of its long half-life, which allows measurements of activity to be made 
conveniently several days following irradiation. Fifty micron thick natCu foils 
were considered the most appropriate for the monitor foil, because they were 
sufficiently mechanically robust. Concurrent measurements were also made of 
62Zn and 63Zn activities in the same foils. In additional foils of 25, 75 and 100 
µm nominal thicknesses were also assessed in an effort to assess the sensitivity 
of analysis methods to foils’ thickness. 
 
The Table 2.1 and Figure 2.6 show the primary beam energy (corrected for 
energy loss in the obligatory Havar® foil vacuum window) derived from the 
activity profiles of all three monitor isotopes in the stacks of natCu foils of 
different thicknesses. The 65Zn measured in 50 µm foils was considered to be the 
‘index’ result. Measurements were performed before and after an upgrade of the 
non-magnetic components of the cyclotron beam control. Estimates of primary 
beam energy were similar for all three monitor isotopes, with a mean value over 
all isotopes and foil thicknesses of 18.06 ± 0.12(SD) MeV (CV = 0.7%; N = 36; 
95%CI =18.02-18.10), and 18.05 ± 0.05(SD) for 65Zn alone (CV = 0.3%; N = 12; 
95%CI = 18.02-18.08; NS).   The value for 65Zn in 50 µm foils alone was 18.03 
± 0.02 MeV (CV = 0.1%; N = 3; 95%CI = 17.98-18.08; NS). 
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The upgrade of the cyclotron included replacement of ion sources and targetry, 
enhancement of RF power, revision of the station supporting the beam strippers 
and the addition of magnetic compensator coils for dual-beam operations. 
However, the basic magnetic field configuration was not changed during the 
upgrade, which suggests that the beam energy at exit should not change 
significantly.  Indeed, measurement following the upgrade with 65Zn using 50 
µm foils revealed an energy of 18.11 ± 0.05 MeV (CV = 0.3%; N = 3; 95%CI = 
18.00-18.23; NS compared with ‘before’) which was in close agreement with the 
other monitor isotopes (62Zn and 63Zn) and their combination. The two sets of 
measurements were separated and bracketed a significant (18 month) period. The 
data clearly demonstrate that alterations to beam management software and 
hardware (including to the beam-stripping apparatus) did not alter the energy of 
the extracted beam. 
 
The monitor isotope 62Zn is not useful if the beam energy is less than about 15 
MeV since the reaction 63Cu(p,2n)62Zn has a threshold energy of 13.5 MeV.  
However, the concordance of 62Zn data with other isotopes in the table show that 
the iterative method is sufficiently sensitive to the shape of the 62Zn excitation 
curve that comparison with only a segment of its lower tail (approximately 14-18 
MeV of the full range 14 to ~36 MeV) is required to produce an accurate 
estimate of the energy (IAEA, 2009).  Examination of the 62Zn curve over its full 
energy range suggests that the iterative method applied to the 62Zn monitor 
reaction alone would be suitable for assessing proton beam energies over the 
continuous range 18 to ~33 MeV. This exceeds the ranges accessible to those 
methods reliant on ratios of cross sections. The ratio for 63Zn at different 
energies addresses the range 11-18 MeV (using a suite of customised beam 
degraders) while the ratio of 62Zn to 65Zn at the same energy spans about 14-24 
MeV (Gagnon et al., 2011; Kopecky, 1985).  In the broader context beyond 
smaller cyclotrons, application of the iterative method of this study to the 
monitor reactions natTi(p,x)48V (relevant for ~10-30 MeV) and 27Al(p,x)22,24Na 
(> 30 MeV) also seems feasible (IAEA, 2009). 
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This indirect method indicates excellent precision (CV = 0.1-0.5%) as shown in 
the table.  Therefore, it is expected to be highly sensitive to changes in beam 
energy (e.g. insertion of a degrader). However, accuracy of the method is likely 
to be poorer because of inherent uncertainties (systematic or otherwise) in 
contributing variables. A predominant contribution to the inherent uncertainties 
are counting statistics (2%), foils thickness (1%), energy straggling (2.7%, based 
on SRIM calculations of average energy spread with target depth, Section 2.2.5), 
stopping power (6%) and published monitor-reaction cross section data (5%).  
Collectively these errors result in an overall uncertainty of approximately 8.6% 
in the absolute value of the beam energy. This level of uncertainty is not 
inconsistent with other indirect methods. 
 
 
Figure 2.6 Measured proton primary beam energy vs. copper foils thickness, 
for monitor isotope 65Zn alone (diamonds) and for combined 
monitor isotopes (circles).  Copper foils of 50 μm thickness were 
used for the measurements following the cyclotron upgrade 
(square).  Some data are slightly displaced along abscissa axis for 
clarity. Uncertainties are + 95% CI. 
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Table 2.1 Primary beam energy determined from each of three Zn monitor 
isotopic activities in stacks of natCu foils of different nominal 
thicknesses. Measurement using the isotope 65Zn and 50 µm foils 
(bold) is considered the most convenient. Comparisons between 
isotopes or between foil thicknesses are not significant. 
 
Foil 
Thickness          
(µm) 62Zn  63Zn 65Zn  All 
          
Before 
Upgrade MeV MeV MeV MeV 
100 17.77 ± 0.10 18.22 ± 0.09 18.12 ± 0.08 18.04 ± 0.23 
75 18.28 ± 0.15 18.24 ± 0.07 18.13 ± 0.07 18.22 ± 0.08 
50 17.86 ± 0.21 18.15 ± 0.05 18.03 ± 0.02 18.01 ± 0.15 
25 17.96 ± 0.03 17.97 ± 0.10 17.91 ± 0.02 17.95 ± 0.03 
*Mean  17.97 ±0.12 18.15 ± 0.08  18.05 ± 0.05 18.06 ± 0.12 
After 
Upgrade         
50 18.12 ± 0.12 18.18 ± 0.11 18.11 ± 0.05 18.14 ± 0.09 
 
*(Mean ± SD MeV, N = 3) 
 
2.4  Conclusions  
 
A novel method that exploits the energy-dependent uniqueness of the shape of a 
monitoring isotope cross section was developed for determination of the energy 
of a degraded beam. The primary beam energy of a nominally 18 MeV 
isochronous proton cyclotron was measured indirectly though precisely, using 
this method, which is a variation of the stacked foils technique.  This method 
exploits the energy-dependent uniqueness of the shape of the profile of 65Zn 
activity in the stack of natural copper foils comprising the irradiated ‘thick’ 
target. The monitor reaction 65Cu(p,n)65Zn was used. This method does not 
require a direct measurement of beam current or extensive calibration of the 
gamma spectrograph. The recommended technique uses activated 50 µm-thick 
copper foils to monitor 65Zn. In this study, the co-produced 62,63Zn was also 
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monitored and the effect of different thicknesses of copper foil was investigated.  
The data showed excellent internal agreement between the three monitor isotopes 
as well as a range of copper foils (25 to100 µm-thick) 
 
This method has some advantages over other published methods (Kopecky et al., 
1985; Gagnon et al., 2011) that utilise ratios of reaction cross sections. In 
particular, the new method has the capacity to measure energies across virtually 
the entire range of a chosen monitor reaction. It also lacks the need for 
customized degraders, without sacrificing the measurement precision attributable 
to these methods.  The method may be applicable to proton energies above 18 
MeV and indeed 30 MeV, using IAEA-recommended (p,x) monitor reactions 
with titanium or aluminum targets. 
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CHAPTER THREE 
EXCITATION FUNCTIONS OF NATZN(P,X) NUCLEAR 
REACTIONS 
 
A version of this chapter was published in: 
 
Asad, A.H., Chan,S., Morandeau, L., Cryer, D., Smith, S.V. & Price, R.I. (2014). 
Excitation functions of natZn(p,x) nuclear reactions with proton beam energy 
below 18 MeV. Applied Radiation and Isotopes, 94, 67-71. 
 
3.1  Introduction  
 
The relatively short half-life of 61Cu (3.33 h) makes it suitable for the 
radiolabelling of small molecules such as ATSM and PTSM, for hypoxia and 
blood flow measurements, respectively (Jalilian, Shanesazzadah, 
Rowshanfarzad, Bolourinovin, & Majdabadi, 2008; Jalilian et al., 2009).  61Cu 
can be produced by cyclotron proton bombardment of natural zinc (natZn) and 
enriched zinc (64Zn) targets. Understanding variation in the cross sections and 
theoretical yields of the desired isotopes and of co-isotopes is essential for 
optimising the energy and current to produce the highest quality (specific activity 
and radionuclide purity) 61Cu for pre-clinical and clinical use. It is also important 
for determining the most reliable, rapid and cost effective method for the 
production of 61Cu.   
 
There are a number of isotopes that are co-produced when bombarding natZn with 
protons. They include 66Ga, 67Ga, 68Ga and 65Zn. The nuclear and decay 
properties of these isotopes and potential nuclear reactions are given in Table 
3.1.  
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There have been several reports of proton induced (up to 100 MeV) excitation 
functions for reactions on natZn target (Barrandon et al., 1975; Little & Lagunas-
Solar, 1983; Nortier, Mills, & Steyn, 1991; Kopecky, 1990; Hermanne, 1997; 
Szelecsényi et al., 2005B; Al Saleh, Mungren, & Azzam, 2007; Uddin et al., 
2007). Al Saleh et al. (2007) reported cross section data for all the Ga and Zn 
isotopes (e.g. 66Ga, 67Ga, 68Ga, 62Zn and 65Zn) up to 27.5 MeV.  Uddin et al. 
(2007) all reported data (at 40 MeV) for the same isotopes including 61Cu. Less 
recently, Szelecsényi et al. (2005B) published the excitation functions of 61Cu 
from natZn, 66Zn, 68Zn at energies up to 100 MeV. On the whole, there are not 
many 61Cu data available to compare in the reported literature to date. Therefore, 
this chapter aims to determine the excitation function in the region relevant to the 
energy range of the IBA Cyclone at Sir Charles Gairdner Hospital (Perth, 
Australia) and to determine which set of reported data is more reliable.  
 
In this study we measured natZn(p,x) excitation functions  of 61Cu, 66Ga, 67Ga and 
65Zn for  energies ranging from the effective threshold of the particular reaction 
up to 17.6 MeV, using the stacked-foils activation technique. Three independent 
experiments were conducted and the data averaged. 
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Table 3.1 Nuclear and decay properties of isotopes produced from natZn 
(p,x) reactions below 17.6 MeV. 
 
Radionuclide Half-
lifea 
*Decay 
modea 
 *Eγ 
(keV)a 
*Iγ 
(%)a 
Reactionsb Eth 
(MeV)b  
61Cu 3.33  
h 
EC 
(38.5%); 
β+ 
(61.5%) 
282.956 
656.008 
12.20 
10.77 
64Zn(p,α) 6 
64Cuc 12.70 
h        
EC 
(43.1%); 
β+ 
(17.4%) 
1345.77 0.776 68Zn(p,αn) 
67Zn(p,α)                                
8.5 
9.5
67Cuc 61.83 
h 
β- 
(99.0%) 
91.26 
93.31 
184.57 
7.0 
16.1 
48.7 
 
70Zn(p,2p)                
 
7.7
65Zn 244.26 
d 
EC 
(98.6%); 
β+ 
(1.4%) 
1115.5 50.60 66Zn(p,d) 
66Zn(p,n+p) 
67Zn(p,t) 
8.9 
11.2 
9.7 
66Ga 9.49 h EC 
(45.3%); 
β+ 
(56%) 
833.537 
1039.231 
5.88 
36.90 
66Zn(p,n) 
67Zn(p,2n) 
 
6 
13.6 
67Ga 3.26   
d 
EC 
(99.8%) 
184.6 
300.2 
21.2 
16.8 
67Zn(p,n) 
68Zn(p,2n) 
1.8 
10.3 
68Gac 67.63 
min 
EC 
(38%); 
β+ 
(62%) 
1077 3 68Zn(p,n) 
 
3.75 
 
Eγ  energies of γ- ray emissions.; Iγ,   probability of γ-ray emission per nuclear disintegration; 
Eth, threshold energy of reaction ; a, data from Table of Nuclides; http://atom.kaeri.re.kr/ (Table 
of Nuclides); b, data from Experimental Nuclear Reaction Database (EXFOR). 
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3.2  Experimental Methods 
 
Excitation functions for the natZn(p,x) reactions were measured by the stacked-
foils activation technique (Qaim, Stocklin, & Weinreich, 1997). High-purity 
natural zinc foils (99.99+% elemental purity), of natural composition (see Table 
3.2) with thickness of 0.025 ± 0.004 (SD) mm were purchased from Goodfellow 
Metals Ltd, UK. Copper monitor foils of 15 mm diameter were employed to 
measure beam flux and energy in the stack using the characteristics of the well-
documented 63Cu(p,n)63Zn and 65Cu(p,n)65Zn reactions (IAEA, 2009). These 
foils had a thickness of 0.025 ± 0.004 (SD) mm (99.99+% elemental purity; 
Goodfellow Metals Ltd, UK). 
 
Table 3.2  Isotopic composition of natural zinc  
 
Isotope 64Zn 66Zn 67Zn 68Zn 70Zn 
Present 
Abundance 
48.6% 27.9% 4.1% 18.8% 0.6% 
 
The foil stacks consisted of appropriate combinations of the Cu and Zn foils, 
with one monitor Cu foil at the target front face, plus single Cu foils interleaved 
with the Zn foils. The energy degradation within each foil including the Havar® 
foil was calculated by SRIM 2011 software (Ziegler et al., 2011).  
 
A typical stack consisted of four units of four Zn foils sandwiched between 
single Cu monitor foils (Cu-4×Zn-Cu), with the last (fifth) stack consisting of 
(Cu-8×Zn-Cu) so that the exit energy of the beam from the final stack was well 
below the threshold energy of the studied reaction. For each experiment, a stack 
was inserted into an external solid targetry beam line, where the target was 
cooled in front by helium gas flow and from behind by a cooled water jet 
(described previously in Section 1.3.1 of Chapter 1). A schematic of the solid 
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targety setup is given in Figure 3.1.  The proton source employed was an IBA 
18/18 MeV isochronous cyclotron (IBA, Louvain le Neuve, Belgium). 
 
Foil stacks were irradiated with a primary beam of energy 17.6 MeV, accounting 
for beam degradation by an obligatory 0.025 ± 0.0005 (SD) mm-thick Havar® 
foil vacuum window.  Irradiation was for 3 min using a target beam current of 5 
µA.  
 
 
 
Figure 3.1  Scheme of solid targetry apparatus. 
 
Activities of the irradiated foils were measured at 3 h post end of bombardment 
(EOB) by cryo HPGe gamma spectroscopy (Canberra, Meriden, USA; S5000 
MCA & GC1018 Ge detector). The distance between the specimen and the end 
cup of the HPGe detector was set at 50 cm, in order to reduce the dead time of 
each measurement to less than 5%.  
 
The gamma spectrometer was independently calibrated with certified standard 
sources of 60Co, 57Co, 137Cs, 65Zn, 109Cd and 133Ba (Canberra Industries, Oak 
Ridge, TN, USA), with an uncertainty in the intrinsic efficiency curve of 5%.  
 
Beam flux for each measurement, was determined using the Cu foils (i.e. 
63Cu(p,n)63Zn and 65Cu(p,n)65Zn reactions) as described in Chapter 2. The 
 
 
 
 
 
Proton Energy 
18 MeV 
Havar 
50µm 
  
He 
cooling 
Foils natZn & natCu  
(99.99%)   
H2O 
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experimental cross sections of 61Cu, 66Ga, 67Ga and 65Zn were calculated using 
the equation: 
 
    )1(
][
t
EOB
e
A
ληφ
σ −−
=
           (1) 
 
where:  [ AEOB] = activity of the respective radionuclide at EOB [Bq] 
                  η   = number of target nuclei per cm  
                  σ   = cross section in cm2 
                       Φ    = incident proton flux (particles s-1.cm-2) 
                  λ    = decay constant for the nuclide (s-1) 
                  t    = bombardment time (s)  
 
The uncertainty in the derived reaction cross section data is a function of the 
independent uncertainties encountered in the act of the measurement. This 
includes beam current (10-12%), detector efficiency (5%), counting statistics (4- 
8%), foil thickness (4-7%) and time of irradiation (1-2%). Thus, the total 
uncertainty in these experimental data ranged from 13 to 16%. The uncertainty in 
the proton energy in each Cu foil was derived from analysis of the 63Zn and 65Zn 
present.  Three independent experiments were performed and the uncertainty in 
the final energy for each cross section was determined from the spread in the 
calculated energy values.   
 
3.3  Results and Discussion 
 
The cross section of each radionuclide produced from the natZn(p,x) reactions as 
a function of proton energy was calculated from equation (1) and are given in  
Table 3.3. Comparisons between the results of this study and the published 
literature are presented in Figures 3.2 to 3.5. 
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Table 3.3  Measured reaction cross sections for the production of 61Cu, 66Ga, 
67Ga and 65Zn radionuclides from natZn target.  
 
 Reaction Cross Section (mb) 
Proton Energy 
(MeV) 
natZn(p,α)61Cu natZn(p,x)66Ga natZn(p,x)67Ga natZn(p,x)65Zn 
17.45 ± 0.25 21.80 ± 3.03 61.84 ± 8.59 101.82 ± 14.14 118.17 ± 12.85 
17.1 ± 0.25 23.36 ± 3.35 67.99 ± 10.86 94.49 ± 15.12 113.26 ± 12.83 
16.75 ± 0.25 26.67 ± 3.73 72.22 ± 11.09 95.42 ± 15.27 102.55 ± 10.71 
16.4 ± 0.25 27.20 ± 3.75 80.06 ± 11.62 90.91 ± 11.82 99.24 ± 10.69 
15.63 ± 0.25 30.64 ± 4.66 98.06 ± 14.10 83.31 ± 12.68 69.58 ± 7.62 
15.26 ± 0.25 29.43 ± 3.96 106.46 ± 14.33 72.46 ± 11.41 55.87 ± 5.69 
14.89 ± 0.25 30.77 ± 4.14 114.12 ± 15.37 75.53 ± 9.82 42.42 ± 4.32 
14.52 ± 0.30 31.47 ± 4.35 123.80±17.60 62.89 ± 8.81 32.47 ± 3.36 
13.68 ± 0.30 31.23 ± 4.31 142.11 ± 20.07 41.34 ± 5.79 11.04 ± 1.17 
13.28 ± 0.30 32.47 ± 4.88 146.75 ± 21.30 33.19 ± 5.38  
12.87 ± 0.35 33.80 ± 4.62 148.61 ± 22.85 25.58 ± 3.50  
11.94 ± 0.35 32.69 ± 4.62 149.88 ± 21.19 20.66 ± 2.69  
11.48 ± 0.35 30.18 ± 3.91 145.64 ± 20.25 19.16 ± 2.99  
11.01±  0.35 28.03 ± 3.91 142.60 ± 19.88 19.51 ± 2.54  
10.53 ± 0.35 24.69 ± 3.65 136.18 ± 20.15 20.37 ± 2.77  
9.18 ± 0.40 22.54 ± 3.07 132.28 ± 18.01 22.22 ± 3.11  
8.36 ± 0.45 18.54 ± 2.52 113.97 ± 15.47 18.44 ± 2.58  
7.77 ± 0.50 14.25 ± 2.16 99.99 ± 15.15 19.13 ± 2.87  
7.13 ± 0.50 10.67 ± 1.43 86.86 ± 11.64 16.29 ± 2.12  
6.46 ± 0.55 6.66 ± 0.89 64.77 ± 8.69 15.46 ± 2.07  
5.73 ± 0.60 3.61 ± 0.50 36.30 ± 5.05 12.87 ± 2.06  
4.92 ± 0.70  9.43 ± 1.37 10.66 ± 1.49  
4.00 ± 0.75  0.85 ± 0.12 7.51 ± 1.14  
3.21 ± 0.85   2.81 ± 1.52  
Uncertainties are ± 2SD. Each data point is derived from the mean of three experiments. 
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3.3.1  natZn(p,α)61Cu Reaction   
 
The excitation function of 61Cu produced from the 64Zn(p,α)61Cu reaction was 
measured in the proton energy range from 17.45 ± 0.25 MeV down to 5.73 ± 
0.60 MeV. The results were compared with previously published data 
(Barrandon et al., 1975; Szelecsényi et al., 2005; Uddin et al., 2007) and are 
plotted in Figure 3.2. The cross section values determined for energy range 14- 
14.5 MeV (peak maximum) in the current study are slightly lower than those of 
Uddin et al. (2007) (39 ± 5.0 MeV) and Szelecsényi et al. (2005) (42.15 ± 4.65 
MeV). The data reported by Barrandon et al. (1975) are significantly different 
from the present study as well as those of Uddin et al. (2007) and Szelecsényi et 
al. (2005). The data obtained in the present study are more likely to be accurate, 
and with more data points than those presented in the other literature. 
 
 
 
Figure 3.2  Measured excitation function of the natZn(p,α)61Cu reaction, in 
comparison with published data. Uncertainties are + 2SD.  
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3.3.2  natZn(p,x)66Ga Reactions  
 
The cross section data for the production of 66Ga acquired in this study are 
shown in Figure 3.3, together with the other published data. The data in this 
study are in general agreement with data from Hermanne (1997), Al Saleh et al. 
(2007), Uddin et al. (2007) and Szelecsényi et al. (2005B) for energies greater 
than 12 MeV.  For energies less than 9 MeV the data are in good agreement with 
Szelecsényi et al. (2005B). However, for all other reported literature the data in 
this present study are consistently higher.  
 
 
 
Figure 3.3 Measured summed excitation functions of the natZn(p,x)66Ga 
reactions, in comparison with published data. 
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3.3.3  natZn(p,x)67Ga Reactions  
 
Gallium-67 is produced from natZn target below 18 MeV via two separate 
reactions: 67Zn(p,n) and 68Zn(p,2n) (Table 3.1).  Figure 3.4 shows the data from 
the current study are in generally good agreement between the summed 
excitation functions for these two reactions as presented in this work as well as 
previous studies (Kopecky, 1990; Hermanne, 1997; Al Saleh et al., 2007; Uddin 
et al., 2007). The exceptions are Szelecsényi et al. (2005B) (at higher energies), 
Little and Lagunas-Solar (1983) and Barrandon et al. (1975). 
 
 
 
Figure 3.4 Measured summed excitation functions of the natZn(p,x)67Ga 
reactions, in comparison with published data.    
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3.3.4  natZn(p,x)65Zn Reactions  
 
The isotope 65Zn is one of the monitoring isotopes used to determine beam flux 
or beam energy using the stacked-foils method. The 65Zn nuclide (t1/2 = 244.26 d; 
β+, 1.4%; EC, 98.6%) can be produced from three different nuclear reactions 
when using a natZn target, as shown in Table 3.1.  65Zn can be used as a standard 
source for calibration of gamma-spectroscopy. It is also suitable for thin layer 
activation (TLA) studies (Uddin et al., 2007).  
 
Accumulated cross section data for the production of 65Zn is given in Figure 3.5. 
Included in the same figure are data from Al Saleh et al., 2007 and Uddin et al., 
2007.  The current data are in good agreement with the literature data. However, 
the energy threshold determined in the present study was significantly higher 
(i.e. 13.7 MeV) as compared to the reported thresholds 11.3 MeV (Al Saleh et 
al., 2007) and 10.7 MeV (Uddin et al., 2007).  This variation may be explained 
by the higher current used in this work. 
 
 
 
Figure 3.5  Measured summed excitation functions of the natZn(p,x)65Zn 
reactions, in comparison with published data. 
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3.3.5  Other Reactions 
 
Copper-64 can be produced from 68Zn (18.8% natural abundance) via the 
68Zn(p,αn)64Cu (Hilgers et al., 2003; Levkovskij, 1991) reaction. The cross 
sections reported in the literature are quite low: the reported maxima are 12 mb 
at 17.6 MeV (Hilgers et al., 2003) and 19 mb at 17.5 MeV (Levkovskij, 1991), 
respectively. Therefore, a thick target using 5 µA for 3 min produces only 1.2 
kBq, which is too low for analysis in the current study, consequently this nuclide 
was not expected to be observed. Despite an extensive search of the published 
literature, there are no published data for 64Cu production via this reaction in the 
relevant energy range. 
 
Copper-67 is produced from 70Zn (0.6% in natural Zn) via the 70Zn(p,α)67Cu 
reaction (Kastleiner, Coenen, & Qaim, 1999). The theoretical thick-target 
activity calculated from data of that study, assuming a beam current of 5 µA and 
3 min irradiation, was only approximately 4.6 kBq. Thus, investigation of the 
reaction 70Zn(p,α)67Cu is restricted in the current study due to poor counting 
statistics. This conclusion is also supported by the previous data (Levkovskij, 
1991).    
 
Gallium-68 can be produced from 68Zn (18.8% in natural Zn) via the 
68Zn(p,n)68Ga reaction using a natZn target (Nortier et al., 1991; Al Saleh et al., 
2007) and by other groups using an enriched target (Szelecsényi, Boothe, Tarács, 
Tárkányi, & Tavano, 1998; Tárkányi, Szelecsènyi, Kovàcs, & Sudar, 1990).  
Indeed, this reaction with an enriched target has been recommended as the 
chosen path for 68Ga production when employing a biomedical cyclotron 
(Sadeghi, Aboudzadeh, Zali, & Zeinali, 2009; Asad et al., 2012). The cross 
section, when corrected for the natural abundance of 68Zn, has a maximum of 
160 mb at 12 MeV. The low current, timing of gamma analysis measurements 
and the relatively short half-life of 68Ga precluded its quantitative assessment in 
this study. 
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3.3.6  Integral Thick-Target Yield   
 
Cross sections were used to determine integral yields for each of the isotopes 
produced in this study. The activities per µA per hour as a function of beam 
energy were calculated by integrating the cross section over the energy range of 
the present data using equation (2). 
                      
  ∫ −−−=
Ep
Eth
t dEE
dX
dEEeINvA .)].().[().1.(. 1σλ                   (2) 
 
In equation (2) Nν is the number of target nuclei for the desired reaction per unit 
area (related to target thickness), I is the incident particle flux (related to beam 
intensity), λ is the radioactive constant of the produced isotope, t is the duration 
of the irradiation, Ep is the beam energy, Eth is the reaction threshold energy, 
σ(E) is the excitation function and dE/dX is the stopping power of the target 
material.  
 
The integral thick-target yields for the production of 61Cu, 66Ga, 67Ga and 65Zn 
produced from a natZn target with primary beam energy 17.6 MeV as a function 
of proton energy were calculated using the excitation functions measured. 
Results are given in Figure 3.6. The results (up to 17.6 MeV) were in good 
agreement with Uddin et al. (2007) but were in less agreement with Szelecsényi 
et al. (2005B), as shown in Figure 3.7. 
   
The results demonstrate that if the natZn target were replaced by a highly 
enriched 64Zn target, then the yield of 61Cu produced could be doubled. For 
example, a simple calculation shows that an enriched 64Zn target of thickness 
100 mm can be used to produce 0.85 GBq of  61Cu at EOB with a 40 µA beam at 
normal incidence and 1 h irradiation using17.6 MeV protons. Furthermore, the 
production of 66Ga, 67Ga, 68Ga and 65Zn contaminants would be significantly 
lower at EOB. 
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Figure 3.6  Calculated thick-target integral yields per µA beam current per 
hour irradiation, as a function of beam energy, for the isotopes 
produced in a natural Zn target from the measured excitation 
functions determined in the current study. 
 
 
Figure 3.7  Calculated thick-target integral yield for 61Cu in a natural Zn 
target per µA beam current per hour irradiation, as a function of 
beam energy, from this study and in comparison with published 
data.  
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3.4  Conclusions  
 
Cross section data for natZn(p,x) reactions yielding 61Cu, 66Ga, 67Ga and 65Zn 
isotopes have been measured using proton irradiation of a high-purity natural 
zinc target, employing the stacked-foils activation technique, at proton energies 
up to 17.6 MeV produced by a conventional isochronous PET production  
cyclotron. The results are generally in good agreement with recent published 
data, except for 66Ga. The results of this study for 66Ga are in agreement with one 
published data set, but are higher than other publications for energies below 10 
MeV. This suggests that further investigation of the cross section for the 
natZn(p,x) production of 66Ga may be necessary, particularly for lower energies. 
All of the produced isotopes could potentially be used in clinical or preclinical 
studies, following chemical separations of the zinc, gallium and copper elements 
(Asad et al., 2012). In the case of 61Cu, higher activities for clinical applications 
could be achieved (and co-produced radionuclidic impurities minimised) by 
using an isotopically enriched 64Zn target. 
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CHAPTER 4 
PRODUCTION AND SEPARATION OF 61CU PRODUCED FROM 
NATZN AND ENRICHED 64ZN TARGETS – SPECIFIC 
ACTIVITY DETERMINATION 
 
A version of this chapter was published in: 
 
Asad, A.H., Smith, S.V., Morandeau, L.M., Chan, S., Jeffery, C.M. & Price, R.I. 
(2015). Production of 61Cu by the natZn(p,α) Reaction: Improved Separation and 
Specific Activity Determination by Titration with  Three Chelators. Journal of 
Radioanalytic and Nuclear Chemistry, 307, 899-906. 
 
4.1  Introduction  
 
Copper has four widely used radioisotopes for positron emission tomography 
(PET) imaging, 60Cu (t1/2 = 20.7 min), 61Cu (t1/2 = 3.33 h), 62Cu (t1/2 = 9.8 min) 
and 64Cu (t1/2 = 12.7 h) (Smith, 2004). 64Cu also has a therapeutic β- emission that 
can be used for radiotherapy. Diacetyl-bis(N4-methylthiosemicarbazone) 
(ATSM) and pyruvaldehyde-bis (N4-methylthiosemicarbazone) (PTSM) have 
been radiolabelled with each of these radionuclides for imaging hypoxia 
(Laforest, Dehdashti, Lewis & Schwarz, 2005) and blood perfusion (Wong et al., 
2008) respectively. While the majority of published works have used the long-
lived 64Cu; the shorter half-life of 61Cu, with its high abundant positron emission 
(β+ = 1.22 MeV, 61.5%; EC = 38.5%) and the absence of β- emission make it a 
potentially more attractive option for imaging hypoxia (Thieme et al., 2013).   
 
Several methods have been reported for the cyclotron production of 61Cu using 
Ni and Zn targets (McCarthy et al., 1999; Szelecsényi et al., 1993; Piel et al., 
1992; Tanaka et al., 1972; Szelecsényi et al., 2005; Asad et al., 2014; Al Saleh et 
al., 2007; Uddin et al., 2007; Cohen et al., 1954). Both 61Ni and 62Ni targets can 
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be used to produce 61Cu via the (p,n) and (p,2n) nuclear reactions respectively 
(McCarthy et al., 1999; Szelecsényi et al., 1993; Piel et al., 1992; Tanaka et al., 
1972). The production of 61Cu via these routes is very high yielding (σ > 300 
mb) and the optimum proton energies for these nuclear reactions [10.3 MeV for 
61Ni (Szelecsényi et al., 1993) and 14 MeV for 62Ni (Piel et al., 1992)] are ideal 
for commercially available low energy cyclotrons.  However, the high cost of the 
61Ni ($37 per mg) and 62Ni ($14.70 per mg) can be prohibitive when one 
considers the total inventory required (which includes chemical loss on recycling 
and recovery) to maintain routine production of 61Cu.  
 
Proton reactions on zinc targets have been studied as an alternative approach to 
Ni targets for the production of 61Cu (Szelecsényi et al., 2005; Asad et al., 2014; 
Al Saleh et al., 2007; Uddin et al., 2007; Cohen et al., 1954) via the (p,α) 
reaction. For example, natural Zn (natZn, with 64Zn natural abundance 48.6%) 
and enriched 64Zn (99%) using the 64Zn(p,α)61Cu reaction have reasonable cross 
sections (39 and 79 mb at 15 MeV, respectively) (Cohen et al. 1954; 
Rowshafarzad et al., 2006). The Zn target materials are considerably cheaper 
(e.g. 64Zn $5 per mg) than the Ni targets. Enriched 64Zn targets also present the 
added advantage of being available commercially as foils. Use of the latter 
avoids the need to establish an in-house electroplating and recycle process as 
well as requalifying procedures for human use, as the 64Zn target is considered a 
consumable.  
 
However, the proton bombardment of the natural zinc target presents some 
challenges, such as the co-production of Ga radionuclides [66Ga (t1/2 = 9.49 h), 
67Ga (t1/2 = 3.26 d) and 68Ga (t1/2 = 68 min)] and of the longer-lived 65Zn nuclide 
(t1/2 = 244 d) (Asad et al., 2014; Al Saleh et al., 2007; Uddin et al., 2007). Figure 
4.1 illustrates the cross sections of natZn(p,x) reactions for incident proton 
energies < 18 MeV, showing that the production of 61Cu can be optimised to 
avoid collateral 65Zn contamination by using proton energies < 13.7 MeV.  
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Figure 4.1 Excitation functions of natZn(p,α) reactions up to 18 MeV for the 
production of  61Cu, 66Ga, 67Ga, 65Zn  (adapted from Asad et al., 
2014) and  68Ga (adapted from Al-Saleh el al., 2007). 
 
Several separation methods have been reported in the literature for isolating Cu 
and Ga from the Zn target materials by cation and anion exchange 
chromatography (Rowshafarzad et al., 2006; Dasqupta et al., 1991; Schwarzbach 
et al., 1995). For example, Rowshanfarzad et al. (2006) irradiated a natZn target 
using 22 MeV proton beam energy at 180 µA.h.  They isolated the 61Cu with a 
combination of cation and anion exchange columns, using large volumes of 
concentrated HCl to separate the Cu from the Ga and Zn by-products.  
Unfortunately, the specific activity of the isolated products was not reported.   
 
Determination of the effective specific activity (ESA) of radiometals is important 
as metallic contaminants can have an impact on the radiolabelling efficiency. 
ICP-MS is one of several methods for determining the specific activity for the 
quality control of radiometals production. However, cyclotron facilities cannot 
always afford its regular use. The other common method to determine effective 
specific activity of Cu isotopes is the titration method using chelators such as 
1,4,8,11-tetraazaclotetradecane-1,4,8,11-tetraacetic acid (TETA). This method 
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consists in incubating the isolated radiocopper isotope in buffered solution in the 
presence of increasing known concentrations of the chelator. After a suitable 
time, the solutions are analysed by Instant Thin Layer Chromatography (ITLC) 
allowing the separation of free Cu from bound Cu; the percentage of [Cu-
TETA]2- bound is calculated (McCarthy et al., 1997; Matarrese et al., 2010; 
Avila-Rodriguez et al., 2007). The estimated concentration of TETA at 50% 
labelling is multiplied by 2 to give the TETA concentration required for 100% 
complexation of Cu and thus the corresponding Cu concentration. The specific 
activity is then calculated in GBq/µL or GBq/µg of Cu after correcting the total 
activity and molecular weight of TETA.   
Thieme et al. (2012) also reported the use of TETA for determining the ESA of 
64Cu and compared the results with the non-carrier-added specific activity (NCA-
SA) determined from ICP-MS data. They found that for 64Cu, the ESA values 
increased by 30% when incubating the mixtures at 80 °C vs. room temperature. 
In all cases, the ESA values were 1-5 fold lower compared to NCA-SA 
determined from ICP-MS, and were dependant on the metallic backing materials 
used for targetry. For 61Cu, the same authors also reported similar ratios between 
the titration method using TETA and ICP-MS when comparing ESA and NCA-
SA, respectively (Thieme et al., 2013). Recently, Mastren et al. (2014) compared 
the use of ICP-MS and ion chromatography HPLC analysis for determining the 
specific activity of 64Cu, with the titration method using TETA at 80 °C.  The 
ESA values obtained with the titration method were 1.5-5.0 fold lower than the 
ones obtained with ICP-MS. 
 
The proposed reason for these consistently lower specific activities obtained by 
the titration method vs the ICP-MS is due to lower selectivity of the titration 
method. ICP-MS is by its nature a highly selective method, where other metal 
ions give distinctly different MS responses to Cu ions. However, while the 
polyazacarboxylate chelators show good complexation with Cu, they are not 
necessarily selective for Cu and will form complexes with other alkali, alkaline 
earth and transition-metal contaminating ions present in solution. For this reason, 
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these chelators would complex other metal ions present in solution, contributing 
to an artificially high percentage activity of [Cu-TETA]2-, thereby giving lower 
resultant specific activities than the ICP-MS method.  More recently, a wide 
range of commercially available polyaza, polycarboxylate and hexa-aza cages 
have been reported to preferentially form complexes with Cu2+ (Smith, 2004, 
Jarrett, Gustafsoon, Kukis, & Louie, 2008; Craft et al., 2012; Jeffery et al., 
2012). It is of interest to assess some of these chelators for determining the 
specific activity of no-carrier-added (NCA) 61Cu by the titration method.   
 
In this chapter, investigation of the production of 61Cu from natZn and 64Zn target 
is described. The development of a novel separation method for 61Cu produced 
from both natZn and 64Zn targets is then given.  Ideally, the separation of 61Cu 
should be faster, more cost-effective and less cumbersome compared to known 
methods. Finally, the NCA specific activity of the resultant 61Cu as determined 
by ICP-MS will be compared to the ESA obtained as determined by the titration 
method using the following three chelators; DOTA-NCS, NOTA-NCS and 
diamsar. These were chosen for their known greater selectivity for Cu compared 
to TETA (Smith, 2004). Their chemical structures are shown in Figure 4.2. 
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Figure 4.2 Chemical structures of the chelators; DOTA-NCS, NOTA-NCS     
and diamsar used to determine ESA.  
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4.2 Experimental 
 
4.2.1  Materials 
Enriched 64Zn metal foils (64Zn 99.30%, 66Zn 0.45%, 67Zn 0.06%, 68Zn 0.17% 
and 70Zn 0.02%) (0.05 mm thick) were purchased from Trace Sciences 
International Corp. (TX, USA). High-purity (99.99%) natZn foils (0.05 mm thick) 
with composition (64Zn 48.6%, 66Zn 27.7%, 67Zn 4.1%, 68Zn 18.8% and 70Zn 
0.6%) were purchased from Goodfellow Metals Ltd. (Cambridge, UK). 
Hydrochloric acid, sodium acetate and TraceSELECT water were purchased 
from Sigma Aldrich (NSW, Australia). Anion exchange resin AG1-X8 (200-400 
mesh) and cation exchange resin AG50 W-X8 (200-400 mesh) were supplied by 
BioRad (NSW, Australia). Cu-Resin (100-150 mm) was purchased from 
Eichrom Technologies (IL, USA). Instant thin-layer chromatography (ITLC-SA) 
paper (Pacific Laboratory Products; VIC, Australia) was used to separate free 
61Cu2+ from complexed 61Cu2+. S-2-(4-isothiocyanatobenzyl)-1,4,7-
triazacyclononane-1,4, 7-triacetic acid (NOTA-NCS; >94%) and 2-(4-
isothiocyanatobenzyl)- 1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid 
(DOTA-NCS; >94%) were purchased from Macrocyclics, (TX, USA). The third 
chelator, 3,6,10,13,16,19-hexaazabicyclo[6.6.6]eicosane-1,8-diamine 
pentahydrate (diamsar; >87%) was purchased from Clarity Pharmaceuticals 
(NSW, Australia) (Figure 2). 
 
4.2.2  Instrumentation 
 
The radionuclidic purity of the final product was determined by γ-spectroscopy 
using a high-purity germanium detector (HPGe; Canberra model GC2018) 
coupled to a calibrated Canberra Inspector 2000 multichannel analyser (Canberra 
Industries; TN, USA) and the data were processed using Genie-2000 software 
(Canberra). The Automatic Wizard 2 Gamma Counter (Perkin Elmer; MA, USA) 
was used for counting TLC strips cut into several pieces to determine the % of 
complexed 61Cu. 
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 4.2.3  Production of 61Cu from natZn and Enriched 64Zn Targets 
 
4.2.3.1  Irradiation of Zinc Foils 
 
To minimise unwanted co-products from the zinc targets, as well as investigate 
the differences between natZn and 64Zn targets, a series of eight irradiations were 
performed. Four targets each of natZn and enriched 64Zn foils were irradiated at 
20-40 µA for 30 min. The foils were positioned in a removable custom-made 
aluminium disc holder with a lid (25 mm diameter and thickness 0.50 mm) 
(Figure 4.3). The front and back of the target holder were cooled with He gas and 
chilled water, respectively (Asad et al., 2014). A graphite degrader (1020 µm 
thick) was used to reduce the proton energy from 17.6 to 11.70 MeV (Asad et al., 
2014). All irradiations were performed using an IBA 18/18 MeV cyclotron (IBA, 
Louvain la Neuve, Belgium). The production activity and impurities were 
measured by γ-spectroscopy. The final activity of 61Cu was calculated as a 
weighted average of its two gamma-lines at 282 keV (12.20% abundance) and 
656 keV (10.77%). The irradiation yield of 61Cu was calculated as the mean of 
four irradiations. 
 
                    
 
Figure 4.3 Zinc foil target that is contained between an aluminium target 
annulus (left) and an aluminium cradle (right). 
 
 
4.2.3.2  Target Dissolution  
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At end of bombardment (EOB) the target remained in the solid targetry 
apparatus for 1-3 h to allow for some decay of the short-lived 68Ga activity (t1/2  =  
68 min). The chemical separation was performed in a shielded fume hood. The 
irradiated natZn or 64Zn foil was first dissolved in 1 mL of 8 M HCl at 150 °C, 
then the solution was evaporated to dryness. High purity TraceSELECT water (1 
mL) was added to the residue and evaporated to dryness; this step was repeated 
once. Finally, the residue was dissolved in 2 mL of 0.01 M HCl and an aliquot (1 
µL) was taken for analysis by gamma spectroscopy. 
 
4.2.4  Separation and Purification of 61Cu 
 
4.2.4.1  From natZn Target  
 
A combination of three columns connected in series was used (Figure 4.4a):  
 
Column 1: Separation of Cu2+ from Zn2+ and Ga3+ on Cu-resin 
 
0.5 mg of Cu-resin was pre-conditioned with 20 mL of 0.01 M HCl solution and 
placed in a small plastic column. The target was dissolved in 2 mL of 0.01 M 
HCl solution and loaded onto the column. The column was then washed with 25 
mL of 0.01 M HCl to remove the Zn target material as well as the 66,67,68Ga 
radionuclides impurities. 61Cu was then eluted off the column with 1.5-2.0 mL of 
8 M HCl, which was directed to the cation exchange column (column 2) 
connected in series with the anion exchange column (column 3) in order to 
remove both residual Zn2+ and Ga3+ impurities. 
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Column 2: Separation of Cu2+ and residual Zn2+ from residual Ga3+ on a   
        cation exchange column.  
 
The cation exchange resin (AG5 W-X8) (1.0 g) was pre-conditioned with 20 mL 
of TraceSELECT water followed by 8 M HCl (5 mL) and was placed in a small 
plastic column. The residual Ga impurities were retained on the cation exchange 
column while the 61Cu and residual Zn impurities were flushed onto the anion 
exchange column 3.  
 
Column 3: Separation of Cu2+ from residual Zn2+ on an anion exchange  
        column.  
 
The final step of the separation process was to elute the 61CuCl2 from the anion 
exchange column (AG1-X8 resin (1.0 g) pre-conditioned with 5 mL of 8 M HCl) 
with 3.0 mL of 2 M HCl. The solution was evaporated to dryness. The residue 
was dissolved in 1 mL of TraceSELECT water and evaporated to dryness; this 
step was repeated three times. The final product was then dissolved in 400-800 
µL of 0.01 M HCl and sampled for analysis by γ-spectroscopy. Comparison of γ-
spectroscopic analysis of radionuclidic composition before and following 
separation is shown in Table 4.1. 
 
4.2.4.2  From Enriched 64Zn Target 
 
Single Cu-resin column 
 
The separation and purification of 61Cu from the irradiated enriched 64Zn target 
material is shown schematically in Figure 4.4b. The solution was loaded onto a 
Cu-resin column, pre-conditioned with 20 mL of 0.01 M HCl. The Zn and Ga 
impurities were eluted with 25 mL of 0.01 M HCl and kept for recovery of 64Zn 
if required. The 61Cu trapped on the Cu-resin column was then eluted off with 
1.5-2.0 mL of 8 M HCl, followed by drying steps as described in the previous 
section. The final product was then dissolved in 400-800 µL of 0.01 M HCl and 
sampled for analysis by γ-spectroscopy.  
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Figure 4.4 Schematic representations of the column chromatography 
purification of 61Cu from (a) irradiated natZn foil target and; (b) 
irradiated 64Zn foil target. 
 
64Zn Target Recovery 
 
In order to test the feasibility of recovery of the enriched 64Zn target material, 
following decay of the Ga radionuclides, the 25 mL of Zn and Ga in HCl 
solution were evaporated to dryness. Then, the residue was redissolved in 5 mL 
of 8 M HCl and transferred to a cation exchange column (pre-conditioned with 
20 mL of Trace-SELECT water), followed by 10 mL of 8 M HCl. The solution 
was evaporated to dryness. The recovery of 64Zn for potential electroplating was 
94 ± 5%. 
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4.2.5  Specific Activity   
 
The specific activity of 61Cu (in GBq/µmol) was determined by the titration 
method, using purified 61Cu in 0.01 M HCl and the chelating agents NOTA-
NCS, DOTA-NCS  and diamsar (Figure 4.2). The specific activity was converted 
to GBq/µg, as described in the Results section.  
 
Complexation of the 61Cu was achieved in a similar manner to that described by 
McCarthy et al. (1997). Briefly, increasing concentrations (1 x 10-9 to 1 x 10-2 
M) of each chelator solution were prepared in 0.1 M sodium acetate buffer (pH 
6.5). Twenty microlitre of each chelator solution was added to 10 µL of the 61Cu 
solution which had previously been adjusted to pH 6.5 with 0.1 M sodium 
acetate buffer. The mixture was then incubated at room temperature for 30 min.  
After incubation, aliquots of 2 µL were withdrawn from each reaction mixture 
and spotted directly onto 10 cm ITLC–SA strips. Different mobile phases were 
used to separate free Cu2+ from complexed Cu2+: 
 
(i) for diamsar the mobile phase was 0.1 M NaCl : 0.1 M EDTA (9:1). 
The retardation factor (Rf) was < 0.2 for Cu-diamsar while free Cu2+ 
migrated to Rf  > 0.8.  
 
(ii) DOTA and NOTA Cu2+ complexes were separated using 0.1 M 
sodium acetate (pH 4.5) : H2O : MeOH : ammonium hydroxide 
(20:18:2:1 v/v) mobile phase.   Cu-DOTA and Cu-NOTA complexes 
migrated at Rf  > 0.8 while free Cu2+ had a Rf < 0.2.  
 
The ITLC strips were cut into 2-cm pieces and counted on the calibrated γ-
counter using a dynamic energy window of 282 keV. The minimum chelator 
concentration for which 100% labelling occurred was estimated by doubling the 
measured value at 50% complexation. The specific activity of 61Cu, in 
GBq/µmol of Cu2+, was then calculated by correcting for the total activity and 
molecular weight of the chelator and 61Cu.  
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After complete decay of the 61Cu samples, aliquots (10-20 µL) from each 
production run were diluted with 1% of HNO3, adjusted to a final volume of 
10mL and sent for inductively coupled plasma mass spectrometry (ICP-MS) 
analysis (Curtin University, WA, Australia).  
 
4.3  Results and Discussion  
 
4.3.1  Production of 61Cu  
 
Production of 61Cu using the nat,64Zn(p,α)61Cu nuclear reaction was performed 
under irradiation at 11.7 MeV with 20-40 µA. Two separate target materials 
were used, natZn and enriched 64Zn. The yield (corrected to EOB) of purified 
61Cu after irradiation of natZn foil target was approximately 9.7-19.7 MBq/µA.h 
which was about 20% of the activity produced from an enriched 64Zn target of 
the same thickness, for the same µA.h irradiation. If considering the natural 
abundance of 64Zn in natZn (48.6%), the activity of 61Cu produced from a high-
purity natZn foil target (99.99%, 0.05 mm thick) was lower than expected 
compared to that of the enriched 64Zn target (99.3%, 0.05 mm thick). 
Rowshanfarzad et al. (2006) reported that the production yield of electroplated 
natZn with an 80µm thickness was 445 MBq/μA.h at a proton beam energy of 22-
12 MeV. The results in the present study were much lower than this result, most 
likely due to the energy, incident angle of the proton beam and the target size 
before and after the separation.  
 
The activity of 61Cu produced from a highly enriched 64Zn foil target (corrected 
to EOB) was within the range 517-723 MBq, for an irradiation of approximately 
20 µA.h. This represented a yield of 29-36 MBq/μA.h. Thieme et al. (2013) 
reported that the yield from electroplated 64Zn with a thickness ranging between 
244-597 µm was 20.7-48.3 MBq/μA.h with a primary proton energy of 16 MeV.  
The comparatively higher yields obtained for the present study are most likely a 
consequence of the higher purity (and possibly density) of the enriched 64Zn foils 
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that were used, compared to electroplated 64Zn layers prepared as targets 
reported in Thieme et al. (2013). 
 
To ensure that no contaminating 65Zn was produced, the incident proton energy 
was reduced to 11.7 MeV (Asad et al., 2012). After EOB, γ-spectroscopy of the 
digested foil prior to separation showed no evidence of 65Zn.  At EOB, the co-
produced activities of 66Ga and 68Ga were significantly higher than that of 61Cu, 
but 67Ga activity was negligible (Table 4.1).  
 
4.3.2  Separation and Purification of 61Cu from natZn and    
 Enriched 64Zn Targets 
 
The desired 61Cu product was separated from the irradiated natZn target using a 
three-step purification process, as illustrated in Figure 4.4(a). The first step 
involved loading the dissolved target onto a Cu-resin column to separate out the 
Zn and 66,67,68Ga impurities. A cation-exchange column was used to separate (by 
retention) any remaining traces of Ga ions from the eluted 61Cu. The final step 
involved an anion exchange column to retain any remaining Zn ions from the 
eluted 61Cu solution, which was collected as 61CuCl2 with a radionuclidic purity 
> 99%. The final product was also analysed by ICP-MS for trace metal 
contaminants.   The results of this analysis are shown in Figure 4.5.  
 
For the separation and purification of 61Cu from irradiation of an enriched 64Zn 
target, only a single Cu-resin column (Figure 4.4 (b)) was necessary since the Ga 
radionuclide contamination was low. Table 4.1 shows the γ-spectroscopy 
analysis of the radionuclidic composition before and following separation: no 
radionuclidic impurity was detected in the 61Cu product obtained from both 
purifications. Figure 4.6 presents the ICP-MS analyses of trace metal 
contaminants for each 61Cu separation.  
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Table 4.1 Typical radionuclidic compositions of digested foils prior to 
column chromatography separation, and purified 61Cu product 
following separation. Results for both target materials are 
corrected to EOB and expressed as percentage of total counts 
attributed to the characteristic photopeak of the radionuclide, 
corrected for the branching fraction of the decay mode.  
 
Target Material Radionuclide Prior to 
Separation (%) 
Purified Product 
(%) 
    
*natZn 61Cu 7.3 100 
 66Ga 12.2 Not detected 
 67Ga 0.2 Not detected 
 68Ga 80.3 Not detected 
 
†Enriched 64Zn 61Cu 90.06 100 
 66Ga 1.67 Not detected 
 67Ga Not detected Not detected 
 68Ga 8.27 Not detected 
    
 
*Target bombarded at 20 µA for 30 min  
†Target bombarded at 40 µA for 30 min  
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Figure 4.5  ICP-MS results from irradiated natural Zn. Relative amount (ppm) 
of Cobalt, Copper, Iron, Gallium, Nickel, Lead and Zinc ions 
present in 47-85 MBq of produced 61Cu. 
 
 
 
Figure 4.6  ICP-MS results from irradiated enriched 64Zn.  Relative amount 
(ppm) of Cobalt, Copper, Iron, Gallium, Nickel, Lead and Zinc 
present in 105-571 MBq of produced 61Cu. 
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Several general separation methods have been reported in the literature for 
isolating Cu isotopes and Ga isotopes from the Zn target materials by cation and 
anion exchange chromatography (Rowshafarzad et al., 2006; Dasqupta et al., 
1991; Schwarzbach et al., 1995). In the case of 61Cu, Rowshanfarzad et al. 
(2006) irradiated a natZn target using 22 MeV proton beam energy at 180 µA.h.  
They isolated the 61Cu with a combination of cation and anion exchange 
columns, using large volumes of concentrated HCl to separate the Cu from the 
Ga and Zn by-products. Unfortunately, the specific activity of the isolated 
products was not reported.    
 
As part of this work, the cation/anion exchange chromatography method as 
described by Rowshanfarzad et al. (2006) was reproduced for the purification of 
product obtained from natZn and 64Zn targets (for results see Asad et al., 2012; 
and Appendix A “purification methods”). This led to the development of an 
improved method outlined in this chapter. This improved method presents the 
following advantages:  
i) Decreased separation time by a factor 4 (from 120 min to 30 min). 
ii) Smaller volumes of acid used for the purification. 
iii) Decreased radiation exposure by 20%. 
iv) Reduced metal contamination and therefore increased specific activity of  
     the final product. 
v) Improved radionuclidic purity (from > 95% to > 99%).  
 
4.3.3  Specific Activity of 61Cu  
 
ICP-MS was used to assess both the total non-radioactive Cu content and the 
presence of the contaminating metal ions Co, Fe, Ni, Pb, Ga and Zn in ‘cold’ 
samples of the purified solutions containing 61Cu. Figures 4.5 and 4.6 summarise 
the trace metal content in each target experiment derived from both types of 
target. The ICP-MS values for Cu were used to determine the no-carrier-added 
specific activity (NCA-SA) of the 61Cu at EOB, and these data are compared 
with the effective specific activities (ESA) obtained by titration with chelators. 
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The ESA values for the 61Cu were determined using three chelators, DOTA-
NCS, NOTA-NCS and diamsar. Typical titration curves for each of the three 
chelators are shown in Figure 4.7. A comparison of ESA and NCA-SA values 
are presented in Table 4.2. 
 
Table 4.2 Comparison between no-carrier-added specific activities (NCA-
SA) of purified 61Cu determined from ICP-MS and effective 
specific activities (ESA) determined by titration with each of three 
Cu2+ chelators: diamsar, NOTA-NCS and DOTA-NCS. 
Uncertainties are ± SD, with 4 experiments for each target 
material.  Experiment numbers equate to those shown in Figures 
4.5 and 4.6. 
 
Target 
Material 
ESA by titration with chelator (MBq/µg) NCA-SA by 
ICP-MS 
(MBq/µg) 
 diamsar NOTA DOTA  
natZn     
Expt #1 185.9 ± 6.5 74.06 ± 2.7 18.6 ± 0.6 233.3 ± 23.3 
Expt #2 92.2 ± 5.1 23.4 ± 1.4 5.9 ± 0.3 191.9 ± 19.2 
Expt #3 84.7 ± 4.7 26.6 ± 1.7 4.7 ± 0.2 143.3 ± 14.3 
Expt #4 137.5 ± 2.8 70.3 ± 4.1 35.9 ± 0.6 169.4 ± 16.9 
     
Enriched 64Zn     
Expt #5 379.7 ± 9.5 31.7 ± 1.1 19.0 ± 1.1 434.4 ± 43.4 
Expt #6 326.5 ± 10.1 63.3 ± 3.7 30.3 ± 1.8 482.1 ± 48.2 
Expt #7 412.5 ± 15.3 82.7 ± 5.4 8.3 ± 0.4 506.2 ± 50.6 
Expt #8 368.9 ± 11.8 19.7 ± 1.1 16.9 ± 0.2 496.4 ± 49.6 
     
 
For 61Cu derived from the natZn target irradiation, the NCA-SA values were in 
reasonable agreement with the calculated ESA values using the diamsar chelator 
(approximately 1.2-2.1 higher). For the 64Zn target they were 1.1-1.5 higher.  
Thus the specific activities determined using titration with diamsar are 
considered to be in good agreement with specific activities calculated from ICP-
MS, particularly as they were achieved in the presence of relatively high 
concentrations of Zn2+ and Pb2+ (Figures 4.5 and 4.6). The metal impurities may 
have arisen from air contamination, since the separation experiments were not 
performed in a certified clean room environment.Titration with the two other 
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chelators NOTA-NCS and DOTA-NCS produced ESA values that were 
significantly lower than the ICP-MS derived values (Table 4.2).  
Thieme et al. (2013) found that the ESA values for 61Cu using the TETA chelator 
were 3-fold less than the ICP-MS values. In this study, we found that diamsar 
was the best chelator to use in determining the ESA with the titration method, if 
the ICP-MS derived NCA-SA is considered as the more reliable ‘gold standard’.  
This is because it has a higher selectivity for the Cu2+ ions over other metal-ion 
contaminants present in the radioactive solutions.  In the case of NOTA-NCS 
and DOTA-NCS, Fe 2+/3+ and Zn2+ ions were likely the main competitors of Cu2+ 
ions. The relatively high concentration of Zn2+ derives from residual zinc target 
material (Zn > 50 ppm) (Chakravarty, Chakraborty, Dash, & Pillia, 2013). 
 
The complexation of 61Cu with the different chelators was analysed after 
incubation at room temperature for 30 min as shown in Figure 4.7. The data 
indicate that the complexation yield of diamsar could be achieved with µmolar 
concentrations of chelator, which was better than NOTA-NCS or DOTA-NCS 
under the same conditions. NOTA-NCS achieved 100% complexation at lower 
concentrations than DOTA-NCS. Heating would likely improve the labelling 
efficiency with DOTA-NCS but also facilitate complexation of other metal ions 
more avidly. These results suggest that the use of diamsar as titration chelator to 
calculate the specific activity is more accurate than the use of DOTA-NCS or 
NOTA-NCS, because of the high selectivity of diamsar towards the Cu2+ ion. 
Furthermore, Smith (2004) reported that > 99.9% complexation of 64Cu could be 
obtained in 2 min with SarAr (functionalised diamsar) at very low concentrations 
(1 µmolar), at room temperature using a 1:1 molar ratio ligand:metal and a pH 
range of 4-9. These findings and the results obtained in the present study support 
the case for further development of the hexa-aza bicyclic cages for clinical and 
pre-clinical studies (Paterson et al., 2014; Wei et al., 2009; Liu, Li, & Conti, 
2014) 
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Figure 4.7 Complexation of 61Cu with increasing concentrations of the Cu2+ 
chelators diamsar, NOTA-NCS and DOTA-NCS (room 
temperature, 30 min reaction). 
 
4.4  Conclusions 
 
The desired 61Cu nuclide was produced from the 64,natZn(p,α)61Cu reaction using 
a 11.7 MeV proton beam energy to irradiate natZn and 64Zn disc targets. This was 
followed by column chromatography separation and purification (three columns 
for natZn, one for 64Zn), yielding 61Cu as 61CuCl2 with high radionuclidic purity 
(> 95%) from each target. Separation and purification from the natZn target using 
a combination of three columns was fast (< 30 min), efficient and 
straightforward.  
 
The overall cost to produce the 61Cu was considerably cheaper using natZn or 
64Zn target, when compared to the cost of using an electroplated 61Ni target; the 
natZn target being the most cost-effective. Effective specific activities of the 
purified 61Cu were measured by the titration method using the three chelators 
diamsar, NOTA-NCS and DOTA-NCS.  These results were compared with no-
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carrier-added specific activities obtained by ICP-MS. While low agreement was 
found for NOTA-NCS and DOTA-NCS, relatively good agreement was found 
with diamsar. This was due to the superior selectivity of diamsar for Cu ion. 
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CHAPTER FIVE 
CONJUGATION AND 64CU-RADIOLABELLING OF 
POLYSTYRENE AND SILICA NANOSPHERES  
 
5.1  Introduction 
 
The application of nano- and micro-materials in the diagnosis and therapy of 
disease has evolved significantly in the last few years. Both organic and 
inorganic materials have been chemically modified to incorporate targeting 
agents and drugs for the treatment of specific diseases (Thorek, Elias, & 
Tsourkas, 2009). These modifications are designed to increase specificity and 
uptake of the desired drug at the site of interest, therefore increasing 
effectiveness of treatments. By varying the charge, size and surface properties of 
the particle, the uptake of drugs to non-specific organs has also been 
significantly reduced (Liu & Welch, 2012). Smaller nanoparticles (100 nm in 
diameter) are comparable in size to antibodies and DNA, and are permeable to 
tumour vasculatures (Gunasekera, Pankhurst, & Douek, 2009). Moderate size 
nanoparticles (< 500 nm in diameter) are used for intravascular targeting; for 
example, they can cross the microfold cells in the Payer’s patch and the 
mesentery on the surface of the gastrointestinal mucosa. Larger particles, 
between 1 and 125 µm, are more suitable for use in the oral delivery of drugs 
(Jain, 2000). For smaller carrier molecules and/or target molecules (such as 
peptides that clear rapidly from biological systems) nanoparticles have been used 
as carriers to lengthen their biological half-life, and so reduce the need for 
frequent administration (Bodmeier & McGinity, 1988). Encapsulation of the 
peptide in a particle has resulted in improvements in their transportation across 
biological barriers, by increasing diffusivity and lowering partition coefficients; 
resulting in significant increased uptake at the target sites (Couverur & Puiseux, 
1993).   
 
104 
 
This chapter explores the radiolabelling of two types of nanomaterials. The first 
type is polystyrene nanospheres, which are non-biodegradable organic particles. 
They are widely used as model and reference particles to study the interactions 
between the particles and cells (Varela et al., 2012). They are non-immunogenic 
and have been shown to have low cytotoxicity in vitro (Papageorgiou et al., 
2007) and in vivo (Yacobi et al., 2008). Polystyrene is easily chemically 
modified, and so one can change the physical properties of the particle (i.e. size, 
surface overall charge, shape and chemical composition) to tailor its interaction 
with cells and blood (Silva, 2007; Yoo, Doshi, & Mitragotri, 2010; Decuzzi et 
al., 2010; Makino et al., 2003; Foged, Brodin, Frojaer, & Sundblad, 2005). 
Because of their hydrophobic nature (Heslinga, Mastria, & Eniola-Adefeso, 
2009) polystyrene particles often localise in lysosomes within the cell (Lorenz et 
al., 2010; Xiao et al., 2010).  
 
The other types of nanomaterials that have been investigated widely are silica-
based particles. These are classified as inorganic materials, with hydrophilic 
surfaces that make them particularly attractive for in vivo applications (Tang & 
Cheng, 2013; Slowing, Vivero-Escoto, Wu, & Lin, 2008; Barbe et al., 2004). 
Silica particles are under development in a number of biomedical imaging, 
assaying, therapeutic delivery and monitoring applications (Liberman et al., 
2014; Desai et al. 2004). In contrast to polystyrene particles, they are 
biodegradable and also have low cytotoxicity in vivo.  Their synthesis is readily 
scalable and the particle surfaces are easily modified to increase drug loading, 
blood circulation and site specific targeting (Liberman et al., 2014).  
 
As discussed in Chapter 1, polyazacarboxylate chelators such as DOTA, TETA 
and NOTA have been widely used for radiolabelling particles (Chapter 1; 
Section 1.6).  There are two significant problems with the use of DOTA or 
TETA chelators; the requirement of heat for radiolabelling (above room 
temperature) and the kinetic lability of the resultant Cu2+ complex in vivo (Bass, 
Wang, Wlech, & Anderson, 2000; Boswell et al., 2004; Rogers et al., 2003, 
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2004).  NOTA chelator has been shown to possess better Cu2+ complexation 
under mild conditions (Chapter 1; Section 1.6).  
 
The charge of the final Cu2+ bifunctional chelator (BFC) complex can influence 
the biodistribution of radioactivity in vivo (Cooper et al., 2012; Lewis et al., 
2001; Dearling et al., 2011). The sarcophagine macrocycles, for example SarAr-
NH2 and MeSar-Ph-NCS, are particularly attractive for use in radiolabelling of 
functionalised particles. The sarcophagine chelators are known to form 
64Cu:BFC 1:1 complexes comparably faster at room temperature at pH 5-9 and at 
µmolar concentration. Both are reported to be effective in radiolabelling a range 
of bioactive target agents (Clift et al., 2008; Di Bartolo, Sargeson, & Smith, 
2006; Kong, Mume, Triani, & Smith, 2013; Mume et al., 2013; Smith, 2004), 
(Chapter 1; Section 1.6) and show high in vivo stability (Paterson et al., 2014). 
Indeed, in vitro and in vivo stability of the resultant Cu2+ SarAr bioconjugates 
have been shown to be at least as stable as the analogous Cu2+ DOTA, TETA and 
NOTA bioconjugates (Liu, 2008; Di Bartolo et al., 2006). Because SarAr forms 
metal:chelator complexes of 1:1 over a wide range of pH, it is particularly useful 
in quantifying functional groups on the particle surface (Hung, Joso, Fuchs, 
Barner, & Smith, 2008). 
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Figure 5.1 Schematics of (a) the SarAr-NH2/EDC conjugation reaction with 
polystyrene nanospheres (PS NS), (b) Conjugation of a BFC (R = 
DOTA-NCS, NOTA-NCS or MeSar-Ph-NCS) onto the surface of 
silica nanospheres (Si NS). 
 
The overall efficiency of the conjugation of BFCs to the NS can be determined 
using a number of routes.  For example, by radiolabelling of SarAr chelator 
conjugated to NS with a radionuclide such as 57Co (t1/2 = 271.8) days (Kong et 
al, 2013) the efficiency can be inferred from a measurement of the final 
radioactivity.  As both metals Co2+ and Cu2+ form complexes of similar geometry 
with all the complexing BFCs under investigation, 57Co was used as a surrogate 
for assessing the stability of the functionalised NS for long range in vitro studies 
 
In this study the polystyrene nanospheres (PS NS) were activated with 
carboxylate groups on their surface while the silica nanospheres (Si NS) were 
activated with amino groups.  The PS NS were conjugated with the SarAr-NH2 
chelator using the classical EDC method (see Figure 5.1 a). The Si NS were 
conjugated with three BFCs, DOTA-NCS, NOTA-NCS and the new MeSar-Ph-
NCS chelator, to form an isothiourea bond with the isothiocyanate groups (see 
Figure 5.1 b) (McDevitt et al., 2007; Lang, Ma, Kiesewetter, & Chen, 2014). 
 
The aim of this chapter is to assess the effectiveness of radiolabelling with a 
range of BFCs (DOTA-NCS, NOTA-NCS, and MeSar-Ph-NCS) on two types of 
functionalised NS. More specifically; 
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a) To radiolabel a series of PS NS of different sizes (i.e. 365, 680 and 840 nm 
diameter) functionalised with carboxylate groups with 57/natCo2+ or 64/natCu2+.  
 
b) To radiolabel amino functionalised Si NS with MeSar-Ph-NCS, NOTA-NCS 
and DOTA-NCS. 
 
c) To compare the number of each chelator conjugated on the surface of the NS. 
 
5.2  Experimental  
 
All reagents and solvents used were of analytical grade and were obtained from 
commercial sources unless otherwise stated. All chemicals used in these studies 
were greater than 99% pure unless otherwise stated. TraceSELECT high purity 
water; anhydrous sodium acetate anhydrous; MES [2-(N-morpholino)-
ethanesulfonic acid], EDC [N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride], styrene [C5H6CH=CH2], inhibitor remover [4,4′-Azobis (4-
cyanovaleric acid)] (≥ 98%), analytical standard solutions of CoCl2 and CuCl2 
(0.01M) and eppendorf tubes (1.5 mL) were purchased from Sigma-Aldrich 
(Australia). The SarAr-NH2 chelator N1, N8-bis [(4-aminophenyl) methyl]- 
3,6,10,13,16,19 hexaazabicyclo [6.6.6]eicosane-1,8-diamine] was purchased 
from Clarity Pharmaceuticals (Australia), in powder form (19.9% chemically 
pure with carrier salt for storage stability). Isothiocyanate derivatives of 
[Mg(CH3)(p-NCS-Ph)sar](CF3SO3)2 (MeSar-Ph-NCS) were kindly provided by 
Dr Paul Donnelly (Melbourne University, Australia). The p-isothiocyanato 
benzyl derivatives of BFCs such as 1,4,7,10 tetraazacyclododecane1,4,7,10-
tetraacetic acid (DOTA-NCS), 1,4,7-triazacyclononane-1,4,7-triacetic acid 
(NOTA-NCS) were purchased from Macrocyclics (USA). Si NS were supplied 
by Corpuscular (NY, USA). Trace SELECT water was used in the preparation of 
buffers and cold solutions of Co2+ and Cu2+. High specific activity (SA) 
radioisotopes, 64Cu (t1/2 = 12.7 h; SA = 6.34 x 106 GBq g-1) and 61Cu (t1/2 = 3.3 h; 
SA = 1.2 x 106 GBq g-1) were obtained from RAPID Labs, (SCGH, Perth, 
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Australia).  57Co (t1/2 = 271.8 days; SA = 3.12 x 105 GBq g-1) was obtained from 
PerkinElmer (IL, USA). Equipment used for this study included a Gamma 
counter Wizard model 2470 (PerkinElmer) and a Multi mixer (TRO-1300) from 
Chromalytic Technology.  
 
5.2.1  Preparation of Polystyrene Nanospheres  
 
PS NS of 365, 680 and 840 nm diameter were a gift from senior research chemist 
Linggen Kong at ANSTO [Australian Nuclear Science and Technology 
Organisation]. Table 5.1 gives the components used to generate each particle 
size.  A typical synthesis involved mixing styrene and NaOH in a 250 mL round 
bottom flask. The styrene was added through a syringe filled with inhibitor. 
Then, water was added until the desired total mass was reached. The flask was 
capped and deoxygenated with nitrogen gas for 15 min, then immersed in a 37 
°C oil bath with constant stirring for at least 20 h. After cooling to room 
temperature, the mixture was centrifuged at 6000 rpm. The polymer particles 
were washed twice with water to remove free monomers, and then resuspended 
in water. A small amount (in triplicate) of the particle suspension was freeze- 
dried to determine the solid content of the slurry.  The size and morphology of 
the PS NS were analysed using transmission electron microscopy [TEM: JEOL 
2000 FXII] and the diameters of individual particles were confirmed (see Figure 
5.2). 
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Table 5.1 Chemical components used to synthesize the polystyrene 
polymer particles and their resultant physical properties.  
 
 
Styrene (mmol) 38 76 76 
Inhibitor (mmol) 0.384 0.768 0.384 
Estimated -
COOH group 
added (mol %) 
2 2 1 
Total mass 
produced (g) 
140 40 40 
Mass of solid 
particles (g) 
3.266 7.028 6.57 
Average 
nanosphere size 
(nm)  (as 
determined by 
TEM) 
365 680 840 
 
 
                                  
 
            
       
                                                 
                            (a)                              (b)                            (c)  
 
Figure 5.2  TEM images of PS NS (a) 365 nm (b) 680 nm (c) 840 nm. 
 
5.2.2  Optimisation of the Conjugation of SarAr-NH2 to  
          Polystyrene Nanospheres  
 
To seven vials (2.0 mg in 100 µL) of 680 nm diameter PS NS in 1.5 mL 
eppendorf tubes were added varying amounts (1, 50, 100, 250, 350, 500, and 
750 nmol) of a freshly prepared solution of SarAr-NH2 in 0.1 M MES buffer 
(pH 5) in presense of an excess of EDC (10:1 EDC/SarAr-NH2 molar ratio). 
The final volume of the reaction mixture was adjusted to 0.9 mL with 0.1 M 
MES buffer (pH 5). The mixture was vortexed then rotated by a MultiMix 
(360 °C continuous rotation) for 2 h at room temperature (23 °C). The 
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suspension was then centrifuged for 10 min at 5000 rpm before the 
supernatant was removed. Conjugated nanospheres (SarAr-NH2-PS NS) were 
washed a further two times with 0.1 M MES buffer (pH 5) in a similar 
manner to that described above to remove unreacted SarAr-NH2. The 
supernatant was discarded each time. The resultant seven batches of 
conjugated nanospheres were then suspended in 100 µL of 0.1 M sodium 
acetate buffer (pH 6.5) for radiolabelling.  
 
5.2.3  Optimisation of the Conjugation of NOTA-NCS and     
  DOTA-NCS to Silica Nanospheres 
     
To six vials (2.5 mg in 100 µL) of 200 nm diameter Si NS in 1.5 mL eppendorf 
tubes were added varying amounts of (1, 50, 100, 250, 350, 500, and 750 nmol) 
of a freshly prepared solution of BFC (NOTA-NCS or DOTA-NCS) in 0.1 M 
PBS buffer (pH 8). The buffer pH value was selected from the optimised pH 
range of 8-9 (Figure 5.3). The final volume of the reaction mixture was adjusted 
to 0.9 mL with 0.1 M PBS buffer (pH 8). The mixture was vortexed, then rotated 
using a MultiMix (360 °C continuous rotation) overnight at room temperature 
(23 °C).  The suspension was then centrifuged for 10 min at 5000 rpm before the 
supernatant was removed. Each conjugated batch of nanospheres (BFC-Si NS) 
was washed a further two times with 0.1 M PBS buffer (pH 8) in a similar 
manner to that described above, to remove unreacted chelator.  The supernatant 
was discarded each time. The resultant six batches of conjugated nanospheres 
were then suspended in 100 µL of 0.1 M sodium acetate buffer (pH 6.5) for 
radiolabelling.  
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Figure 5.3    Effect of pH on radiolabelling efficiency of Si NPs using DOTA-
NCS. Experimental conditions: Si NS = 2.5 mg, DOTA-NCS = 500 nmol, 
radiolabelling at pH 7 at room temperature (23 °C).  (Mean±SD, N = 3) 
 
5.2.4  Optimisation of the Conjugation of MeSar-Ph-NCS to   
          Silica Nanospheres 
 
To six vials (2.5 mg in 100 µL) of 200 nm diameter Si NS in 1.5 mL eppendorf 
tubes were added varying amounts (10, 25, 50, 100, 150 and 200 nmol) of a 
freshly prepared solution of MeSar-Ph-NCS in 0.1 M PBS buffer (pH 8). The 
final volume of the reaction mixture was adjusted to 0.9 mL with 0.1 M PBS 
buffer (pH 8). The mixture was vortexed then rotated by a MultiMix (360 °C 
continuous rotation) for 2 h at room temperature (23 °C), as described previously 
by Paterson et al. (2014).   The suspension was then centrifuged for 10 min at 
5000 rpm before the supernatant was removed. Then, 0.1 M sodium acetate 
buffer (pH 6) was added to the conjugated NS (BFC-Si NS) for up to 2 h for 
further mixing to remove the Mg2+ from the chelator. The suspension was then 
centrifuged for 10 min at 5000 rpm, the supernatant removed and the slurry 
taken in 0.1 M PBS buffer (pH 7). The process was repeated twice to remove 
unreacted chelator. After the last wash, the resultant 6 batches of conjugated 
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particles were then suspended in 100 µL of 0.1 M sodium acetate buffer (pH 6.5) 
for radiolabelling.  
 
5.2.5  Radiolabelling of SarAr-NH2 – Polystyrene Nanospheres  
             Conjugation 
 
The SarAr-NH2 conjugated PS NS (suspended in 100 µL of 0.1 M sodium 
acetate buffer pH 6.5) were exposed to a known amount (1 nmol, 10 µL) of 
57/natCo2+ or 64/natCu2+ in the same buffer. The total volume of the mixture was 
adjusted with acetate buffer (pH 6.5) to 0.9 mL, vortexed and subsequently 
rotated on a MultiMix (360 °C continuous rotation) for 1.25 h to 24 h at room 
temperature (23 °C).  The mixtures were then centrifuged for 10 min at 10000 
rpm and washed with acetate buffer (pH 6.5).  After each wash, the supernatant 
was collected and transferred to a test tube for counting on the gamma counter. 
The washing step was repeated until no further release of radioactivity could be 
detected (up to 4 times). All reactions were conducted in triplicate and results are 
reported as an average of the triplicates. The percentages of radiolabelling 
efficiency and metal ions associated with the particle were calculated from the 
equations (1 & 2) respectively: 
 
                          
   
                                                                                                                   (1) 
   
       (2)                            
 
where Activitypellets  is the total activity of the pellets after the last wash; 
Activitysupernatant is the summed activity of the total washes; Cu2+associated is the 
total number of moles of Cu ions attached to particles and Cu2+initial  is the 
initial number of moles of Cu ions added to the particles.  
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5.2.6  Radiolabelling of Bifunctional Chelators - Silica  
  Nanospheres Conjugation 
 
The conjugated Si NS (NOTA-Si NS, DOTA-Si NS or MeSar-Ph-Si NS) 
suspended in 100 µL of 0.1 M sodium acetate buffer (pH 6.5) were exposed to a 
known amount (1 nmol, 10 µL ) of 64/natCu2+ in the same buffer. The total volume 
of the mixture was adjusted with acetate buffer (pH 6.5) to 0.9 mL, vortexed and 
subsequently rotated on a MultiMix (360 °C continuous rotation) for 2 h at room 
temperature (23 °C).  The mixtures were then centrifuged for 10 min at 10000 
rpm and washed with acetate buffer (pH 6.5).  After each wash, the supernatant 
was collected and transferred to a test tube for counting on the gamma counter. 
The washing step was repeated until no further release of radioactivity could be 
detected (up to 4 times). All reactions were conducted in triplicate and results are 
reported as an average of the triplicates. The percentage of radiolabelling 
efficiency and metal ions associated with the particle was calculated from the 
equations 1 & 2 in Section 5.2.5. 
 
5.3  Results and Discussion  
5.3.1   Optimisation of the Conjugation of SarAr-NH2 to  
   Carboxylate Functionalised Polystyrene Nanospheres
  
   
 
SarAr-NH2 was conjugated to three different sizes of PS NS. The 
conjugationswere performed under mild conditions using EDC activating agent. 
The EDC activates the carboxylate group on the surface of the PS NS allowing 
the rapid formation of an amide bond with the aromatic amine of the SarAr-NH2 
chelator.  The conjugation via this amine has been confirmed in the literature 
(Naoki Nakajima & Ikada, 1995; Vashist, 2012). Optimisation of the conjugation 
reaction was conducted by varying the concentration of the SarAr-NH2 chelator 
exposed to a fixed amount of PS NS. In each case the resultant SarAr-conjugated 
NS were washed and resuspended in acetate buffer (pH 6.5) for radiolabelling 
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with 57/natCo2+ or 64/natCu2+. The radiolabelling solutions contained known 
concentrations of the cold metal ions natCo2+ or natCu2+, spiked with traces 
amounts of 57Co and 64Cu respectively. The gamma emission of the radioisotope 
present was used to determine the amount of isotope complexed and therefore 
the concentration of metal ions complexed to the SarAr-NH2 conjugated 
particles. Uncomplexed metal ions were removed by washing and centrifugation. 
Each wash was checked using the γ-counter and when radioactivity was no 
longer detected in the wash, the final product activity was assessed.  Each batch 
of conjugated NS were radiolabelled with both 57/natCo2+ and 64/natCu2+ solutions. 
Figure 5.4 illustrates typical radiolabelling efficiency curves of a SarAr-NH2 
conjugated nanospheres of 680 nm diameter with both for 57/natCo2+ and 
64/natCu2+. The shapes of the curves are similar and demonstrate that the sites on 
the SarAr-NH2 conjugated NS are saturated when exposed to ≥ 100 nmol of 
SarAr-NH2. A plot of the number of moles of 57/natCo2+ and 64/natCu2+ added vs 
the number of moles of SarAr-NH2 conjugated to the NS is given in Figures 5.5 
a & b.  For the 365 nm and 840 nm diameter PS, the amount of moles of SarAr-
NH2 used for each conjugation was set at an excess of 250 nmoles to ensure 
saturation of all available carboxylate sites based on the Figure 5.4 for 680 nm 
size.  
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Figure 5.4 Effect of concentration of SarAr-NH2 on radiolabelling efficiency 
of PS NS. Experimental conditions: PS NS size = 680 nm, 57/natCo2+ or 
64/natCu2+ = 1 nmol; radiolabelling pH 7 at room temperature (23 °C).   (Mean 
± SD, N = 3) 
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Figure 5.5   Comparison of radiolabelling efficiency of 64/natCu2+ and 57/natCo2+ 
at 1 h and 2 h respectively with 2.0 mg of PS NS size = 680nm (a) 
The number of moles of 64/natCu2+ conjugated to PS NS vs. the 
number of moles of SarAr-NH2 used in the conjugation reaction 
with the NS. (b) The number of moles of 57/natCo2+ conjugated to 
PS NS vs. the number of moles of SarAr-NH2 used in the 
conjugation reaction with the NS. 
 
The radiolabelling conditions of the conjugated SarAr-PS NS with metal ions 
were optimised for reaction time, temperature and amounts of SarAr-NH2. 
Figure 5.6 illustrates the effect of reaction time (up to 24 h) on radiolabelling 
57/natCo2+ with SarAr-PS NS (680 nm size). In this study, the reaction time of 24 
h was used for all three NS sizes because of the expected slower complexation 
kinetics of Co2+ with SarAr-NH2 compared with Cu2+. The reaction temperature 
of the radiolabelling was monitored at 23 °C. In general, it was found that the 
radiolabelling efficiency of 57/natCo2+ at 37 °C was 34 ± 9% SD (n=3; p > 0.01; 
NS) higher than that achieved at 23 °C (using a 1.25 h reaction time) for the full 
range of added 57/natCo2+ nmole amounts. 
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Figure 5.6 Effect of time on the radiolabelling efficiency of 57/natCo2+ with 
BFC-PS NS. Experimental conditions: SarAr-NH2 = 250 nmol, PNS = 680 nm, size 
= 2mg radiolabelling pH 7 at room temperature (23 °C). (Mean ± SD, N = 3). 
 
5.3.2  Determination of the Number of Active Sites per 
Nanosphere 
    
Using the optimised conditions, the conjugation each nanosphere (i.e. 365 nm, 
680 nm and 840 nm diameter) was achieved. The NSs were treated with an 
excess of SarAr-NH2 (250 nmol per 2 mg) and an excess of EDC (2.5 mmol per 
2 mg).  The reactions were conducted in MES buffer (pH 5). The final product 
was then exposed to varying known concentrations of 57/natCo2+ in acetate buffer 
(pH 6.5) and incubated at 23 °C for 24 h. Figures 5.7 a, b & c compare the 
radiolabelling efficiency for each NS diameter, as well as the equivalent number 
of moles of Co2+ bound to the particles. The data clearly show that the amount of 
57/natCo2+ ion required to saturate all available SarAr-NH2 sites varied for each 
NS size. For example, for 365 nm, 680 nm and 840 nm sizes NS, all reach 
saturation at approximately 50 nmol of SarAr-NH2. However, the total number 
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of Co2+ ions attached per NS was greater for NS of 680 nm diameter compared 
to NS of 840 nm diameter. This indicates that for 2.0 mg of 680 nm diameter NS, 
the number of available carboxylate sites present for conjugation of the SarAr-
NH2 was higher than the number of sites present on the 840 nm NS; this would 
normally indicate that the surface area of these NS is higher. Surprisingly the 
radiolabelling efficiency for 365 nm is similar to 840 nm size, at 0.1 nmol of 
Co2+. Figure 5.8 illustrates the Co2+ associated per NS (nmol) with the amount of 
Co2+ added in each particle size. These data suggest that the activated surface 
area (i.e. the number of available carboxylate groups or conjugated chelators) 
did not increase as the particle size decreased, as was expected. These results 
may be due to subtle inconsistencies in the reaction conditions for the 
preparation of the three sizes of activated NS. Alternatively, the degree of 
carboxylate activation of NS may be directly dependent on NS size, though if so 
this relationship remains to be elucidated. 
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Figure 5.7 Radiolabelling efficiency and the number of 57/natCo2+ per NS for 
different amounts of 57/natCo2+ added to reaction mixture. 
Experimental conditions: Amount SarAr-NH2 = 250 nmol, PS NS size (a) 365 
nm (b) 680 nm (c) 840 nm, radiolabelling pH 7 at room temperature (23 °C). 
(Mean ± SD, N = 3). 
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Figure 5.8      The amount (nmol) of 57/natCo2 exposed to SarAr-NH2-NS. NS   vs.    
              actual number of nmoles of Co2+ specifically bound to each NS. 
Experimental conditions: Amount SarAr-NH2 = 250 nmol, radiolabelling pH 7 
at room temperature (23 °C). (Mean ± SD, N = 3). 
 
5.3.3  64Cu-Radiolabelling of SarAr-NH2 - Polystyrene 
Nanospheres Conjugation: Effect of Reaction Temperature 
 
The 680 nm size SarAr-NH2-PS NS were radiolabelled with 64Cu, using the same 
radiolabelling procedure as used with 57/natCo2+. Two experiments were run in 
parallel at different reaction temperatures, with 250 nmol of SarAr-NH2 
conjugated to the surface of carboxylate-activated PS NS by EDC chemistry at 
pH 5 for 2 h at 23 °C.  Several washes were applied to remove unreacted SarAr-
NH2 from the  NS. The mixture was radiolabelled by treatment with a solution of 
Cu2+ doped with 64Cu for 75 min at 23 °C and 37 °C. As the results demonstrate 
(Figure 5.9), no significant temperature-related differences in the 64/natCu2+  
radiolabelling efficiency could be detected. This confirms  the relatively fast 
complexation of 64/natCu2+ by SarAr-NH2-PS NS at room temperature, proceeding 
to completion in the first few minutes of reaction.  
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Figure 5.9 Effect of temperature on radiolabelling efficiency of Cu2+. 
Experimental conditions: Amount SarAr-NH2 = 250 nmol, PS NS size = 680 
nm, radiolabelling pH 7 at (a) room temperature (23 °C) and (b) 37 °C. (Mean 
± SD, N = 3). 
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The physical characteristics of the SarAr-NH2 conjugated PS NS are summarised 
in Table 5.2. The average areas occupied by a SarAr-NH2 molecule on the 
surfaces of 365 nm, 680 nm and 840 nm PS were 8.28, 2.61 and 5.56 nm2, 
respectively. The highest number of conjugated SarAr-NH2 was observed using 
the 680 nm diameter NS, which also demonstrated the highest radiolabelling 
efficiency. The number of SarAr-NH2 groups attached to a typical 840 nm NS 
was considerably less than expected.  This is most likely due to the different 
number of available binding sites and the different chemical components used to 
produce the particles.   
 
Table 5.2  Physical Characteristics of SarAr-NH2 conjugated PS NS. 
 
TEM-
measured 
diameter (nm) 
of NS 
 365 680 840 
Theoretical Number of 
NS in 2 mg 
of solution 
(1010)a  
7.48 1.16 0.61 
 Surface area 
per NS (nm2) 
(105) 
4.19 14.5 22.2 
Experimentalb Co2+ (nmol) 
saturated  
6.28 10.68 4.06 
Calculated SarAr-NH2 
attached to 
NS at 
saturation 
(1015) 
3.78 6.43 2.44 
 SarAr-NH2 
attached per 
NS (105) 
0.50 5.56 3.98 
 Area 
occupied by 
one SarAr-
NH2  (nm2) 
on surface of 
NS 
8.28 2.61 5.56 
aDensity of these particles is assumed to be ~1.05 g/cm3.  b Data taken from Figure 5.8.  
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5.3.4 Optimisation of the Conjugation of Different Bifunctional 
Chelators to Silica Nanospheres  
 
The conjugation of  BFC-NCS with Si NS (200 nm) were optimised using the 
two chelators MeSar-Ph-NCS and NOTA-NCS.  The p-isothiocyanato benzyl 
derivative of each chelator was reacted with the amine group on the surface of 
the Si NS to form an isothiourea bond (see Figure 5.1 b). The conjugation via 
this amine group has been described in the literature (Kong et al., 2013). 
Optimisation of these conjugation reactions was conducted by varying the 
concentration of the chelator exposed to a fixed amount of Si NS. In each case 
the resultant chelator-conjugated nanosphere was washed and resuspended in 0.1 
M acetate buffer (pH 6.5) for radiolabelling with 64/natCu2+. The radiolabelling 
solutions contained known concentrations of cold Cu2+ ion spiked with 64Cu. The 
gamma emission for the radioisotope present was used to determine the amount 
of isotope complexed and therefore the concentration of metal ions complexed to 
the chelator conjugated NS.  Each wash was checked for radioactivity until no 
activity was present in the supernatant. Each batch of conjugated NS was 
radiolabelled with 64/natCu2+ solution. Figure 5.10 illustrates typical radiolabelling 
efficiency curves for 64/natCu2+ of the NOTA-NCS and MeSar-Ph-NCS 
conjugated to 200 nm diameter Si NS.  Figure 5.10 (a) shows that the sites on the 
MeSar-Ph-NCS-conjugated Si NS are saturated when ≥ 125 nmol of MeSar-Ph-
NCS reactant was added. In the case of NOTA-NCS, Figure 5.10 (b) shows the 
NOTA-conjugated NS were saturated when the amount of BFC reacted exceeded 
500 nmol. Similar results were found with DOTA-NCS (not shown). Therefore, 
the conjugation reaction of 100 nm diameter Si NS with MeSar-Ph-NCS, 
NOTA-NCS and DOTA-NCS were set at an excess of 125, 500 and 500 of BFC, 
respectively, to ensure all available amine sites were reacted. 
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Figure 5.10  Radiolabelling efficiency vs. varying concentrations of (a) 
MeSar-Ph-NCS and (b) NOTA-NCS added to the reaction 
mixture. Experimental conditions: silica nanospheres size = 200 nm, Amount 
64/natCu2+ = 1 nmol, radiolabelling pH 7 at room temperature (23 °C).    
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5.3.5  64Cu-Radiolabelling of DOTA-NCS-, NOTA-NCS- and MeSar-Ph-
NCS-Conjugated Silica Nanospheres 
   
5.3.5.1  64Cu-DOTA-NCS-Silica Nanospheres 
 
The conjugation of DOTA-NCS to amino-functionalised Si NS was performed 
by adding 500 nmol of DOTA-NCS to 2.5 mg of 100 nm size Si NS. The 
unconjugated DOTA-NCS was removed by washing the NS 3 times with 0.1 M 
PBS buffer (pH 8). The isolated DOTA-NCS conjugated NS were then exposed 
to varying amounts of 64/natCu2+, including high excess for up to 2 h at 23 °C. The 
radiolabelled NS were washed with 0.1 M sodium acetate buffer (pH 6.5) to 
remove non-specifically bound 64/natCu2+. Figure 5.11 illustrates the 
radiolabelling efficiency of 64/natCu2+ with DOTA-NCS-conjugated Si NS of 100 
nm diameter.  
 
 
 
Figure 5.11  Radiolabelling efficiency of 64/natCu2+- DOTA-NCS-Si NS and 
64/natCu2+ associated with NS (nmol). Experimental conditions; Amount 
DOTA-NCS = 500 nmol; Si NS size 100 nm (mean ± SD, N = 3).  
 
 
 
126 
 
5.3.5.2   64Cu-NOTA-NCS-Silica Nanospheres 
 
The conjugation and radiolabelling of Si NS (at 23 °C) with NOTA-NCS was 
conducted under similar procedures as described for DOTA-NCS. The data are 
illustrated in Figure 5.12 and show clearly that the radiolabelling efficiency for 
NOTA-NCS-Si NS (80%) is significantly higher than that for DOTA-NCS-Si 
NS (49%) using the same conditions for conjugation and radiolabelling.  
 
 
 
Figure 5.12  Radiolabelling efficiency of 64/natCu2+- NOTA-NCS-Si NS and 
64/natCu2+ associated with NS (nmol).  Experimental conditions; Amount 
NOTA-NCS = 500 nmol; Si NS size 100 nm (mean ± SD, N = 3).  
 
5.3.5.3  64Cu-MeSar-Ph-NCS-Silica Nanospheres 
 
Due to the limited supply of MeSar-Ph-NCS ligand, only 100 nm NS were 
conjugated and then radiolabelled with 64/natCu2+. The conjugation of MeSar-Ph-
NCS to Si NS follows a slightly different procedure than that described for 
NOTA-NCS and DOTA-NCS. An extra step was necessary for the removal of 
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the Mg2+ stabiliser from the sarcophagine, before radiolabelling with 64/natCu2+. 
PBS buffer (pH 8) was used to conjugate Si NS with MeSar-Ph-NCS for 2 h at 
(23 °C). This was followed by a washing procedure and a centrifugation step (15 
min at 5000 rpm). After the last wash, in order to extract Mg2+ from the chelator 
it was necessary to drop the pH to 6 by addition of sodium acetate buffer (pH 6). 
The samples were left to incubate (23 °C, 1 h) to allow time for the acetate-
mediated extraction of the Mg2+ before a final centrifugation. The supernatant 
buffer (containing the extracted Mg2+) was then replaced with 0.1 M sodium 
acetate (pH 6.5) in preparation for radiolabelling. Figure 5.13 illustrates the 
radiolabelling efficiency of MeSar-Ph-NCS-conjugated Si NS using the 
conditions 23 °C for 60 min. 
 
 
 
Figure 5.13  Radiolabelling efficiency of 64/natCu2+- MeSar-Ph-NCS-Si NS and 
64/natCu2+ associated with NS (nmol). Experimental conditions: Amount 
MeSar-Ph-NCS = 125 nmol; Si NS size 100 nm (mean ± SD, N = 3). 
 
 
Table 5.3 summarises the estimated number of each BFC on the surface of each 
conjugated nanosphere. The measured number of available conjugated BFCs on 
the Si NS were in the following order MeSar-Ph-NCS (2080) > NOTA-NCS 
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(1260) > DOTA-NCS (980).  One Cu-MeSar-Ph-NCS complex was calculated to 
occupy 15.09 nm2 on the nanosphere surface area. The estimated areas occupied 
for the Cu-DOTA-NCS and Cu-NOTA-NCS on the same size nanosphere were 
larger, at 31.93 and 24.88 nm2, respectively.  
 
Table 5.3  Number of available BFCs conjugated to the surface of a 100 nm  
   diameter Si NS. 
 
 Chelator 
 MeSar-Ph-NCS DOTA-NCS NOTA-NCS 
Measured No. 
chelators 
attached to 2.5 
mg of NS at 
saturation 
(×1015) 
7.65 4.64 3.61 
Measured No. 
chelators 
attached per 
NS   (×103) 
2.08 0.98 1.26 
Calculated area 
occupied by 
one chelator 
(nm2) on the 
surface of NS 
15.09 31.93 24.88 
Density of Si NS taken as ~1.30 g/cm3 
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5.4  Conclusions  
 
Two types of functionalised NS (Si-amino and PS-carboxylate) were conjugated 
with selected BFCs (i.e. SarAr-NH2, MeSar-Ph-NCS, NOTA-NCS and DOTA-
NCS).  A significant difference in the conjugation efficiency of the BFCs to the 
PS NS and the Si NS appears to be reflective of both the availability of the 
function groups (e.g. amino or carboxylate) present on the NS surface and the 
specific chelator’s ability to complex the Cu2+ and Co2+ metal ions.  
Temperature, concentration of reactant, and incubation time each needed to be 
carefully controlled to optimise 57/natCo2+ labelling for all BFCs. 64/natCu2+ 
radiolabelling of BFCs conjugated to the NS proved less sensitive to 
temperature.  
 
The SarAr-NH2 BFC was conjugated to a range of PS NS and the data show that 
NS size was not the dominant factor in labelling efficiency. The data suggest that 
the chemical conditions used to produce each PS NS may have varied and 
therefore, the available carboxylate groups (per unit area) for SarAr-NH2 to 
attach was not consistent across all NS sizes.  
 
A comparison of the efficiency of radiolabelling Si NS using MeSar-Ph-NCS, 
NOTA-NCS and DOTA-NCS showed that MeSar-Ph-NCS had the most 
radioactivity attached per NS.  It was not possible to determine if the same 
number of BFCs (i.e. MeSar-Ph-NCS, NOTA-NCS and DOTA-NCS) were 
attached to each NS, or if the metal complexes formed were so highly charged 
that the neighbouring chelators could not accommodate further metal ions. 
However, the data clearly show the highest specific activity product (i.e. 
radiolabelled Si NS) could be achieved with the MeSar-Ph-NCS. 
 
It is of interest to establish if the charges (due to conjugated chelators) on the 
final product (radiolabelled NS) affect the biodistribution of these labelled NS in 
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animal models.  The following chapter (Chapter 6) will explore the effect of 
bifunctional chelators on the biodistribution of Si NS in animal models.   
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CHAPTER SIX 
IN VIVO BIODISTRIBUTIONS OF COPPER-61 LABELLED 
NANOSPHERES USING DIFFERENT BIFUNCTIONAL 
CHELATORS 
 
6.1  Introduction  
 
Nanomaterials such as gold and iron oxide particles, quantum dots and carbon 
nanotubes have been used as carriers for the delivery of therapeutic and 
diagnostic agents (Pengo & Pasquato, 2015; Sundaresan et al., 2014; Liu et al., 
2016; Razzazan, Atyabi, Kazemi, & Dinarvand, 2015). In recent times, a wide 
range of nanospheres/nanoparticles have been shown to significantly increase the 
residence time of their conjugated chemotherapeutic agents at target sites, while 
reducing the side effects of the applied chemotherapy. There are even reports of 
liposomes, polymer and lipid nanoparticles having the ability to overcome drug 
resistance (Pillai, 2014). Prolonged on-target residence time and a desired drug-
release pattern have been achieved by controlling the size and architecture of 
nanoparticles. 
 
Silica nanoparticles/nanospheres (Si NPs/NS) have been widely used in medical 
applications such as diagnostics (Arap et al., 2013; Wang, Yang, Tan, 2005) drug 
delivery (Slowing, Trewyn, Giri., & Lin, 2007 ; Xie et al., 2016; Lu, Liong, 
Zink, & Tamanoi, 2007) to control drug release (Trewyn, Giri,  Slowing, & Lin, 
2007; Wang et al., 2015), gene transfection (Lin, Zhao, Yan, Hu, Xu, 2015; 
Slowing et al., 2008) and multimodal imaging (Liberman et al., 2014). These 
types of particles can be synthesized using the Stöber method for the size range 
(50 - 1000 nm) (Stöber et al., 1968) or the micromulsion method for the particle 
size ≤50 nm (Osseo-Asare & Arriagada, 1990). Furthermore, Si NPs have been 
used in theranostics (Ryu et al., 2014) and in vitro (Tamba et al., 2015). 
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The size of the particles is an important factor for nanomedicine applications. 
The human body has several filters controlling the size of the drug delivery to 
the specific target. For example, small particles with size up to 5-6 nm are 
excreted by the kidneys (Choi et al., 2007), while the spleen filters any particles 
larger than 200 nm from the blood circulation (Moghimi, 1995).  In addition to 
the size of the particles, the shape and surface are also important factors and can 
be controlled. For example, colloidal Si NPs have a negative charge which 
causes their aggregation in biological fluids (Vanblaaderen, Vangeest, & Vrij, 
1992). This property is explained by the fact that the Si NPs are coated to serum 
proteins (opsonins) that activate the capture by the reticuloendothelial system 
(RES) once they are injected in the blood stream. They are then removed by 
circulation (Moghimi, Hunter, & Murray, 2001; Gref et al., 1995) and 
accumulated in the lungs and capillary vessels (Borchardt, Brandriss, Kreuter, & 
Margel, 1994). There are two ways to avoid the aggregation of the Si NPs and to 
increase their biocompatibility. The first method is to attach short functional 
groups to the Si surface such as free amino, carboxyl, carboxylate, thiol or 
phosphonate groups. This method however does not always protect against 
aggregation since the short functional groups are easily attached to serum 
proteins. In the second method, the surface of the Si NP is conjugated with large 
molecules (e.g. PEG) resulting in an increase in the blood circulation half-life of 
the particles by several orders of magnitude (Ownes & Peppas, 2006). The 
properties of PEG provide high stability of nanoparticles in biological fluids 
(Gref et al., 1994).  
 
Various particles have been labelled with SPECT and PET radioisotopes for 
mapping their clearance and uptake paths, sometimes (in a ’theranostic’ role) 
prior to the delivery of radiotherapeutic doses to kill cancer cells (Liu & Welch, 
2012; Dearling et al., 2011; Rogers et al., 2004; Kong et al., 2013). Passive 
targeting of tumour tissues by nanoparticles loaded with therapeutic agents is a 
size-dependent process. It is also influenced by the pathophysiological 
characteristics of the tumour vessels, such as a leaky vasculature and poor 
lymphatic drainage.  The Enhanced Permeation and Retention (EPR) effect is the 
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term used to describe the extravasation of nanoparticles into the tumour tissue 
and their retention there.  
 
The schematic of NS functionalised with amino groups (1) is shown figure 6.1. 
After a bifunctional chelator (BFC) is conjugated to (1), the resultant complex 
(2) is added to the radiosotope for radiolabelling (3). The radiolabelled NS is 
ready for in vivo administration (4). However, once in vivo, the disintegration of 
this complex, leaving the NS separated from its isotopically-labelled BFC is 
possible. This depends on the stability of the BFC link to the functionalised NS 
(5). ‘Dechelation’ of the isotope from the BFC is also possible. This may 
conceivably happen at any time after the injection, and depends on the 
thermodynamic and (particularly) kinetic stabilities of the chelation mechanism. 
 
In chapter four of this thesis we described a more efficient route for the 
production of 61Cu from a natZn or an enriched 64Zn target. Copper-61 has 
physical properties (t1/2 = 3.33 h; β+max = 1.22 MeV; β+ = 60%, EC = 40%) 
suggesting PET imaging applications where the biological mechanism under 
study has a characteristic lifetime of a few hours.  The capacity to produce 61Cu 
using small biomedical cyclotrons (Asad et al., 2015) at high radionuclidic purity 
(> 99%) makes it an attractive option for potential clinical use. Chapter five 
described the investigation of radiolabelling of silica nanospheres (Si NS) using 
three bifunctional chelators (BFC) i.e. diamsar, NOTA-NCS and DOTA-NCS.  
This chapter investigates aspects of the pharmacokinetics of 61Cu-labelled Si NS 
in immunodeficient inbred mice using the tools of PET imaging and post-
mortem radioactivity biodistribution analysis. Three bifunctional chelators, 
NOTA-NCS and DOTA-NCS and the novel sarcophagine ‘MeSar-Ph-NCS’ 
were used to radiolabel amino-functionalised Si NS (see Figure 6.2). The 
molecule MeSar-Ph-NCS (representing [Mg(CH3)(p-NCS-Ph)Sar](CF3SO3)2 
was developed recently by collaborators of our laboratory (Paterson et al., 2014). 
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Figure 6.1  Schematic for the conjugation of BFC to NS and subsequent radiolabelling with radioisotope [1 to 3] – Breakdown in vivo 
following injection [4 to 5].
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Figure 6.2 Bifunctional Cu2+ chelators used in this study (a) MeSar-Ph-NCS, 
(b) NOTA-NCS and (c) DOTA-NCS.  In MeSar-Ph-NCS, the 
metal protector magnesium ion is extruded from the molecule 
following conjugation to the NS and prior to radiolabelling. 
 
6.2  Materials and Methods 
  
6.2.1  Production of No-Carrier-Added 61Cu  
 
Copper-61 isotope was prepared using a proton beam from an IBA 18/18 MeV 
cyclotron by the 64Zn(p,α)61Cu nuclear reaction, using an enriched 64Zn target 
(though a natZn target would have been possible).  No-carrier-added (NCA) 61Cu 
as the chloride was produced and isolated under optimised conditions by the 
method described previously in Chapter four (Asad et al., 2015). Briefly, the 
irradiated enriched 64Zn target material was dissolved in 1 mL of 8 M HCl at 
150oC and evaporated to dryness. The residue was dissolved in high purity 
TraceSELECT water (1 mL), evaporated to dryness twice and dissolved in 2 mL 
of 0.1 M HCl. The solution was loaded onto a Cu-resin column (pre-conditioned 
with 20 mL of 0.01 M HCl).  The Zn and Ga were eluted with 25 mL of 0.01 M 
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HCl (and kept for recovery of 64Zn if required). The 61Cu trapped on the Cu-resin 
column was then eluted off with 1.5 - 2 mL of 8 M HCl, followed by drying 
steps (addition of 1mL of TraceSELECT water and evaporation to dryness three 
times). The final product was then dissolved in 400-800 µL of 0.01 M HCl. The 
average recovery efficiency of NCA 61Cu from the irradiated target was 95%. 
The radionuclide purity was consistently > 99%. The specific activity assessed 
by the titration method was approximately 1.2x106 GBq/g of copper.  
 
6.2.2  Preparation of 61Cu Labelled Bifunctional Chelator-Silica 
Nanospheres  
 
In separate experiments, three BFCs (MeSar-Ph-NCS, NOTA-NCS and DOTA-
NCS) were used to radiolabel Si NS of nominal diameter 100 nm, as described in 
Chapter five, except that in this study a different Sar molecule (MeSar-Ph-NCS) 
was used. Briefly, 5 mM chelator solutions were prepared by dissolution in 0.1 
M sodium phosphate buffer (PBS), pH 8. To 100 µL of a chelator solution, Si 
NS (100 µL, 2.5 mg) were added and the final volume adjusted to 900 µL with 
the same buffer. The conjugated Si NS were radiolabelled as described in 
Chapter five; 61Cu-chloride (10 µL in 0.01 M HCl, 50-60 MBq) was added to 
each suspension of the conjugated NS and left to incubate for 2 h at 37oC.  
Finally, the radiolabelled NS were then washed with 0.1 M sodium acetate buffer 
(NaOAc) pH 7 to remove any free 61Cu and then resuspended in the same buffer 
for injection in animals. 
 
6.2.3  Surface Charge of Silica Nanospheres 
 
The zeta potential was determined using zetasizer version 7.11 (Malvern 
Instruments Ltd., U.K.). Measurements were performed at 25oC and pH 7. All 
samples were diluted in PBS buffer and injected into the flow cell chamber.  
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6.2.4  In Vitro Stability of Radiotracers 
 
In vitro stability of the 61Cu-BFC-NCS-Si NS, for each BFC was studied in 
triplicate experiments (n = 3) in normal saline at room temperature and also 
separately in foetal bovine serum (FBS) (Sigma-Aldrich, Australia). To 500 μL 
of 61Cu-labelled conjugated Si NS in 0.1 M sodium acetate buffer pH 7 (~3 
MBq) was added 100 μL of saline or FBS. The solution was then incubated at 37 
°C. At specific time intervals, the 61Cu labelled conjugated BFC-NCS-Si NS 
were centrifuged at 5000 rpm for 5 min, the supernatant carefully removed by 
pipette and the pellets formed were counted on a gamma counter (600 µL for 
each sample). New saline or FBS was added to the pellets and they were then 
returned to the reaction mixture.  In vitro results suggest good stability in saline 
and FBS at 1 and 4 h. However, in vivo stability has not been assessed. 
 
6.2.5  Animal Groups for In Vivo Activity Biodistribution Study 
 
All animal studies were performed in compliance with the requirements of the 
Harry Perkins Institute of Medical Research Animal Studies Committee and in 
accordance with the Australian Code of Pratise for the Care and Use of Animals 
for Scientific Purposes, 8th Edn. In this study, healthy female nude mice (Balb/c 
nu/nu) were used to study the biodistribution of each organ. The mice were 
divided into 4 groups of three animals each, as follows: 
 
Group 1 were controls for this study, receiving 61Cu as the chloride, only. 
Group 2 received 61Cu-MeSar-Ph-NCS-Si NS. 
Group 3 received 61Cu-NOTA-NCS-Si NS. 
Group 4 received 61Cu-DOTA-NCS-Si NS. 
Figure 6.3 illustrates the injection and biodistribution sampling protocol.    
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Figure 6.3 Time points for injection of Balb/c (nu/nu) mice, imaging using 
µPET/CT and (finally) dissection and γ-counting following 
sacrifice; in the control group and in groups injected with Si NS 
61Cu-radiolabelled using different bifunctional chelators (BFCs). 
Group 1 were controls injected with 61Cu as the chloride. Groups 
2-4 were administered with 61Cu-MeSar-Ph-NCS-Si NS, 61Cu-
NOTA-NCS-Si NS and 61Cu-DOTA-NCS-Si NS, respectively.  
 
6.2.6  In Vivo Activity Biodistribution Data by µPET Imaging 
 
In all groups, healthy mice weighing 12.5-20.4 g were anesthetized with 1-2% 
isoflurane and injected via the retro-orbital route with 5.4 ± 0.5 (SD) MBq of 
61Cu chloride or 61Cu-BFC-Si NS (0.25 mg of Si NS) in 100-120 µL of a 0.1 M 
NaOAc (pH 6.5) solution in saline. Imaging was performed using a Super Argus 
µPET/CT (Sedecal, Madrid, Spain). Images were reconstructed using an 
ordered-subset expectation maximization (OSEM, 2D) algorithm. At 1 h and 4 h 
the mice were re-anesthetized and then scanned for 15 min for a PET acquisition 
(two bed positions) followed by 10 min to acquire a co-registered CT image. The 
regions of interest (ROIs) were quantified by identifying margins in three 
dimensions in the selected tissues and averaging the activity concentration over 
the summed voxels. ROI analysis was performed using Vivo Quant 2.0 software 
(Invicro, Boston, USA).  
 
139 
 
6.2.7  Dissection Activity Biodistribution Studies 
 
In each group, mice were sacrificed immediately after the last µPET/CT scan (4 
h time point). Blood, organs and tissues of interest were removed, weighed and 
their radioactivity counted in a γ-counter calibrated for photopeak energy and 
energy-dependent detector sensitivity (PerkinElmer, Illinois, USA). The total 
activities in blood, bone and muscle were calculated assuming that these tissues 
represented an average of 6%, 11%, 41% of the mouse weight, respectively (Sun 
et al., 2005). All the data were corrected for physical decay. Uptake in each 
tissue sample was calculated as a fraction of the injected dose. The results were 
expressed as a percentage of injected dose per gram of tissue (%ID/g). 
 
6.3  Results  
 
6.3.1  Zeta Potential  
 
The zeta potentials of the Si NS were measured in PBS buffer at pH 7 and the 
results are shown below (Table 6.1).  The amino functionalised nanospheres are 
positively charged (23.4 mV). The zeta potentials of the NS after conjugation 
with the BFCs were lower, ranging between 2.2-11.3 mV and increased after 
Cu2+ labelling (5.3-20.3 mV).  
Table 6.1  Zeta potential of surface of Si NS in PBS solution   
 
Nanospheres Zeta potential in 0.1 mM 
PBS (mV) 
Si NS 23.4 
Si NS-NOTA-NCS 2.2 
Si NS-DOTA-NCS 4.1 
Si NS-MeSar-NCS 11.3 
Si NS-NOTA-NCS- Cu2+ 5.3 
Si NS-DOTA-NCS- Cu2+ 10.2 
Si NS-MeSar-NCS- Cu2+ 20.3 
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6.3.2   In Vitro Stability of Labelled Bifunctional Chelator-Silica  
 Nanospheres 
 
After 1 and 4 h the 61Cu-radiolabelled BFC-NCS-Si NS were all found to be 
stable in saline (> 93%). However, incubation of the 61Cu labelled BFC-NCS-Si 
NS in FBS at 37 °C all showed significant increase of ‘free’ 61Cu at 4 h (between 
11% and 16%) as shown in Table 6.2.  
 
Table 6.2   Degree of stability of constructs at two time points. 
 
Si NS-BFC-61Cu saline  FBS 
 1 h 4 h 
 
1 h 4 h 
Si NS DOTA-NCS-61Cu 98% 97% 95% 84% 
Si NS-NOTA-NCS-61Cu 98% 93% 94% 89% 
Si NS-MeSar-Ph-NCS-61Cu 97% 95% 97% 86% 
 
 
6.3.3  Dissection-Derived Normalised Activity Biodistributions 
 
Group1; Control mice (n = 3) 
 
The biodistribution of ‘free’ 61Cu (injected as the chloride), derived by dissection 
and γ-counting at 4 h post-injection (see protocol in Figure 6.3) is shown in 
Figure 6.4.  Data for selected organs is shown in Table 6.3. These represented 
controls for this study. Weight-normalised activities in major organs and tissues 
are expressed as percent of injected dose per gram of issue (%ID/g). At 4 h post-
injection 61Cu activity was found mainly in the liver (including gallbladder, since 
these were not separated at dissection) and kidneys, with levels of 26.6 ± 0.6 
(SD) %ID/g and 12.3 ± 3.1%ID/g, respectively. Spleen uptake of ‘free’ 61Cu was 
5.1 ± 3.6%ID/g and bladder with 3.8 ± 2.0%ID/g. 
 
 
141 
 
Groups 2-4; 61Cu-BFC-NCS-Si NS 
 
The biodistributions at 4 h of Groups 2-4 (n = 3, each) injected with 61Cu-
labelled MeSar-Ph-NCS-Si NS, 61Cu-NOTA-NCS-Si NS and 61Cu-DOTA-NCS-
Si NS, respectively and derived by dissection are also shown in Figure 6.4. Data 
for selected organs is shown in Table 6.3. After 4 h, relatively low uptake was 
found in the blood, bone, heart, muscle and stomach. Higher activities were 
measured in the organs of the mononuclear phagocytic system; the liver 
(incorporating gall bladder) and spleen. Liver accumulated 38.5 ± 8.1, 48.1 ± 4.5 
and 44.5 ± 6.0%ID/g of 61Cu-MeSar-Ph-NCS-Si NS, 61Cu-NOTA-NCS-Si NS 
and 61Cu-DOTA-NCS-Si NS respectively. Spleen took up 43.3 ± 9.3, 63.6 ± 4.1 
and 70.2 ± 8.8%ID/g of 61Cu-labelled MeSar-Ph-NCS-Si NS, 61Cu-NOTA-NCS-
Si NS and 61Cu-DOTA-NCS-Si NS, respectively. There was a higher level of 
accumulated radioactivity in lungs for the 61Cu-labelled MeSar-Ph-NCS-Si NS 
(37.4 ± 5.7%ID/g) compared to the polyazacarboxylate conjugated Si NS (i.e. 
NOTA-NCS 7.4 ± 2.2 and DOTA-NCS 17.7 ± 6.1%ID/g) at 4 h.  Kidneys and 
intestines accumulated intermediate activities (9.8 ± 2.3, 6.0 ± 1.1 and 9.4 ± 2.0 
%ID/g for MeSar-Ph, NOTA-NCS and DOTA-NCS [kidneys] and 13.2 ± 2.7, 
5.1 ± 1.1 and 9.3 ± 1.0%ID/g for MeSar-Ph-NCS, NOTA-NCS and DOTA-NCS 
[intestines]). Furthermore, at 4 h there was a high level of washed out 61Cu or 
61Cu-BFC (breakdown, see “6” Figure 6.1) in the bladder for MeSar-Ph-NCS 
(14.8 ± 1.90%ID/g), compared to the free 61Cu group, and the NOTA-NCS and 
DOTA-NCS groups (3.8 ± 2.0%ID/g, 2.4 ± 0.5%ID/g and 4.8 ± 0.8%ID/g).  
 
An interesting observation (due to a reviewer) is that if the kidneys, liver and 
spleen are combined into a single ‘reticuloendothelial system’ and the activity of 
this “super-organ” is calculated, then there are no differences between any of the 
61Cu-BFC-NCS-Si NS, though all are different from the control group (p < 0.01) 
(last column of table 6.3). This supports the tentative conclusion that the lungs 
are differentially trapping extra radiotracer, in the case of 61Cu-MeSar-Ph-NCS-
Si NS.   
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Figure 6.4 Dissection-derived biodistributions of ‘free’ 61Cu (Group 1, 
controls) and 61Cu-BFC-NCS-Si NS (Groups 2-4) in female 
Balb/c nu/nu mice (n = 3 each group) following sacrifice at 4 h. 
The percent injected dose per gram of tissue (%ID/g) was 
determined by normalising for organ weight plus radioactive 
decay correction. Data are represented by the mean ± SD.  
 
6.3.4  µPET/CT Imaging and Biodistribution Studies 
 
Representative maximum-intensity projection uptake PET images of the four 
groups at 1 h and 4 h post-injection are shown in Figure 6.5(a) & 6.5(b), 
respectively. The column marked ‘Group 1’ shows the distribution of activity 
concentration for ‘free’ 61Cu.  The columns ‘Group 2’, ‘Group 3’ and ‘Group 4’ 
represent the equivalent data for the three 61Cu-BFC-NCS-Si NS tracers.  For 
each time point the activity concentration maps for the three BFCs may be 
qualitatively visually compared, but not with the Group 1 controls map which 
has a different activity concentration scale for purposes of visual reproduction. 
At 1 h post-injection the µPET images showed uptake of ‘free’ 61Cu in the liver 
and lungs but not the spleen. For 61Cu-BFC-NCS-Si NS activity was seen 
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primarily in the liver, spleen and lungs. Other organs such as the heart and 
bladder revealed significantly lower signals. In comparing different BFCs, it is 
seen that at 1 h the lungs of group 2 (61Cu-MeSar-Ph-NCS-Si NS) (clearly 
located by µCT) accumulated significant activity as detected by µPET, whereas 
the signals in the lungs of group 3 (61Cu-NOTA-NCS-Si NS) and group 4 (61Cu-
DOTA-NCS-Si NS) were lower. The uptake in the kidneys was probably 
significant at the 1-h time point but was not reported because of marked discord 
between the results for animals within Group 1. The activity of 61Cu-DOTA-
NCS was accumulated in bladder at 1 h (23 ± 0.4%ID/g) but not for other 
groups.  
 
The equivalent images and derived activities for the biodistribution at 4 h are 
shown in Figures 6.5(b).  The results are broadly similar to the 1-h time point 
except for the ‘free’ 61Cu (Group 1) and 61Cu-MeSar-Ph-NCS-Si NS (group 2), 
where the activity has been partly washed out. At 4 h the activity for 61Cu-
NOTA-NCS-Si NS and 61Cu-DOTA-NCS-Si NS is retained in the liver, spleen, 
lungs, whereas the activity of free 61Cu in liver and lungs (with no detectable 
signal in the spleen) decreases faster than physical decay would suggest.  
 
At both time points the activity in the lungs of 61Cu-MeSar-Ph-NCS-Si NS 
exceeds that of the other two BFCs.  This is qualitatively in accord with the 
dissection-derived biodistribution results shown in Figure 6.4 for 4 h post-
injection, and with qualitative examination of the images in Figure 6.5(a) & (b). 
Comparison of the normalised accumulated activities expressed as %ID/g 
between dissection and imaging for selected organs is shown in Table 6.3 and 
Table 6.4. As noted in Section 6.3.3, the equality of activity for all three 
chelators in the combined ‘reticuloendothelial’ organs (though each different 
from control group; see last column of table 6.3) suggests that though these 
organs retain the same proportion of injected activity at 4 h, the 
radiopharmaceutical 61Cu-MeSar-Ph-NCS-Si NS is preferential retained in the 
lungs. 
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Figure 6.5 Representative microPET maximum-intensity projection images for each of the 61Cu-injected groups at (a) 1 h and (b) 4 h 
post-injection. 
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Table 6.3 Biodistributions derived from the same mice by post-imaging 
dissection and radioactive counting (4 h) are shown for 
comparison. Data expressed as mean ± SD in units of % ID/g. 
 Dissection-derived  Biodistributions  
Organ aLiver Spleen Lungs Kidneys Bladder  fReticuloen-
dothelial 
system  
 4 h 4 h 4 h 4 h 4 h 4 h 
Radiotracer       
‘Free’  61Cub 26.6 ± 0.6 5.1 ± 3.6 9.2 ± 3.2** 12.3 ± 3.1 3.8 ± 2.0 19.20 ± 0.7xx 
61Cu-MeSar-Ph-
NCS-Si NSc 
38.5 ± 8.1 43.2 ± 9.3 37.4 ± 5.7 9.8 ± 2.3 14.9 ± 1.9 38.40 ± 6.2 
61Cu-NOTA-NCS-
Si NSd 
48.1 ± 4.5 63.6 ± 4.1 7.4 ± 2.2*** 6.0 ± 1.1 2.4 ± 0.5 42.50 ± 3.6 
61Cu-DOTA-NCS-
Si NSe 
44.5 ± 6.0 70.2 ± 8.8 17.7 ± 6.1* 9.4 ± 2.0 4.8 ± 0.8 45.50 ± 5.0 
a: Incorporating gall bladder. b: Injected as the chloride (Group 1). c:  Group 2.  
d: Group 3. e: Group 4. *:  p < 0.05 Group 4 vs Group 2. **: p < 0.01 Group 1 vs 
Group 2. ***: p < 0.005 Group 3 vs Group 2; fReticuloendothelial system 
combined liver (including gallbladder), spleen and lungs. xx: p < 0.01 Group 1 
compared with all other groups. For the reticuloendothelial system, Group 2, 3 & 
4 were not different from each other. Two-tailed unpaired t-test, with Bonferroni 
correction.   
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Table 6.4 Biodistribution data for selected organs derived from quantitative 
analysis of microPET images of the four groups of Balb/c nu/nu mice (n = 3 
animals each) injected with radiotracers.  Images were collected at (a) 1 h and (b) 
4 h post-injection.  Data expressed as mean ± SD in units of % ID/g. 
(a) 
 MicroPET-derived Biodistributions 
Organ Livera Spleen Lungs Kidneys Bladder 
Time point 1 h 1 h 1 h 1 h 1 h 
Radiotracer      
‘Free’  61Cub 51.3 ± 4.7 N/A 16.3  ± 4.5 # TL 
61Cu-MeSar-Ph-
NCS-Si NSc 
35.0  ± 3.2 12.9  ± 2.4 11.8 ± 0.8 TL TL 
61Cu-NOTA-NCS-
Si NSd 
35.6 ± 2.9 26.9 ± 8.0 6.2 ± 2.2 TL TL 
61Cu-DOTA-NCS-
Si NSe 
31.9 ± 3.1 23.6 ± 9.5 8.1 ± 0.7 TL 23 ± 0.4 
(b) 
Modality MicroPET-derived Biodistributions 
Organ Livera Spleen Lungs Kidneys Bladder 
Time point 4 h 4 h 4 h 4 h 4 h 
Radiotracer      
‘Free’  61Cub 46.3 ±  2.2 N/A 18.1 ± 2.3 26.8 ± 10.3 TL 
61Cu-MeSar-Ph-
NCS-Si NSc 
30.8 ± 2.1 14.4 ± 5.7 8.5 ± 0.2 TL 12 ± 1.1 
61Cu-NOTA-NCS-
Si NSd 
39.2 ± 3.0 34.1 ± 2.1 4.5 ± 0.8 TL TL 
61Cu-DOTA-NCS-
Si NSe 
34.5 ± 2.7 29.2 ± 5.0 6.3 ± 1.0 TL TL 
a: Incorporating gall bladder. b: Injected as the chloride (Group 1). c:  Group 2.  
d: Group 3. e: Group 4. TL: signal too low for quantitation. #: Inconsistent 
results between animals within the group.  
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6.4 Discussion  
 
Quantitative in vivo measurements of the time-dependent biodistribution of a 
radioactively labelled target-specific molecule or nanosphere (‘delivery vehicle’) 
are becoming increasingly important in selected areas of cancer diagnosis and 
molecular radiotherapy (MRT) planning, where the tools of the relatively new 
clinical science of ‘theranostics’ are applicable (Kraeber-Bodéré et al., 2015).  In 
the (idealised) diagnostic phase of theranostics the 4-D spatial-temporal 
distribution of a particular cell or tissue type (for example, tumour cell or mass 
of pathologically formed blood capillaries) can be mapped and the proportional 
dose to collateral organs and tissues for preservation during subsequent MRT can 
be calculated (‘dose-ranging’). In the (idealised) therapeutic phase the (γ or β+ 
emitting) diagnostic-imaging radioisotope (PET or SPECT) is swapped for a (β-, 
α or Auger-electron emitting) therapy isotope with the same Z-value.  Thus, the 
same chemistry is used for binding to the molecular or nanosphere delivery 
vehicle (‘companion theranostics’).  The administered dose of the MRT to the 
target cells can then be titrated according to the calculated maximum permissible 
dose to the most radiosensitive normal tissues to be spared; using data derived 
from the diagnostic scan (Peng, Lutsenko, Sun, & Muzik, 2012). It is in the 
‘diagnostic’ phase of investigatory theranostics that our ‘proof of principle’ 
study belongs. 
 
6.4.1  Goals of These Studies 
 
We evaluated the biodistribution of silica nanospheres in healthy 
immunodeficient mice. These potential drug delivery vehicles of nominal 
diameter 100 nm were conjugated to a novel bifunctional sarcophagine chelator 
(MeSar-Ph-NCS), radiolabelled with 61Cu for µPET imaging. Two other 
conventional macrocyclic chelators NOTA-NCS and DOTA-NCS (Chakravarty 
et al., 2013; Schiller et al., 2013; Yang et al., 2011; Cooper et al., 2012) were 
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used in the same setting for comparison. We also investigated the biodistribution 
of free copper (61Cu-chloride) as a control. Biodistributions were measured at 1 h 
and 4 h by analysis of quantitative µPET images, and at 4 h by dissection and 
radioactive counting following sacrifice, as shown in Figure 6.3.  
 
Our first goal was to determine whether the novel isothiocyanate sarcophagine 
chelator MeSar-Ph-NCS offered advantages in respect of radiolabelling stability 
of the 61Cu2+ radiolabelled complex when conjugated to Si NS, compared with 
the radiolabelled macrocyclic chelators 61Cu-NOTA-NCS and 61Cu-DOTA-NCS.   
The second goal was to determine the biodistributions of these radiotracers using 
both microPET imaging (1 h and 4 h) and post-sacrifice dissection and 
radioactive counting (4 h).  Our final goal was to differentiate the uptake of the 
radiotracers in key organs (liver, spleen, lungs, kidneys, bladder), based on the 
biodistribution results. These studies were in general anticipation of future 
studies examining the use of radiolabelled Si NS in tumour theranostic 
applications (for example, harnessing the EPR effect), including the possibility 
of utilising the companion theranostic combination of 61Cu (diagnostic mapping 
and organ dose-ranging) and 67Cu (molecular radiotherapy).  
 
6.4.2  Zeta Potential  
 
In the literature, it has been reported that both the plasma protein absorbance and 
non-specific cellular uptake in the blood circulation decrease with the negative 
charge of nanoparticles (Li and Huang, 2008; Alexis, Pridgen, Molnar, & 
Farokhzad, 2008; Xiao et al., 2011). Nanoparticles with positive charge are 
known to aggregate in serum proteins (negatively charged) following 
administration (Li & Huang, 2008). In this study the positively-charged Si 
nanospheres accumulated in the liver and the lungs.  
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6.4.3  Bifunctional Chelators Stability Studies 
 
The stability of macrocyclic and sarcophagine macrobicyclic bifunctional 
chelators of copper radioisotopes under physiological conditions is a key 
property in considering their clinical applications. Increasing the stability of 
copper complexes has been a major focus in the development of copper 
radiopharmaceuticals for a variety of copper-based diagnostic and therapeutic 
strategies (Wadas et al, 2007; Liu, 2008; Smith, 2004, 2008; Wei et al., 2009). In 
this study, in vitro stability experiments showed that 61Cu-MeSar-Ph-NCS-, 
61Cu-NOTA-NCS- and 61Cu-DOTA-NCS-Si NS were between 93% - 98% intact 
in NaCl 0.9% at 4 h, whereas their radiochemical stability in FBS at 4 h dropped 
significantly (to approximately 84%).  Other investigators have reported the 
dechelation of copper from tetra-aza macrocyclic chelators under physiological 
conditions (Cutler et al., 2000; Jones-Wilson et al., 1998; Woodin et al., 2005). 
However, our assumption is that the instability arises mainly from the 
deconjugation of the 61Cu-labelled BFCs from the Si NS. (Our method of 
repeated centrifugation and radioactive counting of the supernatant cannot 
uniquely confirm this; see Section (6.3.1).  Clearly, this finding has implications 
for the interpretation of the in vivo images, particularly at the four-hour time 
point, and also for the dissection studies.  
  
6.4.4  Dissection-Derived Biodistributions  
 
The ex vivo dissection-derived biodistributions of ‘free’ 61Cu and 61Cu- BFC-
NCS-Si NS in healthy Balb/c nu/nu immunodeficient mice, at 4 h post retro-
orbital injection are shown in Figure 6.4.  Values expressed in %ID/g are given 
in Table 6.3 for selected organs.  
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Control 61Cu Tracer 
 
The ‘free’ 61Cu is partly accumulated in the liver, which is known to be a 
reservoir for many metals especially copper through binding to serum 
ceruloplasmin (Jalilian et al., 2009). The kidneys were the second organ showing 
relatively high accumulation of the 61Cu-chloride at 4 h, though the radiotracer 
would be expected to wash out via the urinary tract due to the high water 
solubility of the Cu2+ cation (Jalilian et al., 2009). On the other hand, the uptakes 
of other organs were low. Peng et al. (2012) reported dynamic microPET 
biodistribution studies of 64Cu-chloride with knock-out mice and wild type (WT) 
C57BL mice. Their results at 1 h for the WT mice are in qualitative agreement 
with our data for the liver, kidneys, lungs, heart; as regards ranking of copper-
accumulating organs.  However, their results are about 50% less than this study. 
This broad difference could be attributed to differences between the studies in 
regard to the method of assessing biodistributions, the time points for 
comparison and the type of mice.  
 
From an examination of the uptake of ‘free’ 61Cu in the kidneys (Group 1, Figure 
6.4) and the observed deconjugation at 4 h of labelled 61Cu from Si NS in the in 
vitro stability experiments conducted with foetal bovine serum (Section 6.3.1), it 
is possible that the kidney activity of 61Cu-BFC-NCS-Si NS at 4 h mainly 
reflects 61Cu labelled BFC or ‘free’ 61Cu. This explanation may also apply to 
those organs with small uptakes such as bone and heart, where the ‘free 61Cu’ 
and 61Cu-BFC-NCS-Si NS uptakes are similar.   
 
BFC 61Cu Tracers; Particularly in Lungs 
 
According to the dissection results, the three 61Cu-BFC-NCS-Si NS radiotracers 
accumulated predominantly in the liver (including gallbladder) and spleen within 
four hours post-injection (see Figure 6.4). However, at this time point the lungs 
uptake of 61Cu-MeSar-Ph-NCS-Si NS was also significant, and higher than that 
for NOTA-NCS and DOTA-NCS. The precise reason for the relatively enhanced 
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uptake of the sarcophagine-conjugated Si NS in the lungs is unknown.   
However, an hypothesis is that it is caused by a net positive charge of the 61Cu-
MeSar moiety that confers cationic properties.  In support of this notion are the 
following observations; (i) the renal uptake of a 64Cu-labelled antibody 
conjugated with a series of Sar derivatives with decreasing charge was 
proportional to the net positive charge of the conjugated sarcophagine, with 
SarAr (with the highest charge) delivering a relatively high dose to the kidney 
(Dearling et al., 2015). (ii) This was postulated to be a cationic effect resulting in 
increased binding of the labelled antibody to the negatively charged basal cells of 
the glomerulus. (iii) Interestingly, the interstitium of the lung also carries a net 
negative charge (Charan & Carvalho, 2002). The interstitium includes the 
alveolar epithelium, pulmonary capillary endothelium, basement membrane, 
perivascular and perilymphatic tissues. Thus it is possible that the same cationic 
effect is operating in the lung as it acquires a sarcophagine-complexed 
radiolabel. (iv) This preferential accumulation and retention of nanoparticles in 
the lungs is likely not due to unique properties of the Si NS.  Blanco, Shen, & 
Ferrari  (2015) note that the penetration of tissues by nanospheres depend in part 
on their size, shape and charge. Other factors equal, nanospheres of spherical 
shape and diameter ~100 nm can penetrate lung tissue, but not the kidney, which 
requires the size to be < 5 nm.  This would explain, for example, how the lungs 
could accumulate a high activity of a sarcophagine-conjugated Si NS, while in 
the same animal the kidneys did not; even though the basal cells of the 
glomerulus are negatively charged (Dearling et al., 2015)  (Figure 6.4 & Table 
6.3).  The modest (and approximately equal with ‘free’ 61Cu) activities of 61Cu-
BFC-NCS-Si NS in the kidneys at four hours may mainly reflect ‘free’ 61Cu, 
arising from the in vivo part-breakdown in stability of these complexes by that 
elapsed time (Section 6.4.2), as noted in the above paragraph. 
 
This difference in lung activity between the macrobicyclic sarcophagine and 
poly-aza macrocyclic labels was not so markedly reflected in the data derived 
from imaging, at either time point. This difference between techniques is 
unlikely to be the result of selective contamination of the Group 2 excised lungs 
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by blood, since the uncertainties in the lung measurements of Groups 2-4 shown 
in Figure 6.4 are similar. 
 
Comparison Between µPET-Imaging and Dissection-Based Biodistributions 
 
There was qualitative agreement between dissection-plus-counting and imaging 
at 4 h for the liver (see Table 6.3 & Table 6.4). The mean liver & gall bladder 
activity for the three BFC-NCS-Si NS radiolabels at 4 h measured by γ- counting 
(43.7 ± 4.9%ID/g) was 20% higher than the equivalent activity measured by 
µPET quantification (Figure 6.4 & Figure 6.5), which showed an average of 34.9 
± 2.0%ID/g at 4 h. The average spleen activity revealed a larger variation 
between the two methods; yielding mean values of 59.0 ± 14.0%ID/g with 
dissection-plus-counting versus 25.9 ± 10.3%ID/g with µPET (see Table 6.3 & 
Table 6.4). In this study, reliable activities for the kidneys at either time point 
could not be obtained from the BFC-NCS-Si NS images because of problems 
with detecting the organ boundaries. This was also true of other organs such as 
the heart and muscle with low activities.  
 
6.5 Conclusions  
 
This study compared the in vivo activity biodistributions of three 61Cu-labelled 
bifunctional chelators (BFCs) conjugated to amino-functionalised silica 
nanospheres in a ‘normal’ immunodeficient murine model using microPET 
imaging (1 h and 4 h post retro-orbital injection) and dissection-plus γ-counting 
(4 h). One of the BFCs, MeSar-Ph-NCS, was a novel sarcophagine molecule 
developed by a collaborating laboratory. In this study, MeSar-Ph-NCS was 
examined for the first time for its capacity to link a radiocopper isotope to a 
nanoparticle capable of carrying targeting diagnostic and therapeutic agents. 
Copper-61 injected as the chloride was employed as a control. The principal 
findings were; (i) by four hours, all three BFC-conjugated Si NS radiotracers 
accumulated predominantly in the liver and spleen. (ii) The radiotracer utilising 
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the macrobicyclic sarcophagine BFC MeSar-Ph-NCS showed elevated 
accumulation in the lungs at 4 h, in comparison with those tracers based on the 
tri- and tetra-aza macrocyclic BFCs NOTA-NCS and DOTA-NCS. This 
preferential uptake in the lungs warrants further study, including the possibility 
of it being a disadvantage of sarcophagine BFCs when conjugated to 
nanospheres. A possible explanation that warrants further study is that it is 
caused by the cationic behaviour of the 61Cu-MeSar-Ph-NCS moiety when 
passing through lung interstitium, which is net negatively charged. (iii) The PET 
isotope 61Cu (t1/2 = 3.33 h) can be efficiently prepared with high radionuclidic 
purity and NCA specific activity in a facility with access to a standard 
biomedical proton-beam cyclotron and solid-targetry facilities.  
 
I would be argued that the relatively rapid clearance of all 61Cu-BFC-NCS-Si NS 
from the blood (Figure 6.4) would not be an adventure if the EPR effect were to 
be harnessed for tumour treatment. However, we found that these chelators had 
significant uptake in reticuloendothelial tissue. Two of these chelators (DOTA & 
NOTA) have been used for EPR studies in the literature (Orcutt et al., 2014; 
Chakravarty et al., 2015). Furthermore, nanospheres are known to accumulate in 
liver and spleen and clear fast from the blood if they not attached with pegylation 
(PEG) to give them long blood circulation time. Therefore, in the future, we will 
do further studies with two types of nanospheres (Si NS & PS NS) in small sizes 
(i.e. 50 nm) with PEG attached on the nanospheres surfaces. 
Nerveless, the relatively fast clearance from blood and its uptake in 
reticuloendothelial tissue of the BFC-NCS-Si NS in the study is a concern when 
exploiting the EPR effect in tumours, especially in therapy using NS. The ideal 
would be a compound with a relatively long blood circulation, waiting to be 
passively taken up by the tumour. These a reduction in the size of NS is a first 
step towards a achieving this, with the current model.    
 
The positron-emitting radiometal copper-61 is eminently suited to radiolabelling 
of amino-functionalised silica nanospheres using a range of complementary 
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bifunctional chelators. These labelled complexes are subsequently able to elicit 
quantitative microPET images in a murine model, at least to four hours post-
injection. This work shows that the choice of BFC is an important factor, as it 
can have an impact on the organ-specific in vivo distribution of the radiolabelled 
Si nanospheres. 
 
Additional comments:  
The in vitro stability of the copper chelates does not infer stability in vivo and 
should be viewed cautiously. Furthermore, molecular transformation of each 
complex e.g. the breaking of the thiourea bond to give small 61Cu-complexed 
fragments will also contribute to overall non-specific signal. Also potential trans-
chelation of 61Cu by endogenous peptides in vivo is possible, particularly in the 
liver. Since these were no studies performed to look at the tissue, plasma or urine 
metabolites, the types of fragments of the 61Cu-chelator confirm that are still 
capable of chelating copper are unknown. Most radiopharmaceuticals are 
metabolised over time. Hence, the total readout of activity in any of the organs, 
particularly those involved in metabolism and clearance such as liver, kidney, 
spleen, and bladder (derived either from tissue biodistribution or PET imaging) 
is sun of the 61Cu activity irrespective of the species. 
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CHAPTER SEVEN 
DISCUSSION AND FUTURE DIRECTIONS 
 
7.1  Discussion  
 
Over the last three decades cyclotron-produced radioisotopes have attracted 
considerable interest for biomedical applications. For example, the positron 
emission tomography (PET) isotopes 18F, 11C, 13N and 15O have established roles 
in diagnosis and management of human diseases, or research into their 
mechanisms, particularly in oncology, cardiology and neurology. However, in 
recent years many advanced cyclotron sites have also added solid targetry 
systems to produce PET radiometals and radiohalides with half-lives ranging 
from several minutes (e.g. 60Cu) to several days (e.g. 89Zr & 124I).  The 
predominant reactions are (p,x), usually with equipment-limited primary proton 
energies of less than 19 MeV. These transmutations facilitate chemical extraction 
and purification of products with high no-carrier-added (NCA) specific activities 
because the product atomic number (Z) is usually different from that of the 
target. The relatively long physical half-lives of some of the products are in 
accord with the characteristic lifetimes of biodistributions of numerous 
therapeutic and diagnostic (‘theranostic’) agents that utilise monoclonal 
antibodies, their engineered constructs, or nanoparticles as target-seeking 
platforms. A typical target would be a tumour-cell surface receptor.  Though the 
radioisotope may be chosen for its half-life and radioactive emission, its 
independent chemical properties may pose challenges for bonding or complexing 
to a targeting ligand. Copper radioisotopes are an exemplar. 
 
Recent advances in the complexation of copper isotopes using bifunctional 
macrocyclic chelators such as DOTA or NOTA and sarcophagine (sar) 
derivatives have facilitated biomedical applications of the PET-reporter isotopes 
61Cu and 64Cu, as well as the promising radiotherapy isotope 67Cu.  With its 
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‘intermediate’ physical half-life of 3.33 h and relatively high positron branching 
ratio (β+ = 61.5%; EC = 38.5%), 61Cu seems particularly well-positioned to; (i) 
map the biodistributions of engineered-antibody immunoPET constructs such as 
diabodies and minibodies; (ii) label nanospheres capable of delivering 
theranostic agents to tumours using the enhanced permeation-retention (EPR) 
effect and; (iii) provide a tool for constructing metal-chelator imaging 
compounds such as Cu-ATSM that target hypoxic tissue; for example in heart, 
brain and the cores of some solid tumours.  However, in order to apply these 
tools to phase-I studies of human diseases, numerous preliminary validation 
studies (including dosimetry) are required to be performed on cell cultures and 
on animal models. 
 
This thesis describes novel contributions to the preparation, chelator-labelling 
and subsequent application of 61Cu as a preclinical PET imaging probe. In the 
first category of this work, we studied the cyclotron-based production and 
subsequent purification of 61Cu. In the second category, we investigated the 
chemistry of complexation of 61Cu to bifunctional macrocyclic and sarcophagine 
Cu2+-chelators.  In the final category of studies, we investigated the application 
of three 61Cu-labelled bifunctional chelators to mapping the in vivo temporal 
biodistibution of functionalised silica nanospheres injected in a ‘normal’ 
immunocompromised murine model. Biodistributions were measured using 
micro-positron emission tomography and post-mortem dissection plus γ-
counting.  
 
7.1.1  Optimisation of Production of 61Cu 
 
The first phase of the first category of studies (Chapter 2) addressed the precise 
measurement of the primary proton beam energy of a cyclotron, facilitating 
optimisation of the beam energy used for the subsequent production of the 
radiometal. In turn, this would lead to better yields and less contamination from 
other radioisotopes (Asad et al., 2015). The copper stacked-foils technique using 
natCu(p,xn) monitor reactions, together with a novel iterative computational 
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technique, was used to measure the primary proton-beam energy. Measurements 
were performed before and after a major upgrade of the ion sources and non-
magnetic beam controls, converting a (nominal) 18/9 MeV (proton/deuteron) 
configuration to 18/18 MeV (proton/proton).  Measured proton beam energy was 
18.03 MeV ± 0.02 (SD) and 18.11 MeV ± 0.05 (NS) before and following the 
upgrade, respectively. This indicated that major alterations not affecting the 
magnetic configuration or basic beam geometry of the cyclotron leave the 
primary energy unchanged. The technique was also applied to the experimental 
validation of a custom-built graphite beam-degrader designed for 61Cu 
production, the thickness of which had been predicted using the method of 
Ziegler et al., (2011) plus the experimental primary-beam energy measurement. 
Agreement was within reproducibility error (0.5%). The novelty of the technique 
is that it has advantages over published methods that utilise ratios of reaction 
cross sections; namely the capacity to measure energies across virtually the 
entire range of a chosen monitor nuclear reaction and lack of the need for 
customized degraders for specific energy ranges, while maintaining high 
measurement precision (0.3-0.5%). The method may also be applicable to proton 
energies above 18 MeV and indeed 30 MeV, using IAEA-recommended (p,x) 
monitor reactions with titanium or aluminum as target (Asad et al., 2015). 
 
In the second phase of the first category of this study (Chapter 3) we measured 
excitation functions of nuclear reactions directly or indirectly relevant for 61Cu 
production. Copper-61 belongs to an interesting class of radioisotopes that can 
be produced by proton-induced reactions in natural zinc (natZn), that also include 
66Ga, 67Ga, 68Ga and 65Zn. These isotopes are used as reporters in PET or single-
photon emission computed tomography (SPECT) diagnostic or preclinical 
studies, depending on their radiation characteristics.  Copper-61 arises from the 
64Zn content in natZn (48.6%) via the 64Zn(p,α)61Cu reaction.  It was useful to 
investigate the feasibility of its production from the cheaper natZn target (in 
comparison with an enriched 64Zn target), even though the radioactive by-
products co-produced in natZn must be separated out in the purification process.  
In preparation for 61Cu production via the natZn pathway, we measured the 
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excitation functions of accessible natZn(p,x) reactions up to 17.6 MeV using the 
stacked-foils activation technique (Asad et al., 2014). Activated foils were 
measured using high-purity Ge γ-spectroscopy to quantify the radionuclides 
61Cu, 66Ga, 67Ga and 65Zn produced from the reactions. Thick-target integral 
yields were also deduced from the measured excitation functions, which aided in 
the design of 61Cu production runs. These results were compared with the 
published literature and were found to be in good agreement with the most 
reliable and recent reports. Thus these data can contribute to the statistical 
weighting of published data for assembly of the ‘best’ composite excitation 
function from published results, for most of the reactions of the natZn(p,x) 
reaction set. 
 
7.1.2  Purification of 61Cu and its Complexation by Chelators 
 
The second category of studies, described in Chapter 4, devised improved 
methods for the production and chemical separation of 61Cu from natZn or 
enriched 64Zn targets. Also, the complexation of 61Cu by three different 
bifunctional chelators was compared, using the macrocyclics NOTA-NCS 
(NOTA) and DOTA-NCS (DOTA) plus the macrobicyclic sarcophagine 
diamsar. The significance of these investigations, including as preparation for 
radiolabelling of nanospheres is discussed below. 
 
Copper-61 can be produced in high yields and with high radionuclidic purity 
from a highly enriched 64Zn target. However, as this target material is expensive 
and its supply in foil form is limited, we developed an improved method for the 
purification of 61Cu resulting from the bombardment of natural zinc material. 
This was achieved by using a combination of 3 columns (Cu-resin, anion and 
cation exchange resins) within 30 min compared with 120 min as reported for  
previous methods (Asad et al., 2012, 2015). This yielded 61Cu as chloride, with 
> 99% radionuclidic purity. This method is a fast and cost-effective option for 
the potentially routine production of 61Cu. 
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The purification of 61Cu resulting from the bombardment of enriched 64Zn target 
was also investigated using a Cu-resin column. In this case, a one-column 
purification was sufficient to separate 61Cu in high radionuclidic purity (> 99%) 
from the co-produced gallium radionuclides and the target material (allowing 
recycling of the enriched target material, if relevant).  Either method employing 
a zinc target is considerably cheaper than the method based on an electroplated 
61Ni target using the reaction 61Ni(p,n)61Cu, because of the relatively high cost 
of the nickel enrichment. 
 
The effective specific activity of each of eight 61Cu batches (n = 4 replicates in 
each) was assessed using the titration method with the bifunctional chelating 
agents DOTA, NOTA and diamsar. These results were compared with the 
corresponding NCA specific activities obtained via ICP-MS analysis. 
Reasonable agreement was found between the two estimates of specific activity 
for diamsar, for 61Cu derived from either natZn or enriched 64Zn targetry.  
However, for NOTA and DOTA the specific activity obtained via ICP-MS 
analysis was 2.4-32.5 fold higher than that determined using the titration 
method.  Generally, NCA specific activities for 61Cu derived from a natZn target 
were approximately one half of those from the enriched 64Zn source.  As shown 
in Table 4.2 of Chapter four, natZn results ranged from 143 to 233 MBq/µg 
compared with 434-506 MBq/µg for 64Zn (EOB-corrected), a consequence of 
the approximately 50% dilution of 64Zn in natZn. ICP-MS analysis also revealed 
that the concordant results for diamsar were achieved, despite relatively high 
background concentrations of Zn+2 and Pb2+ (Figures 4.5 & 4.6 of Chapter four). 
Collectively, these findings demonstrated the high specificity of the 
sarcophagine chelator diamsar for Cu2+. Generally, zinc, lead and iron compete 
with Cu2+ for chelation.  The robustness of diamsar to this effect lends credence 
to the use of a copper chelator based on a macrobicylic sarcophagine cage.  
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7.1.3  Nanospheres; 61Cu-Radiolabelling and Preclinical Imaging 
 
Fortunately, we were able to incorporate a novel sarcophagine-based molecule 
as one of the bifunctional chelators in the final stage of this project (Chapters 5 
& 6); namely; (i) characterisation of the 64Cu- and 61Cu-radiolabelling of 
nanoparticles using different bifunctional Cu2+-chelators (BFC); and, (ii) the 
investigation of the biodistributions of one species of radiolabelled nanospheres 
in a ‘normal’ immunocompromised murine model using micro-positron 
emission tomography and also post-sacrifice dissection plus γ-counting. The use 
of Balb/c nu/nu mice was in anticipation of extending the study to xenograft 
‘tumourised’ mice. 
 
In Chapter 5 we investigated the conjugation and 64Cu-radiolabelling of 
carboxylate-functionalised polystyrene nanospheres (PS NS) of three sizes (365, 
680 & 840 nm). These were conjugated with the sarcophagine SarAr-NH2 and 
radiolabelled with 57Co2+ and 64Cu2+ (the latter for 680 nm only). We found that 
increasing the labelling temperature (23oC to 37oC) and reaction time (1.25 h to 
24 h) did not improve the labelling efficiency for 64Cu (the radiochemical 
surrogate for 61Cu). This study provided valuable pilot data for the subsequent 
61Cu-radiolabelling of functionalised silica nanospheres (Si NS) using a novel 
sarcophagine; a major objective of this work.  
 
As discussed in Chapter 6, in separate replicated experiments amino-surface-
functionalised Si NS of nominal diameter 100 nm were conjugated with the 
bifunctional macrobicyclic sarcophagine Cu2+-chelator ‘MeSar-Ph-NCS’, 
followed by 61Cu-radiolabelling.  This was repeated for the macrocyclics NOTA-
NCS and DOTA-NCS.  These constructs were compared for labelling stability 
plus chelator occupancy density on the nanosphere surface. ‘MeSar-Ph-NCS’ is 
the novel Cu2+-chelating sarcophagine, [Mg(CH3)(p-NCS-Ph)Sar](CF3SO3)2, 
recently developed by collaborators of our laboratory, where the metal protector 
magnesium ion is extruded from the molecule following conjugation to the 
nanosphere and prior to radiolabelling (Paterson et al., 2014). It was found that 
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the in vitro stabilities of all 61Cu-BFC-Si NS complexes were approximately 
equal, though dissociation under ‘physiological’ conditions was 11-16% at 4 h. 
However, the occupancy areal density of 61Cu-radiolabelled MeSar-Ph-NCS 
molecules on the silica nanosphere surface was approximately double that of the 
areal densities of radiolabelled NOTA-NCS or DOTA-NCS.  This suggested that 
MeSar-Ph-NCS linkage may be a superior mechanism for maximising the 
labelling activity on the Si-NS. These experiments were the first time that this 
novel bifunctional chelator had been used to radiolabel nanospheres. 
Following validation of the radiolabelling, the tracer 61Cu-chloride, plus the 
radiolabelled nanospheres 61Cu-MeSar-Ph-NCS-Si NS (61Cu-MeSar-Si NS), 
61Cu-NOTA-NCS-Si NS (61Cu-NOTA-Si NS) and 61Cu-DOTA-NCS-Si NS 
(61Cu-NOTA-Si NS) (collectively, 61Cu-BFC-Si NS) were injected into Balb/c 
nu/nu ‘normal’ immunodeficient mice. The biodistributions of these tracers were 
measured in vivo by microPET imaging at 1 and 4 h post-injection and also ex 
vivo by dissection plus γ-counting of tissue samples at 4 h. The most important 
findings from this study were as follows: 
 
• The control tracer injected as 61Cu-chloride (and representing ‘free’ 61Cu in 
circulation) showed significant uptake in liver, kidneys and (to a lesser extent) 
in the lungs at both time points of imaging, as revealed by both techniques 
(Figures 6.4 & 6.5, Table 6.3 & Tables 6.4 & 6.5).  
 
• 61Cu-BFC-Si NS showed uptake and retention in the liver (including 
gallbladder), spleen and (to a lesser extent) the lungs and bladder, as shown in 
the quantitative µPET images at 1 and 4 h.  At 4 h post-injection, these results 
were broadly reflected in the dissection-derived biodistribution data.  These 
data also revealed that all three 61Cu-BFC-Si NS normalised activities were 
broadly similar in the liver (range 39-48%) and spleen (range 43-70%; Table 
6.3). 
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• However, the normalised activity of 61Cu-MeSar-Si NS in the lungs (37.4 ± 
5.7%ID/g) significantly exceeded that of 61Cu-NOTA-Si NS (7.4 ± 2.2; p < 
0.005) or 61Cu-DOTA-Si NS (17.7 ± 6.1; p < 0.05) (Table 6.3).  This result 
was also reflected qualitatively in the µPET image-derived data, though the 
difference was less marked.  The precise reason for the relatively enhanced 
uptake of the sarcophagine-conjugated Si NS in the lungs is unknown.  As 
postulated in Section (6.4.3) a possible explanation is a relatively high net 
positive charge on the 61Cu-MeSar moiety (Paterson et al., 2014), leading to 
binding of the sarcophagine-mediated complex to the net negatively charged 
lung interstitial tissues. The relatively high uptake of 61Cu-MeSar-Si NS was 
not seen in the kidneys compared with NOTA and DOTA, where net 
negatively charged basal cells of the glomerulus might have been expected to 
elicit the same qualitative effect as in the lungs (Figure 6.4). However, as 
noted in Section (6.4.3) the silica nanospheres’ (Si NS) size of about 100 nm 
may preclude any of the 61Cu-BFC-Si NS complexes from accumulating in 
the kidneys, which are refractory to NS sizes above about 5 nm (Elvin, Shen, 
& Ferrari, 2015). Indeed, the absence of a ‘spike’ in accumulation of 61Cu-
MeSar-Ni NS in the kidneys, relative to other BFC-tracers (since kidneys and 
lungs both contain tissues with net negative charges), is explained by the 
discriminatory effect of the size of Si NS used in this study, on the kidneys – 
for all 61Cu-BFC-Ni NS complexes.  As noted in Section (6.4.3) it is possible 
that the modest (and approximately equal with ‘free’ 61Cu-tracer) activities of 
61Cu-BFC-Si NS in the kidneys at 4 h may actually reflect mainly ‘free’ 61Cu, 
arising from the in vivo breakdown in stability of these complexes by that 
elapsed time. 
 
The murine biodistribution studies had several limitations. (i) Possible 
breakdown in vivo of the 61Cu-BFC-Si NS complexes and release of either 61Cu-
BFC or ‘free’ 61Cu (mechanisms ‘5’ & ‘6’, respectively of Figure 6.1). This may 
have confounded the results for organs and tissues with lower uptakes for the 
nanospheres, particularly the kidneys and particularly at 4 h post-injection. (ii) 
The uneven accord between results from imaging and dissection, particularly the 
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inability to detect a PET image signal from the kidneys for 61Cu-BFC-Si NS 
(Table 6.3 vs Tables 6.4 & 6.5).  This suggests that different techniques should 
be applied to analysing these images, and that the injected doses of tracers may 
need to be increased. (iii) The lack of a ‘tumour-based’ arm to the study; for 
example, the inclusion of ‘tumourised’ animals for investigation of an EPR 
effect.   
 
7.2  Summary: Outcomes of Potential Clinical  
                 Significance  
 
This is a report on the synthesis and purification of the positron-emitting 
radiometal 61Cu, its complexation to selected bifunctional Cu2+-chelators (sar 
macrobicyclic and poly-aza macrocyclic), an application to radiolabelling of 
silica nanospheres and finally a preliminary study on the measurement of their 
biodistributions in a murine model, by two related techniques. The first 
significant outcome, broadly focussed on eventual clinical applications, is the 
demonstration of the feasibility of the production and purification of 61Cu in a 
clinical-radiopharmaceutical routine laboratory setting using a ‘biomedical’ 
cyclotron with the predominant daily task of producing 18F. Solid targetry 
systems operating at less than (say) 19 MeV on such a cyclotron do not require 
complex and expensive external commercial beamlines, as demonstrated by 
Scharli et al., (2012).   
 
The second outcome was the finding that the sarcophagines were superior to the 
macrocyclics DOTA and NOTA for Cu2+-labelling of silica nanospheres in three 
respects; (i) relatively benign chemistry is required for their chelation (using 
diamsar and SarAr as archetypes), (ii) higher NCA radiolabelling specific 
activities were achievable (diamsar), and (iii) a higher areal density of 
conjugated 61Cu-BFC complexes was achievable on the nanosphere surface 
(using the novel bifunctional sarcophagine MeSar-Ph-NCS).  
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The final outcome of potential clinical significance was the first report of 
biodistribution studies in an animal model, for silica nanospheres conjugated 
with the novel radiolabelled bifunctional sarcophagine complex 61Cu-MeSar-Ph-
NCS.  The ‘head-to-head’ comparison with the biodistributions for the poly-aza 
macrocyclics DOTA and NOTA revealed few differences of significance, except 
in the lungs.  In that organ (but not in the kidneys for a plausible reason based on 
nanoparticle size), there was the suggestion that a net positive charge on the 
61Cu-sarcophagine moiety may be important for its activity accumulation and 
retention.   
 
The work in this thesis has spanned applied nuclear physics; radiometals 
separation, purification and labelling chemistries, comparison of bifunctional 
chelators (BFC) for ease of synthesis, stability and  areal density of surface 
conjugation; and finally micro-PET imaging plus dissection-based measurements 
of the biodistributions of 61Cu-radiolabelled silica nanospheres using these BFCs 
in a mousemodel. There are several clear directions in which these studies can be 
extended. 
 
7.3  Future Directions 
 
The most promising aspect in this research has been the “proof of principle” 
application of different 61Cu-labelled bifunctional chelators in determining the 
biodistributions of silica nanospheres in an animal model - exemplifying a 
potential theranostic platform for diagnostic and therapeutic agents. Some 
immediate extensions of this work are; (i) improving the in vivo stability of the 
61Cu-BFCs; (ii) comparison of the biodistributions 61Cu-BFC-NCS labels, alone, 
in the mouse model, thus excluding effects of the nanospheres, and (iii) inclusion 
in the study of sarcophagine BFCs known to have different net positive charges – 
in order to examine the hypothesis for explaining the relatively high 
accumulation of 61Cu-MeSar-Si NS (and possibly other sarcophagines) in the 
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lungs. Until this effect is elucidated, the use of sarcophagine-based chelators in 
combination with nanospheres is in doubt.  
 
More sophisticated extensions would be directed to refining the techniques for 
further preclinical and ultimately clinical studies. These could include (i) 
determining the utility of 61Cu-labelled silica nanospheres in identifying tumours 
that exhibit the EPR effect. Initial experiments would use a xenografted 
immunocompromised murine model (e.g. Balb/c or non scid), utilising both 
micro-PET and dissection. (ii) The PET-imaging isotope 64Cu could easily 
replace 61Cu in experiments that sought to extend measurements of the 
pharmacokinetics of nanosphere metabolic pathways from several hours to 
several days. (iii) Following biodistribution analysis and ‘dose-ranging’ using 
either 61Cu or 64Cu, the silica ‘nanoplatform’ could be ‘loaded’ with the therapy 
radioisotope 67Cu (without any changes in chemistries), for investigating a 
‘companion theranostic’ treatment model.   It is possible that one application of 
such models would be as an adjunct to conventional external-beam radiotherapy 
treatments, for certain classes of tumours (Wessels et al., 2008).   
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